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Preface 
This thesis uses the tool of mathematical modelling to address timely research questions in 
the field of HIV and sexually transmissible infections (STI) population health. An evaluation 
of the drivers of epidemics in South East Asia and Australia is conducted along with 
projection of epidemic trajectories according to various scenarios. Economic implications of 
public health and clinical decisions in HIV and STI control and care are also assessed. The 
main chapters of this thesis have been reproduced from papers that have been published or 
submitted for peer-review. The citations to these papers are provided at the start of each 
chapter. At the time of writing, Chapter 1 had not yet been published but was in preparation 
for submission to an international scientific journal. Content of all chapters appear as 
published but minor alterations were made to the format of the papers; these include the 
placement of figures and tables and references to supplementary material now refer to the 
appropriate appendix. Reference styles were also changed to be made consistent throughout 
the thesis.  
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Introduction and review of relevant literature 
 
Approximately 4.1 million people, of the estimated 33.3 million people living with HIV 
worldwide, live in South and South East Asia [1]. The Asia-Pacific region is vast and diverse, 
and being home to 60% of the world's population there is no single "Asian HIV Epidemic"[2]. 
However, HIV epidemics in Asia have tended to follow patterns which are distinct from HIV 
epidemics in other regions. The primary drivers behind the epidemics in Asia have been 
identified as commercial sex between female sex workers and male clients, anal sex 
(commercial and non-commercial) between men / transgendered men, and drug injection [2, 
3]. The distribution of HIV infection in countries that are classified as having a "generalised 
epidemic" is not homogeneous throughout the general population. Most infections still 
remain in subpopulations that participate in the higher-risk activities already mentioned or 
through sexual contact with those who do, for example, spouses of men who are clients of 
female sex workers.  
This thesis utilises mathematical modelling to answer a number of different questions that 
arise from a common theme of sexually transmitted infections. 
Firstly, modelling is used to investigate answers to the question of how effective the 
implementation of a public health policy can be in mitigating an HIV epidemic. Models are 
applied in two widely differing epidemiological settings: one country that is high-income, the 
other that is low-income; one that has an epidemic that is predominantly within the 
population of MSM, the other where heterosexual intercourse if the cause of the majority of 
infections. We then use mathematical modelling from a fiscal point of view to evaluate the 
implementation of public health strategies in terms of cost-effectiveness. These strategies 
cover the frequency of testing specific populations such as sex workers and men who have 
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sex with men, changing the criteria for the eligibility for antiretroviral treatment and the 
provision of antiretroviral therapies for free. 
 
HIV in Cambodia 
 
Cambodia is a country which has experienced an HIV epidemic following chains of 
transmission among different at-risk population groups. The first documented case of a 
positive HIV diagnosis in Cambodia was in 1991. The number of new HIV infections rapidly 
expanded with an estimated (via sentinel surveillance) peak epidemic prevalence of 3% 
among the adult population in 1998. By 2003, it was estimated (also via sentinel surveillance) 
that prevalence decreased to 1.9% and through a large household survey HIV prevalence is 
currently estimated to be approximately 0.6% [4]. The primary driver behind the initial 
epidemic has been identified to be heterosexual transmission between female commercial sex 
workers (FSWs) of both the direct (establishment-based) type (DSW) and the indirect 
(karaoke bar, massage parlour) type (ISW) and their male clients, with onward transmission 
to the regular sexual partners of male clients [5]. Motivated by the important need to design 
HIV prevention responses that are based on evidence, decision-makers should be informed by 
knowledge of the dynamics and modes of HIV transmissions in a population and 
understanding of the effectiveness of past HIV responses as well as the combination of 
strategies likely to have greatest impact in the future. To meet this need, a new tool was 
developed to evaluate and project Cambodia’s HIV epidemic. In Chapter 1 background 
information is provided about the response to Cambodia’s HIV epidemic, evaluation of the 
impact of this response, as well as description of the development of the tool used to conduct 
evaluations and projections and some summary results. In Chapter 2 we present an evaluation 
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of the impact of the Global Economic Crisis on the spread of HIV in Cambodia and Papua 
New Guinea. 
 
Test and treat as an intervention and cost effectiveness 
 
There is growing evidence showing that by reducing the viral load in an HIV-positive patient 
through the administration of antiretroviral treatment, this will reduce the rate of onward 
transmission. Whilst the primary motivation of treatment is usually for the health and well-
being of the patient, this secondary benefit of decreased transmission is significant and should 
be considered as an intervention in appropriate settings. Evidence of this beneficial effect is 
largely obtained from epidemiological and observational studies, a few of which will be 
reviewed briefly below. Most recently however, for the first time, a large-scale randomised 
clinical trial demonstrated that early initiation of antiretroviral treatment to HIV-infected 
persons reduced transmission to uninfected sexual partners by 96% [1]. 
Viral load in the blood of an HIV-positive person has been found to be a key indicator of how 
likely transmission is to occur. The major finding of the study of heterosexual transmission 
by Quinn et al. [2] was the strong association between increasing transmission risk with 
increasing serum levels of HIV-1 RNA, with an increase in risk of a factor of 2.45 for each 
log increase in viral load. 
 
Whilst the amount of HIV-RNA in blood is routinely monitored in developed nations, it is 
likely that the level of virus in genital fluids is of greatest importance for influencing 
infectiousness associated with sexual transmission. The findings of Vernazza et al. [3] show 
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that in patients that have reduced their viral load to less than 400 copies per millilitre of blood 
due to ART, the probability of having detectable HIV in semen is less than 4%. In a recent 
study Baeten et. al [17] examined the relationship between viral load in blood, endocervical 
swabs, semen and risk of sexual transmission. They found for each log HIV-1 RNA 
copies/mL increase in plasma, there was an associated with a 0.52 log copies/swab increase 
in endocervical viral load and a 0.46 log increase in semen. In terms of transmission, for each 
log increase in endocervical viral load there was an associated 2.20-fold increase in risk and 
similarly, a 1.79-fold risk for each log increase in seminal viral load. Overall they found 
higher genital viral concentrations were associated with greater risk of heterosexual HIV-1 
transmission, and this effect was independent of plasma HIV-1 concentrations.  
 
In addition to seeing the positive effect of antiretroviral treatment at the micro-level within an 
infected individual and to their potential for transmission to their partners, it is possible to 
take a macro-view of the benefit at the population level. In 2010, Montaner et al.[4] aimed to 
estimate the association between HAART coverage, plasma HIV-1 viral load, and number of 
new diagnoses of HIV in a population-based study of the Canadian province of British 
Columbia (BC). The drivers of the localised HIV epidemic in BC have been identified as 
three key sub-populations: MSM, IDUs and FSW [5]; these risk-groups carry the bulk of the 
disease burden. For the years 1996-2009, surveillance data were obtained for the number of 
HIV tests performed, the number of new HIV diagnoses, the number of individuals actively 
receiving HAART, CD4 cell count and viral load (from the British Columbia Centre for 
Disease Control and British Columbia Centre for Excellence in HIV/AIDS). These data were 
then analysed for associations using Poisson log-linear regression models. They found that in 
the population, for every 100 additional persons put onto HAART, the number of new HIV 
cases decreased by 3%. Similarly, for every log10 reduction in estimated average community 
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viral load, there was a corresponding 14% decrease in new diagnoses. It is important to note 
that this is purely an ecological study and does not mean there is causation at the population 
level. However, the large-scale randomised clinical trial that demonstrated a 96% reduction in 
transmission due to ART is a study of higher rigor and produced comparable qualitative 
results and quantitative implications [1]. 
 
Demonstrating the benefit of a healthcare intervention for a population is not enough for it to 
be implemented as policy. For this, it is usually necessary to demonstrate that the intervention 
being considered would also be cost-effective, that is, cost no more than a pre-defined 
"willingness to pay" threshold per quality-adjusted (QALY) or disability-adjusted (DALY) 
life year gained. 
 
In British Columbia, a revision of guidelines for the provision of HAART in 2008 led to a 
substantial increase in the number of those eligible to receive treatment. Based on the new 
guidelines, Lima et al.[5] explored the potential impact of differing coverage scenarios in 
comparison to the previous eligibility guidelines. They constructed a transmission model 
comprised of four ordinary differential equations (ODEs) for three most-at-risk groups: men 
who have sex with men, injecting drug users and female sex workers. Each ODE represented 
a disease and treatment state, and also incorporated stage-dependent infectiousness. The 
scenarios explored were 50%, 60%, 75% and 100% of those medically eligible to receive 
HAART, with an assumption that 25-30% of those infected are undiagnosed. In terms of cost 
effectiveness, disability-adjusted life years were used to estimate HIV-related morbidity and 
mortality, costs were in terms of provision of first-line therapy for one individual in BC for 
one year disregarding inflation or discounting. Their results showed that an intervention 
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leading to even a marginal increase in HAART coverage to 50% of eligible individuals, in 5 
years at least 1360 infections could be averted, in addition to the gain of 4155 DALYs and 
approximately CAD$ 21 million in costs. According to this simulated scenario, such an 
intervention would initially be cost-effective and cost-saving within a decade. 
 
Whilst there is obvious benefit gained from using targeted interventions in concentrated 
epidemics, there remains the possibility that such an intervention could also be beneficial in a 
generalised epidemic. In their paper ''Universal voluntary HIV testing with immediate 
antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical 
model" [6], Granich et al. simulated an intervention of universal voluntary HIV testing 
followed with immediate treatment with ART upon diagnosis. Using this strategy, they then 
analysed conditions under which the elimination of the HIV epidemic could be achieved, 
where elimination is defined to have occurred when incidence is fewer than one case per 
1000 people per year. In order to achieve this goal, the case reproductive number R0 would 
need to be reduced to less than one. Two mathematical models were implemented to explore 
the effect of the intervention strategy proposed: a stochastic model of R0; and a deterministic 
transmission model of the long-term disease dynamics. In the stochastic model, CD4 count 
determined the stage of infection, and transmission varied between the acute and chronic 
phases of HIV infection with an adjusting factor for those who were currently on ART. 
Initially, a person's CD4+ cell count and expected survival time were sampled from an 
observed population distribution. It was then assumed that cell count immediately decreased 
by 25% post-infection and linearly thereafter. The deterministic compartmental model was 
fitted to an observed Weibull survival distribution model. The model tracked the infected but 
untreated as well as the treated populations' progression from infection to AIDS stage but this 
component of the model was decoupled from the infectivity of the acute and final phases that 
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were modelled stochastically. As disease progresses, infected persons in the model can switch 
from untreated to treated at a rate equal to that of the treatment rate and return due to 
treatment failure or non-adherence. It was also assumed in the model that transmission 
decreases with the overall population prevalence. 
 
Universal testing and immediate treatment was modelled independently and in unison with 
other combined adult interventions such as: adult male circumcision, condom promotion, 
treatment of other sexually transmitted infections and behaviour change programmes. When 
being modelled with the same roll-out rate as the ART programmes, it was assumed that the 
combined interventions would reduce transmission by 40%. Their model suggested that 
whilst other interventions could reduce HIV incidence substantially for a generalised 
heterosexual epidemic, universal voluntary HIV testing and immediate initiation of ART was 
necessary to reduce transmission to the defined elimination point within ten years. 
 
It is equally important, if not more so, to consider the cost-effectiveness of interventions in 
developing countries with generalised epidemics. With the availability of less expensive 
medications due to the advocacy and financial support from large international organisations, 
the financial benefit has the potential to be much greater than what could be realised in 
industrialised countries with localised epidemics. In their study, Vickerman et al. [7] estimate 
the epidemiological impact and cost-effectiveness of interventions with various combinations 
of periodic presumptive treatment (PPT), syndromic management of bacterial STIs and 
provision of condoms to female sex workers in Johannesburg, South Africa. Using a 
deterministic compartment mathematical model to calculate the expected number of new HIV 
and other STD infections in one year with and without the intervention, they then use 
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economic analysis to determine the cost-effectiveness. They found that by correctly treating a 
large number of STIs, the full intervention resulted in 3.1% decrease in HIV incidence in 
FSWs with a corresponding 2% reduction in the general population. An expected 53 HIV 
infections and 1413 DALYs were averted at a cost of $78 per DALY, well below the 
recommended upper bound of $141 per DALY as a willingness to pay threshold. Their 
analysis shows that such an intervention has the potential to be even more cost-effective if it 
is implemented earlier in an epidemic. 
 
In their paper "Examining the promise of HIV elimination by `test and treat' in hyperendemic 
settings" [8] Dodd et al. also examined the possible impact of test-and-treat interventions in 
the context of a generalised epidemic. Their deterministic partial-differential equation model 
included variation over the course of an infection in HIV transmissibility and sexual risk 
behaviour and incorporated observed HIV survival rates. The model considers transmission 
via heterosexual sex with and without ART, where men and women are categorised into low 
or high-sexual activity groups. Modelled interventions were evaluated for when the epidemic 
was sustained in either both sub-populations or in the high-activity group only. This was in 
conjunction with extensive or limited sexual mixing between the groups, giving rise to three 
epidemic scenarios with differing degrees of robustness. Key to the model is the assumption 
that those on treatment are less infectious and have a survival time dependent upon the 
promptness of treatment initiation, and those who are untreated survive for 11 years post 
infection. As would be expected, they found that earlier initiation of treatment with higher 
levels of coverage had the greatest impact. For example, they found that an intervention that 
results in testing 80% of the population every 2 years with immediate treatment could be 
expected to reduce incidence by more than 95% for an epidemic where risk is evenly 
distributed. However, this decrease in incidence is reduced to 85% in an epidemic that is 
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sustained in the smaller population group at higher risk where sexual mixing was assumed to 
be random. Incidence reduced further to 60% when the sexual mixing was assumed to be 
assortative (that is, people mix with people of the same population group). In these last two 
scenarios, such an intervention would fail to reduce the epidemic to elimination, and similar 
impact could be achieved with less frequent testing. Overall, the findings from their model 
highlight that whilst an intervention such as test and treat can reduce HIV transmission 
significantly, it is highly context specific. The impact of a proposed intervention on HIV 
transmission may be less for one epidemic type than another, or conversely, the same results 
may be achieved with less expenditure of resources. When the cost-effectiveness of a scheme 
is crucial for its implementation, a highly epidemiologically-effective intervention such as 
testing every year and treating immediately, may not necessarily be the most efficient fiscal 
strategy. Additionally, they showed that test-and-treat interventions that do not reach full 
implementation or coverage could potentially increase ART costs in the long-term. 
 
In Chapter 3 we present a modelling study that evaluates the effectiveness of a test and treat 
intervention amongst men who have sex with men in South Australia. In the following 
chapter we present an economic argument for the provision of free antiretroviral medication 
in South Australia. In Chapter 5 we demonstrate that the frequent mandatory screening of 
female sex workers in Victoria is not cost-effective for the prevention of disease in their male 
clients. 
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Serosorting 
 
The practice of choosing a preferential sexual partner based on the concordance of HIV 
serostatus is known as serosorting [6-8]. The primary purpose of serosorting is to reduce the 
risk of HIV transmission occurring. This practice is becoming increasingly common among 
men who have sex with men (MSM) in various locations around the world when seeking to 
form casual sexual partnerships and enables unprotected anal intercourse without fear of risk 
of HIV transmission [8-14]. In addition to choice of partner, the disclosure of serostatus is 
likely to influence negotiated safety and strategic positioning, that is, the use of a condom and 
which sexual position each man will take [8-14]. In a discordant partnership, the receptive 
role carries more risk than the insertive position. In sexual acts where the partnership is 
thought to be concordant, HIV-negative men are less likely to use condoms and are more 
likely to take a receptive role [15]. As such, the safety of the serosorting practice is highly 
dependent on the rate of undiagnosed infections. It is possible that serosorting may lead to an 
increased risk if a partner's status is misreported [15]. In a recent modelling study, serosorting 
was found to be partially effective in Seattle, Washington [16]provided the proportion of men 
unaware of their infection is less than 20%. In Chapter 6 we assess the effectiveness of 
serosorting at reducing the transmission of HIV in a variety of settings with different levels of 
undiagnosed infections. We investigate the expected effectiveness of serosorting using a 
mathematical model. Threshold levels at which serosorting increases transmission risk are 
estimated for different settings. 
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Chapter 1: The Cambodian HIV Epidemic Model (CHEM): 
Evaluating the drivers of the past epidemic, understanding the 
present and assessing the impact of interventions in the future. 
 
Introduction  
 
In this chapter background information is provided about the response to Cambodia’s HIV 
epidemic, evaluation of the impact of this response, as well as description of the development 
of the tool used to conduct evaluations and projections and some summary results.  
Cambodia has seen a substantial decrease in overall HIV prevalence. The reasons for this are 
likely a combination of natural epidemic dynamics and specific HIV prevention programmes. 
In response to their epidemic, Cambodia has implemented two key health strategies: (i) the 
promotion of 100% condom use in transactional sex for female sex workers and (ii) access to 
antiretroviral medications for pregnant women, which was subsequently expanded to include 
access for other HIV-infected people. The degree to which these programmes contributed to 
declines in HIV prevalence, versus other programmes or natural epidemic dynamics, is 
unknown. In this study, these programmes are evaluated.  
In 1998, the 100% condom use program (CUP) among DSW was initiated in Cambodia in the 
Sihanouk Ville province and expanded nationally in 1999 [1]. This intervention provided 
outreach support to FSWs, facilitated access to regular STD check-ups, Voluntary 
Confidential Counselling and Testing (VCCT) centres and other services, education about 
sexual health and ensured availability of condoms at all sexual-entertainment venues [2]. 
19 
 
Between the years of 1998 and 2003, condom use in DSW for transactional sex increased 
from 53.4% to 96% and continued to do so until  2007 to 97-99% and then dropped to 89-98% 
in 2010 [3-5]. Average levels of condom use among ISW followed a similar trend, starting at 
approximately 30% in 1998, increasing to 84% in 2003, continued upwards to 93% in 2007 
and decreased to 82-95% in 2010. Ecological associations between condom usage and 
prevalence among sex workers suggest that 100% CUP may have had an epidemiological 
impact. Over the period of increased condom usage there was a corresponding decrease in 
HIV prevalence in DSW, from 45.8% in 1998 to 20.8% in 2003 to 14% in 2006. Similarly, 
prevalence in ISW decreased from 15.6% in 2000 to 11.7 % in 2003. However, with the 
increase in non-brothel sex-work and DSWs becoming ISWs, prevalence in entertainment 
workers is dependent upon the number of sexual partners per week. Women who have seven 
or less partners per week are reported to have a prevalence of 3.6% in 2010, and women with 
more than seven partners per week had 14%. An association does not necessarily imply 
causation and the decline in prevalence may have been expected due to epidemic dynamics. 
Therefore, more rigorous investigation is required. 
Treatment of HIV-infected pregnant women at the time of delivery with nevirapine was 
implemented in the Cambodian capital of Phnom Penh in 1999[6]. Providing access to 
antiretroviral treatment to all HIV-infected people with advanced disease became a priority in 
2003 with the launch of the Operational Framework for the Continuum of Care for People 
Living with HIV/AIDS that August. This programme initially provided treatment to 2230 
people at four sites and has continued to expand ever since. Currently, for a patient to qualify 
for the receipt of antiretroviral medication his/her CD4 count (key immune cell measure) 
must be less than 350 cells per millilitre of blood. Antiretroviral treatment not only 
substantially reduces HIV-related morbidity and mortality among those receiving it, but it 
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also acts to reduce transmission. The preventative impact of treatment programmes in 
Cambodia, in terms of infections averted, has not been assessed. 
In addition to evaluation of these past programmes, for informing public health planning, in 
this study, projections of HIV epidemic trajectories for Cambodia are carried out according to 
numerous intervention conditions. Interventions that could be considered in the future in 
Cambodia include male circumcision, needle and syringe exchange programs (NSPs) and 
scaling-up of the existing HIV testing and treatment framework. Increasing testing and 
treatment frameworks and implementing NSPs have already commenced in Cambodia. 
However, programmes around male circumcision have not been implemented in Cambodia. It 
has been shown that in countries with generalised epidemics, that male circumcision can 
reduce the risk of men acquiring HIV by 60% for female-to-male sexual transmission [7, 
8][12, 13]. 
In an assessment of the potential effects of male circumcision on HIV incidence at the 
population level as predicted by mathematical modelling [9], it was shown that in countries 
such as Uganda that have lower HIV incidence and prevalence, the number of male 
circumcisions required to avert an infection is greater than in high-prevalence settings. A 
modelling consensus reaching process led to the conclusion that interventions with a focus on 
subpopulations with a high HIV incidence and prevalence such as men who have multiple sex 
partners (e.g. clients of female sex workers ) could have substantial impact on HIV incidence. 
It was also identified that subpopulations with low rates of male circumcision would also 
benefit from such a programme. In a country such as Cambodia where male circumcision is 
not custom, there are little data on what proportion of the male population are circumcised. It 
has been estimated that the rate of circumcision in Cambodia is as low as 1.6%, but is 
generally agreed that it is less than 20% [10]. Since male circumcision is one of the few 
21 
 
proven HIV prevention strategies, it may be worth consideration of the potential benefit that 
could be achieved by increasing circumcision rates in a setting like Cambodia. 
The evaluation of the epidemiological impact of these past programmes is extremely difficult 
through purely empirical means. Mathematical models, informed by setting-specific 
programme, epidemiological and behavioural data, can be used to estimate the possible 
impact of these programmes. Similarly, epidemic models can be used to make projections of 
epidemic trajectories under different scenarios which may represent relative changes 
associated with new intervention strategies. There are a limited number of mathematical 
models that have been applied to the HIV epidemic in Cambodia and the most important of 
which are reviewed in brief before describing a new tool that was developed specifically for 
this purpose. 
In 2004, the UNAIDS Estimation and Projection Package (EPP) [11] was released. This Java-
based software package, under construction since 2001, was used for countries with 
generalised HIV epidemics as a tool for estimating and projecting HIV prevalence levels. The 
package allows users to define the overall epidemic in terms of population subgroups and/or 
geographical regions, allowing for modelling of the disproportionate contribution a certain 
risk- or geographical-group may have on the spread of HIV. Available HIV surveillance data 
(such as prevalence estimates from BSS and DHS surveys or from antenatal clinics) are then 
input into the model for all groups that are of interest. The model behind the package is 
numerical, employing four key epidemiological parameters to best fit an epidemic curve to 
the input data points via least squares minimisation. These four parameters are: the start year 
of the epidemic, the proportion of the population that are at risk of infection at the beginning 
of the epidemic, the epidemic growth rate, and the net change in the at-risk population size. If 
it is determined by the user that the curve fitted, whilst mathematically the best fit, is not 
epidemiologically appropriate it is possible for the user to change any or all of the key four 
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parameters to change the shape. “EPP smoothing” is still commonly applied to sentinel 
surveillance reporting in Cambodia, despite the change in the epidemic profile. 
Also in 2004, Brown et al. presented their work “The Asian Epidemic Model: a process 
model for exploring HIV policy and programme alternatives in Asia”   [12]. Rather than 
implementing the curve fitting of surveillance data techniques of the EPP, the Asian 
Epidemic Model (AEM) is a transmission-based model that includes inputs such as HIV 
transmission probabilities, risk behavioural data, and regionally-appropriate cofactors such as 
the prevalence of other STIs. The model incorporates the dominant routes of transmission 
seen in Asian epidemics and separately includes components for each of the key at-risk 
groups: direct female sex workers, indirect female sex workers, male sex workers, males who 
are clients of sex workers, men who have sex with men who are not sex workers, injecting 
drug users (divided into higher and lower risk sharing networks) and males and females of 
the general population. Inputs are specified annually such that important changes in 
behaviour can be captured and include frequency of sexual acts for each partnership type, as 
well as the applicable condom usage rate, rate of sharing and frequency of injections for 
IDUs, the prevalence of other STIs for each sexual/shared injection partnership and the size 
of each key population. Curves are then fitted according to the input data and applied to the 
underlying transmission model. Like the EPP, this model is most appropriate for a 
generalised epidemic setting. Additionally, a much larger number of more complex inputs is 
required for the AEM than EPP which can limit the ease in which it can be applied. This 
model was initially applied successfully in Thailand [13] and Cambodia [14] (and then also 
applied to other settings throughout Asia) and is still used in Cambodia for annual reporting 
of prevalence [15]. 
Motivated by the notion that in-country decision makers should base public health policy and 
program decisions on evidence, UNAIDS promoted the Know Your Epidemic / Know Your 
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Response activities [26, 27]. As part of this, a modelling tool was created and released called 
“The Modes of Transmission” (MoT) spreadsheet [16]. This model has been applied to 
Cambodia. The purpose of the model is to calculate the expected incidence of HIV infections 
for the coming year. The distribution of new infections is also calculated by classifying the 
adult population into groups according to their predominant exposure to HIV. Inputs to the 
spreadsheet are: current HIV and other STI prevalence, sizes of the relevant populations, 
number of partners and acts an individual in each population has, the proportion of acts that 
are protected by condoms and the appropriate transmission probability. The model assumes 
that a member of the population can only belong to one risk category, even though they may 
have several different exposure risks. Also, as this model is static and calculates point 
estimates via risk equations, to estimate short-term incidence levels, individuals cannot move 
between risk-group categories.  
The simplistic nature of the EPP makes it highly accessible to the end user but due to its 
development as a tool for use in settings of generalised epidemics, its on-going use may be 
less informative in the Cambodian context. It is also not possible to incorporate behaviour 
change explicitly, and hence evaluate modes of transmissions. The AEM addresses this gap 
and adds extra important inputs, but with its large data requirements, need for a deep 
understanding of the model framework for implementation and analysis, and best 
applicability to only generalised epidemics, this reduces its usability and relevance. 
Addressing this disparity motivates the development of the Cambodian HIV Epidemic Model 
(CHEM) as a new evaluation and projection tool. In this study we aim to evaluate the 
effectiveness of previous prevention interventions upon the HIV epidemic in terms of the 
expected prevalence and number of infections averted and forecast epidemic trajectories 
according to a variety of scenarios related to combinations of interventions appropriate to the 
Cambodian setting. These projections are made via the design and implementation of a 
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mathematical model specific for the unique behavioural and epidemiological context of 
Cambodia. 
 
Methods 
 
Determined through a consultative process with the National Center for HIV/AIDS, 
Dermatology and STD (NCHADS), the following key distinct population groups of 
importance in Cambodia were determined for inclusion in CHEM: direct female sex workers 
(DSW), indirect female sex workers (ISW), clients of female sex workers, men who have sex 
with men (MSM), men who have sex with men and women (bisexual) (MSMW), injecting 
drug users (IDU), (non-injecting) amphetamine-type stimulant users (ATS), and males and 
females in the general population. Many of these groups exist in other countries but some 
groups are not common elsewhere, for example, the ATS drug users are of interest because 
their sexual risk behaviour is influenced by their drug use and they make up a larger 
proportion of the population than IDUs. Additionally, men who have sex with men are split 
into two types: “longhairs” (MSM) - men who are exclusively homosexual many of whom 
are transgendered in appearance and “shorthairs” (MSMW) – bisexual men who generally are 
masculine in appearance. These two groups have differing risk behaviours and therefore are 
likely to influence the epidemic in varying ways. The CHEM was designed to be a 
deterministic compartmental model that uses behavioural, clinical and biological data to track 
for each priority group the number of new infections and the number of those in each 
progressive stage of HIV disease over time.  
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CHEM was developed to capture transmission and disease history of HIV in Cambodia. In 
the model, ordinary differential equations (ODEs) track the number of people in the 
population over time in each state of HIV disease stage: uninfected, infected but not yet 
diagnosed, diagnosed but not on treatment and on ART. For each subpopulation, all HIV-
infected individuals are classified according to their stage of HIV disease, based on CD4 
count: CD4 count greater than 500 cells per mL, between 350 cells and 500 cells per mL, 
between 200 cells and 350 cells per mL, less than 200 cells per mL. Additionally, the model 
tracks the number of people who initiate first-line ART, the rate of treatment failure, and 
progression to second- and subsequent-lines of ART. HIV/AIDS-related deaths and other 
causes of death are also included in the model. A schematic diagram of the natural history 
described by the model is presented in Figure 1, how each of the subpopulations mix is 
shown in Figure 2  and the governing equations of the model are presented in Equation 1.  
 
 
Figure 1: HIV health states in CHEM 
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Figure 2 - Partnership mixing between populations 
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Equation 1: Governing equations of the model 
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The model was informed by biomedical inputs such as (1) infectiousness due to disease stage 
(which is strongly associated with viral load) (2);  type of exposure to HIV (heterosexual or 
homosexual intercourse; injection), effectiveness of condoms, circumcision, ART,  and 
needle-syringe cleaning in preventing transmission; and (3) rates of natural and HIV-related 
death. Behavioural inputs for sexual transmission included changing rates of condom use and 
HIV testing over time, average number of casual and regular homosexual and heterosexual 
partnerships per person, and the average frequency of sexual acts per partnership. For 
intravenous transmission, parameters included the number of injecting partners per person per 
year, frequency of sharing injecting equipment, the percentage of shared syringes that are 
cleaned prior to re-use, and the number of injection acts per year.  
In order to effectively predict possible epidemic trajectories for the future, it is essential that 
the model is able to reflect observations of the past and present. In order to achieve this, 
given the uncertainty around all parameter values, within confidence intervals or plausible 
bounds, an optimization procedure was used. This procedure determines how the complex 
interactions of all the parameters can be reconciled together to match the available 
population-level data. To calibrate the model, weights were assigned to each of the input and 
output parameters (e.g., condom usage rates and prevalence, respectively). A goodness-of-fit 
function was defined as the sum of squared differences between the available data and the 
model inputs and outputs, multiplied by the assigned weights. A trust-region-reflective 
algorithm [17, 18], a gradient-descent method with a dynamically updating step size based on 
the curvature of parameter space, was used find an optimal set of input parameters. Briefly, 
this method perturbs each input parameter in turn, evaluates the model and its goodness-of-fit 
after each perturbation, calculates the gradient of the resulting set of goodness-of-fits, and 
modifies the parameter values in the direction of the gradient. Starting from the modified 
parameter set, the process repeats, until one of the following stopping criteria is met: (1) the 
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gradient is always positive (i.e., a local minimum has been reached), (2) the goodness-of-fit is 
within a predetermined tolerance limit, or (3) the number of  iterations has exceeded a 
predetermined maximum. In the present case, optimization usually terminated due to the 
second stopping criterion. 
Since parameter values used in the model are not precisely known, it is necessary to conduct 
uncertainty analyses to determine the range of possible model outcome values related to the 
range of input parameter values. In order to carry out this analysis, minimum and maximum 
plausible limits are assigned to input parameters. The estimated 2.5, 50, and 97.5 percentiles 
were used to numerically define a nonparametric distribution for each parameter, with first- 
and second-order continuity provided by spline interpolation mapped onto the desired 
interval by means of an inverse error function. Time-varying parameters were assigned 
uncertainty bounds in the model up to ± 20% of the best parameter estimates. Furthermore, 
all parameters were defined to have ‘hard’ limits to their bounds to ensure realism (e.g. all 
fractions must be bounded between 0 and 1). Uncertainty in outcomes were generated by 
running 40 simulations, each simulation using a different set of parameters sampled from the 
defined uncertainty distributions associated with each model input. In this model we used a 
95% uncertainty limit defined by the 2nd and 39th values of 40 simulations at each time step. 
By matching the available epidemiological and behavioural data for the years 2000 to 2010, 
the model can evaluate the effectiveness of past campaigns by calculating how many 
infections could have been expected otherwise had they not been put into place. Then by 
predicting future epidemiological trajectories under current conditions, the possible impact of 
future interventions can also be measured. Projections are carried out to represent the time 
period from the year 2011 to 2020.
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It is not possible to know for certain all indirect effects an intervention had on behaviour 
through its implementation. For example, the 100% CUP for direct sex workers increased 
condom use for both direct and indirect sex workers in commercial and non-transactional acts. 
This increase was a direct result of the education and support provided to FSWs. This 
education however, may have possibly increased condom use in general females with FSWs 
educating their female relatives and friends in turn. Another possible flow-on effect could be 
increased condom use in clients for non-transactional sex-acts, with clients becoming more 
aware of the risk of contracting HIV through their interaction with FSWs. In order to assess 
the effectiveness of the 100% CUP campaign, we therefore take a conservative approach and 
only consider the effect of retaining condom use rates in FSWs at the same level as they were 
in 1998. It is also possible that other programmes in operation over this period may have had 
an impact on increasing condom use among FSWs, however, 100% CUP was the only 
intervention specifically targeted FSWs. Therefore, it is argued that an assumption that 
condom use would have remained at 1998 levels in the absence of 100% CUP is reasonable. 
Similarly, we can evaluate the impact that the introduction of ART in 2003 had upon the 
epidemic. As reviewed in Chapter 2, a person’s infectivity is greatly reduced with effective 
antiretroviral treatment. It could be assumed that without the scale-up of antiretroviral 
treatment the reduction in infectiousness for those receiving effective antiretroviral treatment 
would not occur. 
To estimate the number of infections averted due to these programmes the CHEM can be 
simulated over the relevant historical time periods according to the assumptions without the 
programmes and compared with the epidemic trajectories under the optimized, calibrated 
model. The difference in the estimated incidence provides an indication of the expected 
number of infections averted due to the programmes. The CHEM is also used to project 
epidemic trajectories according to changes in conditions, associated with the implementation 
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of different interventions. Intervention types investigated with CHEM are described in the 
following paragraphs.  
Heterosexual condom use outside of transactional-sex is low. According to the 2010 
Cambodia Demographic and Health Survey [19], approximately 2.7% of married women 
have used condoms at some stage during the previous year. In MSM, condom use is much 
more consistent, with 83% of ‘short-hair’ MSM reporting condom use at last sex and 94% of 
‘long-hair’ MSM in the 2007 Behavioural Sentinel Surveillance [3]. We take the efficacy of 
condoms to be 95%, and simulate epidemic trajectories according to condoms being used in 2% 
of acts to 10, 20 and 40%.  
Circumcision levels in Cambodia are unknown, but are estimated to be very low. For 
modelling purposes, it is more conservative to overestimate the prevalence of circumcision, 
which in turn would lead to an underestimation of new infections, particularly in males. 
Therefore, we assume the current circumcision level in sexually active males in Cambodia is 
five percent. We examine a potential intervention that would result in small increases in 
circumcision prevalence to 10, 15 and 20%, as large increases are not likely to be attained. As 
circumcision is of greater benefit to men, especially those with low condom use, we focus on 
targeting circumcision to adult men of the general heterosexual population that do not belong 
to any higher-risk groups. 
Therapeutic replacement of heroin to reduce injection frequency, education about safer 
injecting habits and increased access to clean needles and syringes for those who inject drugs 
could be an efficient means of reducing HIV incidence in that population. As the current 
enrolment in the MMT program is very low, we focus solely on needle and syringe programs. 
In the model we assume that for those who share injection equipment, approximately 60% of 
injections are shared.  We evaluate an intervention that through the provision of equipment 
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and education, reduces the proportion of injections that used shared equipment for those 
injectors who share from 60% to 45%, 30% and 15%. Sharing rates of 15% are still common 
in settings of high access to needle and syringe programmes [25], and therefore this sharing 
rate is considered as a best target. 
Changing guidelines on access to antiretroviral medications such that more people qualify as 
eligible for treatment benefits not only the HIV-infected individuals but also reduces the 
community viral load. A reduction in community viral load reduces the average 
infectiousness and therefore population incidence. Those diagnosed with HIV infection are 
currently deemed eligible when their CD4 count drops below 350 per millilitre of blood. We 
use CHEM to investigate the impact of raising this criterion to treating those with levels less 
than 500/mL and also treating all of those that are diagnosed. Whilst it is not feasible to 
enforce treatment upon all of those diagnosed, it is a useful exercise to evaluate the full 
benefit of antiretroviral medication. The evaluation is also conducted in combination with an 
increase in testing rates in general males and females from 2% to 10% and 20%.  
Clearly, a public health response to an epidemic affecting multiple population groups and for 
which there are different intervention options should involve the implementation of more 
than one targeted strategy concurrently. We project the relative impact of combinations of 
initiatives which are thought likely to be effective and feasible to implement and maintain, in 
terms of acceptance and adherence in the targeted population.  As testing rates in general 
males and females are low, we recommend a target of a relatively small increase in testing to 
10% per year, in conjunction with providing antiretroviral medication to all of those 
diagnosed with a positive infection and reducing the percentage of shared injections for those 
who shared from 60% to 30%. We then evaluate the same scenario with a 20% testing rate in 
general males and females and then once more with the addition of increasing condom use in 
non-transactional heterosexual acts from approximately 2% to 10%. 
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Results 
 
For the years 2000 to 2010, the model calculated that there were approximately 72427 (95% 
confidence interval: 32607, 164536) new infections in the population overall. The breakdown 
of infections by risk-group can be seen in Table 1. The proportion of new infections incurred 
in and attributed to each sub-population can be seen in Figure 2 (a-d). General females (who 
cannot be classified in a behavioural most-at-risk population group) account for the largest 
proportion, with 47% of new infections between the years 2000-2010. The large absolute 
number of infections in this group is due to the large population size compared to the 
relatively small population groups most at risk that have high per-capita rates of infection. 
General males and clients of sex workers are the next most-at-risk groups with 36% and 11% 
of incident cases respectively. The proportions are similar for attribution of infections; overall 
general females are the largest group with 49%, general males follow with 37% and clients 
contribute 11%. The profile does change over time, with infections caused by female sex 
workers in 2010 less than half the proportion in 2000. Prevalence in general males, general 
females and ATS users remains low and relatively constant. The model suggests there has 
been a continual reduction in prevalence in direct and indirect sex workers and their clients. 
Populations at higher risk, such as MSM and IDU, had a delayed peak in their prevalence 
with a noticeable decline in prevalence among MSM and a more modest decline among IDU 
that could be tending towards a plateau. Injecting drug users have the highest prevalence 
overall by 2010, estimated at 22.8%.  
In Table 2 we present the results from evaluating the effectiveness of the 100% CUP 
campaign, the introduction of antiretroviral treatment and the two programmes in 
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combination. In the absence of 100% CUP, the model predicts there would have been an 
approximate 78415 (34860, 181517) new infections for the years 2000-2010, meaning there 
would have been 5988 (2253, 16981) or 8.3% more infections than what would have been 
expected otherwise. The majority of these extra infections would likely have occurred in male 
clients of FSWs, with an extra 3381 (1480, 8039) (42.1%), followed by general females with 
an extra 1466 (399, 5124) (4.3%) and FSW with 632 (267, 1570) (69.8%). Had ART not 
been implemented, in the population overall the model predicts there would have been 81994 
(36744, 185140) HIV infections between 2000 and 2010 which equates to an extra 13.2% 
(9567) more infections than otherwise expected. Broken down into key risk groups, general 
females would have accounted for 3872 (17243, 85777) of these infections (an extra 13.5% 
for that risk group), 9127 (4258, 19847) among clients of FSWs (extra 13.7%), and1040 (488, 
2389) HIV or 14.8% more infections among FSW.  These two interventions did not occur in 
isolation, but concurrently. However, the number of infections averted due to the two 
interventions will not be the sum of the separate estimated impact as they both affected the 
same population sub-groups but in different ways. In absence of both interventions, there 
would have been an expected 88882 (39350, 204256) infections in the population overall, of 
which 39903 (17684, 91418) would be in general females, 13099 (5997, 29116) in clients 
and 1776 (799, 4185) in FSW. That is, the two interventions were estimated to result in an 
aversion of 16455 HIV infections in total, or 22.7% of all incident infections. 
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Figure 3: Incident infections and infections caused by risk group 2000 - 2010 
 
 
Figure 4: Prevalence by risk group 2000 - 2010 
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The model was then used to project trajectories under current conditions to assess the impact 
of other intervention strategies which may be considered for implementation in the future. 
The projection for future prevalence and incidence under current conditions is presented in 
Figures 5 & 6 and Table 3 (N.B. In Figures 5 & 6 trajectories for General Males, General 
Females and ATS overlap). 
 
Figure 5: Prevalence by risk group 2011 - 2020 
 
 
Figure 6: Incident infections by risk group 2011 - 2020 
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The projected incidence for increasing condom use for non-transactional sex in heterosexuals 
can be seen in Table 4. If condoms are used in 10% of all relevant acts, we could expect 11.2% 
less infections across the entire population. If condoms are used in 20% or 40% of acts, this 
increases to 23.7% or 44.8%. Population groups that would benefit most, in terms of absolute 
numbers, from such an intervention would be general males and general females who 
proportionally have the most infections averted due to the largest population sizes. 
Increasing the prevalence of circumcision in men from 5% to 10, 15 and 20%, in the 
population overall would avert an estimated 708 (182, 3284), 1382 (355, 6401) and 2051(528, 
9485) infections in the years 2011 to 2020 respectively, translating to 2.4, 4.7 and 6.9% as 
seen in Table 5.  The greatest benefit is seen in general males at low-risk of infection and an 
increase in circumcision to 10% will avert 3.6% of infections; increasing circumcision levels 
to 15% is estimated to avert 7% of infections in this group and circumcision levels of 20% is 
estimated to avert 10.4% of infections among the general male population. Male clients of 
sex-workers would likely gain almost as much benefit as other males, with a corresponding 
3.4% (100 infections), 6.9% (200 infections) and 10.3% (299 infections) reduction in 
incidence.  
Decreasing the percentage of shared injections for those IDU who share, from 60% to 45%, 
was projected to avert 249 (55, 697) or 34.7% of new HIV infections in IDUs over the next 
10 year period as show in Table 6. As the IDU population in Cambodia is relatively small, 
this intervention would lead to only a 1.1% reduction in incident infections the population 
overall. If it is possible to reduce the proportion of shared injections for those who share to 
15%, 587 (138, 1761) or 81.9% of infections that would otherwise be expected for IDUs 
could be averted. There is a small flow-on effect for this intervention in general females with 
reductions in incidence from 0.5-1.3% (72-179 infections averted). 
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Increasing the scale-up of antiretroviral use, by raising the treatment-eligibility criteria from a 
CD4 count of 350 to 500, with treatment initiation for all diagnosed individuals and assuming 
no change in testing rates, approximately 240 (65, 1048) infections (0.8%) would be averted 
from 2011 to 2020 in the overall population. This reduction increases to 2.1% if testing rates 
in general males and females were raised from 4% to 10% and would increase again to 3.7% 
with a testing rate of 20%. With no change in current testing rates, by treating all of those 
diagnosed, approximately 3127 (791, 14494) of otherwise expected infections would not 
occur in the overall population, equivalent to 10.5%. This increases to 15.4% and 21.5% if 
the testing rate for general females and males rises to 10% and 20% respectively. These are 
presented in Tables 7 & 8. 
As shown in Figure 6, the most at-risk populations in terms of incidence are general females 
and males and clients of female sex workers. In terms of HIV prevalence (Figure 5), IDUs are 
clearly an important risk-group with prevalence greater than 20%. It is important to ensure 
that all key groups are targeted when implementing health policy and no single intervention 
will do this. Therefore, it is necessary to combine interventions that will be effective at 
reducing incidence in these groups whilst still remaining feasible in terms of implementation 
and acceptance to those whom are targeted. The resultant trajectories for the combination of 
some interventions is presented in Table 9. A public health policy that results in: an HIV 
testing rate in the general (those not belonging to higher-risk groups) population of 10%; 
provides access to treatment for all of those diagnosed; and reduces the proportion of shared 
injection acts to 30% would reduce incidence overall by 16.9%, with reductions in individual 
risk groups varying between 10.5% and 70.3%. Increasing the testing rate in the general 
population to 20% would result in a reduction of 22.9% overall with reduction in risk groups 
varying between 21% and 70.6%. These increase to 31.2% and between 26.3% and 70.7% 
respectively with an increase in condom use for non-transactional heterosexual sex acts to 10%
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Discussion 
 
As expected, when evaluating past interventions, the combination of 100% CUP and the 
introduction of antiretroviral treatment was more effective at averting infections than either 
programme in isolation with 18.5% (17.1%, 19.4%) infections averted. When analysing 
either intervention separately, it is interesting to note that whilst the introduction of ART 
reduced incidence more overall (11.7% vs. 7.6%), 100% CUP was more effective in FSWs 
(41.1% vs. 12.9% averted) and in clients (29.6% vs. 12%). This highlights the importance of 
continuing efforts in sexual education and  condom promotion in commercial sex-acts, 
especially with the numbers of indirect sex workers increasing as brothels are closed down in 
Cambodia [4].  
In terms of future interventions, as a stand-alone initiative, an increase in condom use in 
heterosexual non-transactional sex acts provided the highest reduction in incidence in the 
projected epidemic trajectories, followed by provision of treatment to all. Whilst needle-
syringe programmes currently seem to not benefit the population overall, even small 
reductions in sharing of injecting equipment result in large decreases in incidence, making it 
an important harm-reduction strategy for IDUs. Additionally, if the numbers of those who 
inject were to increase, the potential benefit of scaling up NSPs is likely to be even greater 
than currently estimated. 
When considering the implementation of public health policies, it is important to consider the 
acceptability and feasibility of their implementation. Not only do we mean in a fiscal sense in 
terms of funding and possible infrastructure required, but also the acceptability of the 
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interventions to the people to whom such policies are targeting. For example, in a country 
such as Cambodia where rates of male circumcision are already extremely low, it is not likely 
that an intervention promoting adult male circumcision would have a high uptake rate. 
Increased condom use may be more successfully implemented, but without continued 
promotion and education, there is a risk that condom-fatigue will occur and rates drop to 
previous levels.  
Needle and syringe programs and increased access to testing and antiretroviral treatment are 
highly effective at reducing incidence and provide additional health benefits to the individual. 
Both of these schemes however, require infrastructure for their implementation and 
expansion. For Cambodia, this would likely require funding from government and 
international sources. Large financial investments required to significantly increase treatment 
coverage is likely to be a limiting factor in its implementation.  It is not realistic to consider 
universal testing and treatment of all diagnosed individuals in Cambodia, as has been 
proposed [20]. In addition, some people may refuse to test for HIV or may refuse medication 
upon diagnosis. As this is the choice of the individual, it is an important ethical issue to 
consider the removal of such right as part of a universal testing and treatment programme. 
However, the substantial epidemiological benefits that can be gained through using treatment 
as prevention is likely to be highly worth increased investment to ensure that at least people 
who have advanced disease progression and need therapy to reduce the risk of HIV-related 
morbidity and mortality receive this life-sustaining therapy. Adherence to ART may also 
become an issue in the future as patients live longer, with increased risk of drug resistance 
development. Consequently, it is also important to procure more expensive second- and 
subsequent lines of antiretroviral therapy. 
Our model has limitations due to the data sourced for its construction. Behavioural surveys 
are conducted only every 3 or 4 years, the risk groups studied change between reports and do 
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not cover all groups of interest in this model. Similarly, little is known about the behaviour of 
the general lower-risk population and the two household census surveys conducted in 
Cambodia are the main source of data. Population sizes of the most-at-risk groups are 
difficult to determine and can influence the outcomes of the model. The model can be 
improved by more behavioural and sentinel surveillance data, General females may have 
lower-risk behaviour but are most-at-risk of infection. Unknown sexual risk behaviours have 
been calibrated for the overall populations groups. Other studies have shown that strata of 
risk is important, but generally only for interventions targeting individuals. As the model had 
been calibrated to reflect the epidemiology of each group, unidentified strata of risk 
behaviour would not substantially influence the overall levels of transmission with respect to 
primary transmissions and prevent infections. However, there is a possibility that secondary 
transmissions could be affected. The emerging IDU population and the shift in sex workers 
from direct brothel-based type to the indirect entertainment-worker type may pose new 
challenges in the fight against the epidemic and should continue to be monitored. Another 
limitation is that we are required to estimate proportions of people in each CD4 category 
using best available knowledge on disease progression as CD4 count is not routinely reported 
for people newly diagnosed in Cambodia. As transmission probabilities are based on disease-
stage, any improvements in this reporting could only improve the model predictions further. 
We have not conducted a cost-effectiveness analysis in this study. In addition to the 
considering the benefit gained from possible interventions discussed in this paper, it would be 
useful to determine benefit gained in terms of quality-adjusted life years gained and to 
investigate if any schemes would be cost effective or even, cost saving. 
This modelling study has demonstrated that past public health programmes have been 
effective and that in order to mitigate future epidemic trends combinations of interventions 
should be implemented that target all populations at risk of HIV infection. As HIV still 
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affects numerous groups in Cambodia, it is important that public health surveillance, coupled 
with knowledge of  routes of transmission, remain in place to inform the prioritization of 
public health strategies and allocation of resources. In 2009, Sopheab et al. [4] presented the 
findings of the first national population-based survey that was conducted in 2005. This study 
investigated HIV transmission in the general population to estimate patterns of prevalence in 
men and women aged 15-49 years, not just the most-at-risk groups. Numerous observations 
from this study support the hypothesis that the predominant source of new infections among 
men is related to sex-work and that new infections in women are generally caused by 
transmission from spouses. The model supports the hypothesis that sex-work was originally a 
predominant driver behind infections in the past and is still a source currently, but less so. 
Prevalence in sex-workers of both types and their clients has declined, as has the proportion 
of infections attributed to sex workers from ~11% to less than ~3%. The proportion of all 
infections represented by general females is almost equal to that represented by general males 
and clients, the predominant groups of whom these women would be married to. As the 
percentage of infections caused by FSW (and to a smaller extent, clients) has decreased, there 
has been a corresponding increase seen in general females and males. This also supports the 
hypothesis that low-risk are generally becoming infected due to their spouse or ‘sweetheart’ 
(term used to describe their regular sexual partners). It was also reported in the Country 
Progress Report for Cambodia [12] that the epidemiological data presented in the 2010 
Behavioural Sentinel Surveillance (BSS)  and the "Estimation of HIV Prevalence among 
General Population in Cambodia 2010" Report [21] shows that there is a real risk of a second 
wave of new HIV infections among female sex workers, men who have sex with men (MSM) 
and injecting drug users (IDUs).  Due to forced brothel closures, Cambodia has seen a rapid 
increase in non-brothel-based sex work in massage parlours, beer gardens and karaoke bars. 
This diversification of sex-work increases the difficulty for outreach programmes to reach the 
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women and their clients with HIV prevention services, especially as many of these women do 
not identify themselves as being in the sex trade. Additionally, the BSS shows that condom 
use for ISW with their sweethearts remain low. As model-predicted prevalence is still high 
among those women who were originally classified as DSW, we believe any relaxation in 
their adherence to safe-sex practices, work-based or otherwise, would pose a risk for a new 
wave of infections. For MSM and IDU, it was identified that there is need for capacity 
building and additional resources in order to scale up national HIV prevention programmes. 
In the report “Estimation of HIV Prevalence among General Population of Cambodia” [21] it 
was shown that men who have sex with men and women (MSMW) consistently have higher 
prevalence of HIV than exclusively homosexual or heterosexual men. When prevalence is 
stratified by age, those aged 35-44 years have the highest prevalence in all three groups, with 
MSMW estimated to be at 14.3%. Similarly, survey data ([17] [27]) have revealed that whilst 
over 90% of IDUs knew where to get clean needles and syringes, 35.5% shared a needle and 
syringe at last injection (including those who never share) and only 53% were aware that 
Voluntary Confidential Counselling and HIV testing (VCCT) services were available in their 
community. With model-predicted prevalence for MSM and IDU  greater than 10% and 20% 
respectively, we agree identification of addressing male sexual health needs in order to 
destigmatise MSM and the provision of quality needle and syringe programmes (NSP) and 
methadone maintenance treatment (MMT) to IDUs as necessary interventions and guidelines 
have been put into place for their implementation [12]. More recently, a small programme 
focusing on heroin users has been implemented. A methadone maintenance treatment (MMT) 
as a secondary harm-reduction intervention for IDUs was established in July 2010. As of 
October 2010, only 61 of the estimated 1,500-10,500 heroin users were enrolled [23]. 
Primary harm reduction is still lacking. As of 2009 in Cambodia there were only two non-
government organisations licensed to provide a limited number of syringes to IDUs in Phnom 
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Penh [24]. This leaves great scope for health strategies to be targeting IDUs with the scale-up 
of provision of clean injecting equipment and education for needle and syringe safety for 
those inject.  
In conclusion, it is important for any future public health policy to include strategies that 
protect those who have lower-risk behaviours but remain at risk of infection due to their 
relationship type – for example women who are spouses of men who participate in 
transactional sex and injecting drug users. Interventions such as promoting condom use, 
increasing testing rates and scaling-up the provision of ART in combination provide the most 
benefit. 
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Abstract 
Objective: To evaluate the potential impact of the current global economic crisis (GEC) on 
the spread of HIV. 
Design: To evaluate the impact of the economic downturn we studied two distinct HIV 
epidemics in Southeast Asia: the generalized epidemic in Cambodia where incidence is 
declining and the epidemic in Papua New Guinea (PNG) which is in an expansion phase. 
Methods: Major HIV-related risk factors that may change due to the GEC were identified and 
a dynamic mathematical transmission model was developed and used to forecast HIV 
prevalence, diagnoses, and incidence in Cambodia and PNG over the next 3 years. 
Results: In Cambodia, the total numbers of HIV diagnoses are not expected to be largely 
affected. However, an estimated increase of up to 10% in incident cases of HIV, due to 
potential changes in behavior, may not be observed by the surveillance system. In PNG, HIV 
incidence and diagnoses could be more affected by the GEC, resulting in respective increases 
of up to 17% and 11% over the next 3 years. Decreases in VCT and education programs are 
the factors that may be of greatest concern in both settings. A reduction in the rollout of 
antiretroviral therapy could increase the number of AIDS-related deaths (by up to 7.5% after 
3 years).  
Conclusions: The GEC is likely to have a modest impact on HIV epidemics. However, there 
are plausible conditions under which the economic downturns can noticeably influence 
epidemic trends. This study highlights the high importance of maintaining funding for HIV 
programs.  
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Introduction 
 
The Asian Economic Crisis in 1997 led to a slowdown in HIV programs in many Southeast 
Asian countries [1, 2]. Similar reductions could occur due to the current Global Economic 
Crisis (GEC). While the potential impact of the GEC on the spread of HIV is unclear, falling 
government revenues may lead to reductions in international aid and funding for HIV 
programs in developing countries. Economic conditions may also have an indirect impact on 
HIV epidemics by affecting the behavior of some people (e.g. due to unemployment) which 
may influence HIV transmission. To evaluate the potential impact of the GEC on HIV 
epidemics we focused on two contrasting epidemics in Southeast Asia. We investigated the 
well-defined and generalized epidemics in Cambodia (where incidence is declining) and 
Papua New Guinea (PNG) (where incidence is increasing). 
Cambodia is particularly vulnerable to global financial perturbations due to its reliance on 
international exports.  After strong growth in recent years Cambodia’s economy has slowed 
markedly [3]. It has also felt the effects of political instability in Thailand, one of the main 
transit points for Cambodia, and  experienced similar decreases in tourist arrivals [3]. Though 
Cambodia’s HIV epidemic is declining the infection has invaded diverse population groups. 
The decline in incidence and prevalence has been linked to behavioral changes in sex work 
with an increase in condom use between sex workers and clients and a decrease in the 
number of men visiting sex workers [4-8]. There has also been a strong commitment from the 
Cambodian government and external donors resulting in targeted public health interventions 
and a large scale-up of antiretroviral therapy (ART) for people with HIV infection.  
The economy of PNG has been underpinned by high commodity prices in recent years, 
leading to relatively strong economic growth. The GEC is expected to reduce this growth 
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because of reductions in exports and commodity production. In addition, PNG’s already high 
unemployment rate is expected to further increase especially in the mining industry; ~80% of 
adults do not have formal employment and an estimated 40% of PNG’s population live in 
poverty [9]. Since 1994, PNG has been experiencing a steadily increasing HIV epidemic with 
cases detected in all regions of the country. HIV is mainly transmitted heterosexually but key 
factors that have been linked to HIV transmission in PNG include transactional sex, mobility, 
sexual violence, and gender inequality [10-12]. Recent programs have led to increases in 
condom use and HIV testing, with first-line ART being rolled out in numerous provinces. 
Most HIV programs are newly established and may be relatively fragile to economic 
reductions.  
To investigate the potential impact of the GEC on HIV epidemics in Cambodia and PNG, 
mathematical models incorporating country-specific behavioral and epidemiological data 
were developed for both settings. These models were calibrated to accurately reflect the past 
and present HIV incidence, HIV prevalence, and the number of people on ART in each 
country. The models were then used to forecast epidemic trajectories over the next 3 years 
under assumptions that behavioral or program conditions may change due to economic 
conditions.  
Methods  
 
We carried out detailed discussions with key stakeholders and representatives from national 
HIV bodies in Cambodia and Papua New Guinea, as well as economists, behavioral 
researchers, and international policy and development experts (listed in acknowledgements). 
A list of major HIV-related risk factors were identified that may change as a result of the 
GEC (Table 1). These factors were grouped into two categories: (i) those that have direct 
effects on HIV/AIDS program resources and (ii) those that may affect the social and 
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behavioral interactions of individuals. This list is not exhaustive and other factors may be 
influenced by changes in the economy, however, these factors are thought to be the most 
important for potentially affecting HIV epidemics.  
Direct effects on program resources 
The GEC makes commitments of overseas development assistance more uncertain.  In 
Cambodia and PNG only a small proportion of funding for HIV responses comes from their 
own governments, with the majority of assistance coming from international funding 
agencies such as the Global Fund and AusAID. Some donors have signaled their intention to 
scale back their aid budgets. Reductions in program funds may lead to:  
1) Decreases in voluntary counseling and testing (VCT) services, resulting in a decrease in 
testing rates, counseling and other prevention services.  This may lead to a reduction in 
condom use and testing of the general population. 
2) Decreases in education and prevention activities. If there is a reduction in media 
campaigns and other educational activities then condom use may decline and the rate of 
partner change may increase.  
3) Changes in the availability of ART or slowed rate of increase in provision. In Cambodia 
there is almost universal access (~85%) to first-line ART for eligible individuals. In PNG 
provision of ART is currently scaling up; currently ~30% in need have access and the plan is 
to increase this to ~50-70% over 5 years. The majority of ART provision in both countries is 
externally funded and external economic pressures could have a significant impact on 
treatment strategies. 
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Behavioral and social factors 
The GEC could have complex behavioral and social effects on heterogeneous groups of 
people. Key behavioral factors relevant to HIV epidemics that may be influenced by the 
economy include:  
1) Increases in unemployment. The economic downturn may lead to increased unemployment 
and to support themselves some unemployed women may turn to transactional sex work. The 
number of sex workers (supply) could increase, but the number of men engaging their 
services (demand) may decrease. In Cambodia it is anticipated that the total number of 
women seeking to engage in direct and indirect sex work will increase over the short-term, 
mainly due to a decline in the garment industry. Reductions in tourist arrivals in Cambodia 
will also decrease the demand for sex work. In PNG, a relatively large proportion of women 
engage in transactional sex of some form. As money is not always involved in transactional 
sex, it is expected that transactional sex work could increase. However, newly unemployed 
individuals in PNG are likely to stay with their extended family in the short term and may not 
initially turn to transactional sex work. 
2) Decrease in injecting drug use in Cambodia. The majority of drug use in Cambodia 
involves an amphetamine type stimulant (ATS); however, there is a small population of 
injecting drug users (IDUs) in Cambodia. With disposable income likely to decrease, use of 
intravenous drugs could be expected to decrease.  
3) Change in alcohol consumption and the prevalence of violence in PNG. There are very 
few IDUs in PNG [13], however, alcohol is commonly brewed at home and its consumption 
is expected to increase with higher unemployment. Alcohol consumption is linked with 
decreased condom use and increased sexual assault which also tends to be unprotected. 
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4) Change in migration patterns. A decrease in employment could lead to male migrant 
workers returning home in Cambodia, particularly in the declining construction industry. In 
PNG, there is net population growth in urban settings due to rural-to-urban migration. It is 
expected that increased unemployment will reduce the flow of people moving from rural to 
urban settings. Though people losing employment from the mining sector in PNG may go to 
towns and cities for other employment, the expectation is for a net decrease in migration rates 
to urban areas. 
 
Table 1: Assumed change in HIV-related risk factors due to the economy 
Risk factor Potential change within 12 months 
HIV programs Cambodia PNG 
VCT services Optimistic HIV testing steady 
condom use steady 
HIV testing steady 
condom use steady 
Intermediate HIV testing rate ↓  
5% 
condom use ↓  5% 
HIV testing ↓  7.5%  
condom use ↓  7.5% 
Pessimistic HIV testing  rate↓  
10% condom use ↓  
10%  
HIV testing ↓  15%  
condom use ↓  15% 
Education and prevention Optimistic condom use steady 
partner change 
steady 
condom use steady 
partner change 
steady 
Intermediate condom use ↓  5% condom use ↓  5% 
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partner change ↑  3% partner change ↑  
3% 
Pessimistic condom use ↓  10%  
partner change ↑  5% 
condom use ↓  10% 
partner change ↑  
5% 
Availability of antiretroviral 
therapy (coverage of 
diagnosed) 
Optimistic ↑  10% over 5 years  ↑  40% over 5 years 
Intermediate ↓  2.5% over 5 years ↑  25% over 5 years 
Pessimistic ↓  5% over 5 years ↑  10% over 5 years 
Change in behavior of people Cambodia PNG 
Unemployment Optimistic 
 
no. sex workers 
steady 
demand for SW ↓  
10%  
no. sex workers 
steady 
demand for SW 
steady 
Intermediate  no. sex workers ↑  
10%  
demand for SW ↓  5%  
no. sex workers ↑  
5% 
demand for SW ↑  
5% 
Pessimistic no. sex workers ↑  
5% 
demand for SW 
steady 
no. sex workers ↑  
10% 
demand for SW ↑  
10% 
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Injecting drug use 
(Cambodia); Change in 
condom use and sexual 
activity due to alcohol 
consumption (PNG)  
 
Optimistic drug use ↓  10%  condom use steady 
sex activity steady 
Intermediate drug use ↓  5% condom use ↓  10%  
sex activity ↑  5%  
Pessimistic drug use steady condom use ↓  20% 
sex activity ↑  15% 
Migration Optimistic regular partners 
steady  
Steady, 15% in 
urban 
Intermediate contact w/ partners ↑  
7.5%  
14% in urban 
Pessimistic contact w/ partners ↑  
15% 
13% in urban 
Absolute changes are assumed for condom use and treatment uptake; others are relative 
changes. 
 
Mathematical model 
To describe the history of HIV epidemics and to forecast potential epidemic trends in the 
future, a mathematical transmission model and a static risk model were developed (specific 
details of these models are presented in the Supplemental Digital Content). These models 
describe the risk of HIV acquisition for six population subgroups: 1) general males, 2) male 
clients of female sex workers (including pimps and other core groups of men), 3) men who 
have sex with men (and possibly women) (MSM), 4) injecting drug users (IDUs), 5) general 
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females, and 6) female sex workers (FSWs). The PNG population is divided into rural (85% 
of total population) and urban settings, with clients and FSWs only living in urban areas. 
Heterogeneous interactions between all of these population groups is included to reflect the 
complex and polymorphous nature of sexual behavior and mixing in these settings [14]. 
Parameter assumptions for the models are presented in Table 2. Data specific for each setting 
was used to inform the mathematical models; where data was unavailable for Cambodian 
populations, data from Thailand was used. All model simulations and calculations were 
executed with Matlab® R2009a.  
The transmission model describes the overall population-level transmission of HIV using 
four ordinary differential equations. These equations describe the temporal change in the 
number of people who are susceptible, HIV-infected but undiagnosed, diagnosed with HIV, 
and on ART. A schematic diagram of the model is shown in Figure 1; this schematic is 
replicated for urban and rural settings in PNG with migrating people remaining in the same 
disease stage. In Cambodia we assume that migration describes the movement of workers 
between their workplace and home. Thus, any increase in unemployment likely results in 
men having more contact with their regular partner at home. Any migratory increase of the 
number of FSWs in Cambodia is incorporated in the increasing unemployment scenario. This 
model was used to forecast potential trends in HIV epidemics from 2009 to 2012 for each 
scenario in Table 1.  
To more accurately account for the variation in HIV risk and prevalence in each population 
group, a static risk equation model was used to estimate the probability of HIV acquisition 
per uninfected person per year. The static risk equations, weighted by the population sizes, 
were consistent with the overall population-level ‘force of infection’ term for incidence in the 
dynamic models applied to Cambodia and PNG. The annual risk of acquiring HIV infection 
per uninfected person was calculated for each population group and as a weighted average 
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across all groups. These risks were calculated for 2009 and 2012. The potential change in 
annual risk of acquiring HIV per uninfected person due to the GEC was then calculated. The 
estimated number of people on treatment in 2012 was provided by the transmission model.  
Table 10 
Parameter Cambodia Urban PNG Rural PNG 
Males 
Average number of regular sexual partners per 
year 
0.58a 2[15, 16]  2[15, 16] 
Average number of casual sexual partners per 
year 
0.88 a 6.9[11, 17, 
18] 
9a 
Condom use in casual partnerships with general 
females 
30%[12, 19-
21] 
10%[16] 10%[16] 
Condom use in regular partnerships with general 
females 
30%[12, 19-
21] 
5%[17] 5%a 
Prevalence of HIV 0.8% [14, 
22] 
1%[23] 2%[23] 
Prevalence of other sexually transmitted 
infections 
1% a 5%[23-26] 15.7%[25] 
Male clients of female commercial sex workers 
Proportion of the population 6.5%[27] 26% 0%a 
Number of visits to sex workers per year 62[28, 29] 18[10, 11, 
15, 30] 
N/A 
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Condom use in acts between clients and sex 
workers 
95%[28] 60%[16, 17] N/A 
Prevalence of HIV 5% a 2%[23] N/A 
Prevalence of other sexually transmitted 
infections 
1.5% a 1.5%[23-
26] 
N/A 
Men who have sex with men (MSM) 
Proportion of the population 1.5%[22, 
31-35] 
3%[16, 17] 3%[16, 17] 
Average number of male sexual partners per 
year 
25[28, 36] 30[11, 17] 5a 
Average number of female sexual partners per 
year 
3[28, 36]  30[11, 17] 10a 
Condom use in penetrative acts between MSM  80%[28, 36] 23%[11, 17, 
23] 
7.5%a 
Condom use in penetrative acts between MSM 
and women 
80%[28, 36] 50%[11, 17, 
23] 
7.5%a 
Prevalence of HIV 7.5%[36]   2.5%a 3%a 
Prevalence of other sexually transmitted 
infections 
1.3%[28, 
36] 
20%[11] 20%a 
Injecting drug users (IDUs) 
Proportion of the population 0.25% [37-
41]  
0%a 0%a 
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Average number of injecting partners per year 2[42] N/A 
Average frequency of injecting per year  400[43-45] N/A 
Percentage of injections using equipment from 
other IDUs  
15%[42] N/A 
Percentage of shared syringes that are cleaned 
before re-use 
70%[46] N/A 
Average number of regular sexual partnerships  0.5 females 
0.25 FSW 
[21, 47, 48] 
N/A 
Average number of contacts IDUs have with 
FSWs per year 
2[21, 47] N/A 
Prevalence of HIV 15%[46] N/A 
Prevalence of other sexually transmitted 
infections 
16%[46] N/A 
Females (including those that engage in transactional sex) 
Prevalence of HIV 0.8%[49, 
50] 
1.5%[23] 2%[23] 
Prevalence of other sexually transmitted 
infections 
1%[51] 6%[24, 25] 15.7%[25] 
Sexual behavior parameters Balance with male behavioral values 
Female commercial sex workers (FSWs) 
Proportion of the population 1.5%[52-54] 2%[10] 0%a 
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Average number of regular sexual partnerships 0.5[28, 36] 1.4[10, 11, 
55] 
N/A 
Condom use in acts between FSWs and regular 
partners 
85%[28, 56] 40%[16, 17] N/A 
Average number of casual sexual partnerships, 
outside sex work, that FSWs have per year 
3.2[28, 36] 8.9a N/A 
Condom use in acts between FSWs and casual 
partners 
80%[28, 36] 60%[10, 23] N/A 
Prevalence of HIV 15%[49] 15%[30, 57, 
58] 
N/A 
Prevalence of other sexually transmitted 
infections 
3.5%[51] 25%[30, 59] N/A 
Sexual activity between FSWs and clients Balance with client behavioral values 
a: Assumption. The population is split 1:1 between men and women for Cambodia and 1.2:1 for 
PNG [60]. The model also assumes the following. The presence of an STI increases HIV 
transmission risk by 4-5 fold [61-63]. A casual partnership involves 1 penetrative sex act and a 
regular partnership involves 75-100 acts per year. The baseline probability of HIV transmission 
per sexual act is 0.0008 for female-to-male transmission [64, 65], 0.001 for male-to-female 
transmission [64, 65], and 0.008 for male-to-male transmission [66]. Treatment reduces the 
transmission rate by 95% [67]. HIV transmission risk using a contaminated needle/syringe is 
0.008 [68, 69]. The effectiveness of condoms is 90% [70, 71] and cleaning of syringes has 
effectiveness of 75% [72, 73]. People remain in the sexually mixing population for 45 years for 
PNG and 35 years for Cambodia, the rate of diagnosis of HIV-infection (i.e., testing rate) 
increased linearly from 0.14 (2003) to 0.5 (2009) for Cambodia, and is taken to be 0.2 for urban 
PNG and 0.12 for rural PNG. The time from infection to AIDS-related death for untreated HIV-
74 
 
infected individuals is 10 years [74-76], and rate of death for treatment-eligible individuals on 
ART is 0.05 [77-80]. The rate at which diagnosed cases initiate therapy is taken to linearly 
increase from 0 in 2003 to 1.2 in 2009 for Cambodia. Before 2009, this rate is taken to be 0.25 
and 0.125 for urban and rural PNG, respectively, and then increases to match treatment plans. 
The rate at which HIV-infected people on ART stop treatment is assumed to be 0.5. 
 
 
 
 
 
 
 
 
 
Results  
 
The dynamic transmission model accurately reflected the HIV epidemics in Cambodia and 
PNG (Figure 2). Forecasts of the expected impact of the economic crisis on HIV diagnoses, 
incident infections, and prevalence, for intermediate assumptions (Table 1) suggest that the 
GEC may have a relatively modest impact on the HIV epidemics in these countries.  
In Cambodia, HIV incidence may increase moderately (by an estimated maximum of ~10% 
over three years) if changes in VCT and education lead to reductions in HIV testing and 
Figure 1: Schematic diagram of mathematical model 
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condom use, and increases in partner change (Figure 2b). The increase in incidence is not 
expected to translate into increases in HIV diagnoses. The change in the number of HIV 
diagnoses due to the GEC is likely to be minimal (Figure 2c) because the GEC is expected to 
cause only a small increase in the overall number of undiagnosed people living with HIV, 
even with the expected changes to VCT.  
In contrast, HIV incidence and diagnoses in PNG could be considerably affected by the GEC 
(Figures 2e, f). Intermediate assumptions for increased violence and alcohol use could lead to 
increases in incidence and new diagnoses of 17% and 11% respectively over 3 years. 
Pessimistic assumptions (Table 1) could lead to larger increases in incidence and new 
diagnoses, however, moderate assumptions for most potential scenarios lead to relatively 
little change (Figures 2e, f). For PNG the model predicts that there will be a slight decrease in 
diagnoses in the scenario of decreasing VCT as less people will be tested each year.  
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Figure 2: Model-based projections for Cambodia and PNG based on changes due to the 
economy: (a) HIV prevalence in Cambodia; (b) HIV incidence in Cambodia; (c) number of 
diagnoses in Cambodia; (d) HIV prevalence in PNG; (e) HIV incidence in PNG; (f) number 
of diagnoses in PNG. The blue dots represent available data in these countries since 2004. 
Figure 2a 
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Figure 2b 
 
 
 
Figure 2c 
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Figure 2d 
 
 
 
 
Figure 2e 
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Figure 2f 
 
Figure 3 illustrates the estimated change in the risk of HIV acquisition for each population 
subgroup. The factors of greatest concern in Cambodia are decreases in VCT and education. 
These particularly affect male clients and FSWs. For these population groups increased 
unemployment is likely to reduce HIV risk due to decreased demand for sex work (Figure 3a). 
However, the increase in the number of sex workers in the population means that the number 
of new HIV infections among FSWs is expected to increase. In PNG, the factors of greatest 
concern are increases in violence and alcohol, decreases in ART roll out, and decreases in 
VCT and education (Figure 3b). Increasing unemployment in PNG is expected to lead to only 
a minimal increase in risk for clients and negligible change in risk for FSWs. Similarly, 
migration away from urban areas has minimal effect on risk because the majority of people 
live in rural areas. Finally, changes in ART roll out in PNG have a larger effect on clients and 
FSWs because treatment is more accessible in urban areas. These results suggest that the 
effects of the economy on HIV programs could have a greater impact on epidemics than 
those related to unemployment. 
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Figure 3: Change in HIV incident risk per person in each population group (blue dots) and overall (red dots) 
due to the economic crisis in (a) Cambodia and (b) PNG. Error bars denote incident risk due to optimistic and 
pessimistic assumptions. For PNG the results for Male Clients and FSW only apply to urban settings. For other 
population groups the change in risk is for the urban and rural populations combined. In our model we assumed 
there were no IDUs in PNG. 
Figure 3a 
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Figure 3b 
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The models predicted that a reduction in ART coverage or rollout has little impact on HIV 
incidence and diagnoses (Figure 2). However, ART may have a significant impact on the 
number of HIV/AIDS-related deaths. The model suggests that the coverage of ART is the 
most important factor determining the number of AIDS-related deaths in Cambodia over the 
next 3 years; however, the total number of deaths is unlikely to be highly influenced by the 
GEC: -1.2% in the optimistic case, ~0.4% in the intermediate case, and ~0.8% increase in 
HIV deaths for the pessimistic case. In contrast, the number of AIDS-related deaths in PNG 
could be highly affected by economic change. ART availability is being scaled-up 
substantially in PNG from the relatively low levels at present. If the economy reduces this 
planned provision of ART then it could greatly affect the number of AIDS-related deaths (by 
~10%). In PNG other factors that lead to increased incidence (such as decreases in condom 
use) can also result in increases in AIDS-related deaths. The combined effect of all possible 
scenarios in PNG (Table 1) results in a ~2.1% increase in AIDS deaths in the optimistic case, 
~7.5% increase in AIDS deaths in the immediate case, and ~14% increase in AIDS deaths in 
the pessimistic case from 2009 to 2012.  
 
Discussion 
 
This study estimated the effect that the GEC was likely to have on selected factors that are 
understood to play an important role in modulating HIV transmission rates. Pessimistic, 
intermediate, and optimistic scenarios were considered for each factor. Mathematical models 
were used to investigate the expected epidemiological effect in Cambodia and PNG to 
determine whether the economic crisis may potentially have a significantly adverse impact on 
HIV epidemics. The model-based results suggest that HIV risk, incidence, and diagnoses will 
be only modestly affected due to the GEC with decreases in HIV programs having a higher 
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impact than changes in unemployment and population movement. Overall, the model predicts 
that HIV epidemic profiles in established and emerging epidemics are not likely to alter 
significantly due to the economic crisis. For example, the effect of the economy on the HIV 
epidemic in Cambodia could be ‘hidden’ by the surveillance system (Figure 2c).  
These findings are consistent with other qualitative reports on the potential impact of the 
global economic downturn on HIV/AIDS epidemics [81]. The current study highlights the 
high importance of maintaining HIV prevention and treatment programs, particularly VCT 
services and the provision of ART, which are largely funded by external sources. VCT and 
ART are well-established in Cambodia with an increase in more costly second-line therapy 
needed as the failure rate of first-line ART increases. In PNG, both VCT services and first-
line ART are relatively new initiatives and are not well-established. Any volatility in these 
programs could be largely detrimental to PNG’s HIV response, which aims to increase VCT 
services and achieve universal treatment access over the next 5-10 years. This volatility in 
external funding suggests that Governments will need to play a greater role in directly 
funding HIV programs. This is particularly pertinent for PNG, where Government 
expenditure for HIV has decreased (despite an increasing epidemic). However, such an 
increase should be considered in the context of other funding priorities such as reducing 
poverty and unemployment, and increasing the provision of food. 
In this study, potential changes in key factors of relevance to HIV and the GEC were 
explored, along with sensitivity ranges around these assumptions. The models developed in 
this study were calibrated to accurately reflect the unique epidemiology of Cambodia and 
PNG and were based on the best data available, but they cannot capture the full degree of 
complexity that exists in transmission-related mixing, behavior, and HIV programs. 
Furthermore, some of the assumptions regarding the impact of the GEC (Table 1) are 
speculative and are not empirically based as there are limited sources of data on how the 
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economic crisis may affect HIV/AIDS program funds or social determinants related to HIV 
risk. More study is required to ascertain such behavioral shifts and to inform the response 
required to prevent adverse consequences for HIV incidence, morbidities and mortalities. For 
instance we assumed that the GEC will decrease drug use in Cambodia, however, it is 
possible that drug use may be stable or actually increase with unemployment [82]; though 
such an increase would have a similar moderate effect on our results. We also assumed that 
any change due to the GEC is maintained from 2009 to 2012 and ignored any potential 
improvements in economic conditions over the short term or behavior changes that are likely 
to have a short duration. Overall, the modeling highlights that prevention efforts must 
continue among the core groups that could be affected by the GEC in both settings (Figure 3) 
and among those most at risk for acquiring HIV. The trends in HIV epidemics are not 
expected to change markedly in the coming years. This may indicate the relative 
independence of HIV risk from economic fluctuations. However, one area where the GEC 
may have an important impact is on those living with HIV. A weaker economy may affect 
access to therapy (e.g., affording transport to clinics) and food security and, hence, disease 
progression. This was not considered in the current model. 
The last decade has been strong economically, enhancing international efforts to manage the 
HIV pandemic [83]. For example, funds have been intensified and mobilized for the large 
scale-up of ART in resource-constrained countries [84]. The majority of funds for HIV 
prevention, care and treatment in Cambodia and in PNG are externally provided from the 
Global Fund, international government development organizations (such as AusAID), and 
non-government organizations. Despite this increased commitment, the United Nations 
health-related targets of the Millennium Development Goals are unlikely to be achieved by 
2015 [85] and all commitments for HIV programs are unlikely to be fully realized. A 
downturn in the funds available for the provisions of antiretroviral drugs may result in 
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declining supplies, a smaller range of medications, particularly second and third line 
medications, and decreased availability to life-sustaining ART for the many people in need. 
This could also result in poorer treatment compliance, increased viral resistance and possibly 
transmission of resistant viral strains. HIV prevention efforts may also be unsustainable due 
to decreases in program funding. A judicious mix of funding sources and disbursement 
channels could be important for responding to HIV epidemics [86]. We are in an age where 
HIV still infects more people than the rate of ART roll-out [87]. It is of very high importance 
that funding for HIV programs are maintained, if not increased, by external donors and 
governments, regardless of the economic conditions.  
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Abstract 
 
There is considerable discussion currently taking place in the international HIV/AIDS 
community around increasing HIV testing and initiating earlier use of antiretroviral therapy 
(ART) among people diagnosed with HIV as a prevention method to reduce the spread of 
HIV infection.  In this study we explore the expected epidemiological impact of adopting this 
strategy in a relatively small population in which HIV transmission is predominantly 
confined to men who have sex with men (MSM). A biologically realistic deterministic 
mathematical transmission model was constructed to investigate impacts of strategies that 
increase testing and treatment rates and their likely potential to mitigate epidemics of HIV 
among MSM. This model is applied to the population of MSM in South Australia and is 
informed by detailed location-specific data. Results from the model indicate that increasing 
testing rates alone, from the current high levels, will have minimal impact on reducing the 
expected number of infections compared to current conditions. However, in combination with 
increases in treatment coverage this strategy could lead to a 59-68% reduction in the number 
of HIV infections over the next 5 years. Targeting men who are socially engaged with the gay 
community would result in the vast majority of potential reductions in incidence with only 
minor improvements possible by reaching all other MSM. Investing in higher coverage and 
earlier initiation of treatment for the purposes of reducing infectiousness of HIV-infected 
individuals could be a highly effective public health strategy for reducing incidence in a 
population of MSM.  
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Introduction 
 
Currently within the international HIV/AIDS community there is discussion around using 
antiretroviral therapy (ART) as a method of prevention for HIV infection.  Results from a 
modelling study conducted by a World Health Organisation group suggested that annual 
universal testing with immediate commencement of antiretroviral therapy of all those 
diagnosed (a practice known as “test and treat”) could if not eradicate, substantially reduce 
generalised heterosexual HIV epidemics [1]. This proposed strategy is an extension of 
available evidence that the infectiousness of a HIV-infected person is strongly associated 
with their viral load [2] and it is known that ART substantially reduces HIV RNA in plasma 
and genital fluids [3-6]. Additionally, there have been two recent studies that have shown a 
92% reduction in incidence among heterosexual discordant couples in which the HIV-
infected partner was on ART compared with HIV discordant couples in which the HIV-
infected partner was not on ART [7, 8]. Whilst the feasibility of elimination or wide-scale 
implementation of a ‘test and treat’ strategy has been challenged, along with its ethical and 
clinical implications (e.g. [9-11]),  a strategy such as “test and treat” should lead to a decrease 
in HIV incidence due to effective ART resulting in a reduction in average community viral 
loads and therefore infectiousness. The available evidence of ART reducing HIV 
transmission risk is from studies of heterosexuals and there are no available data on the effect 
of ART on transmission for higher risk routes of exposure, such as sharing injecting 
equipment and penile-anal intercourse [12]. Although there have been recent observations of 
decreased population incidence among men who have sex with men (MSM) coinciding with 
decreases in community viral load [13], HIV diagnosis rates among MSM in most resource-
rich countries have increased over the last decade [14-16]. Furthermore, a recent estimate of 
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the per-contact transmission probability of HIV among MSM was found not to differ largely 
from pre-ART estimates [17]. 
Despite the lack of solid evidence for the relationship between HIV transmission and use of 
ART for activities associated with riskier exposures, there has been investment in some 
resource-rich settings for implementation of “test and treat” or “seek and treat” strategies to 
prevent HIV infections occurring from these transmission routes. An evaluation of the new 
guidelines of the expansion of treatment eligibility in British Columbia reports an expectation 
of a reduction in incidence [18] due to the increase in treatment rates where the epidemic is 
largely comprised of MSM and people who inject drugs. It is more feasible to expect a 
proactive implementation of a large-scale program like this in a resource-rich setting. It could 
also be expected that this strategy would be most feasible in a population that is relatively 
small and in which there is a concentrated epidemic among a core behavioural at-risk group. 
This study aims to explore the potential epidemiological impact of a strategy of increasing 
testing and treatment rates when applied to an HIV epidemic in such a setting, namely, South 
Australia.  
Cumulatively to the year 2008 there were 1155 people who were diagnosed with HIV in 
South Australia. Of these diagnosed cases, an estimated 300-400 have died from AIDS or 
other HIV-related illnesses. The majority of infections are attributable to intercourse between 
MSM [19]. Of all diagnosed cases, approximately 76% receive antiretroviral therapy [20]. 
Despite this, there have been moderate but significant increases in HIV diagnoses in South 
Australia over the past 10 years [19]. However, the population of MSM in South Australia is 
also relatively small which may assist in implementation of such a universal strategy across a 
population. There are an estimated 12,000 homosexual and bisexual men in South Australia, 
based on Australian census data and the Australian Study of Health and Relationships [21]. 
This suggests that the HIV prevalence within the MSM population is approximately 6-7%. 
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This rate is considerably lower than the HIV prevalence levels in the Eastern States of 
Australia [21], but substantially higher than that of the general population of South Australia 
at 0.1% [19].  
In this study we investigate the impact of increasing testing rates and using treatment as a 
form of prevention on the trends of HIV infection in South Australian MSM, assuming that 
the relative reductions in infectiousness observed among heterosexuals also applies to 
homosexual exposure; we also investigate a range of relative reduction levels in an 
uncertainty analysis. We forecast epidemic trajectories according to current conditions and 
under scenarios where differing levels of testing and treatment are combined to mirror 
possible public health interventions being implemented. The primary method for these 
projections was the development and analysis of a mathematical transmission model. The 
deterministic compartmental model uses behavioural, clinical and biological data to track the 
number of MSM in South Australia over time that are in progressive stages of HIV disease 
infection and HIV transmission to MSM. The modelled population is also categorised into 
those who are socially engaged with the gay community or to other MSM to reflect the actual 
population as suggested by behavioural and social data [22, 23]. As far as we are aware this is 
the first time any mathematical model has made this distinction and we believe it is an 
important one because public health campaigns are likely to be more effective at reaching 
men who are socially engaged to the gay community. The model was calibrated to reflect the 
past and present epidemiology of HIV in South Australia. The differing outcomes of the 
scenarios were then evaluated for their expected effectiveness in reducing population-level 
incidence. 
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Methods 
 
We developed a mathematical transmission and disease history model for HIV in South 
Australia. The model is based on sets of equations that describe HIV transmission risk for 
various transmission routes via penile-anal intercourse: receptive with ejaculation, receptive 
with withdrawal prior to ejaculation and insertive. These risk equations are used in 
conjunction with a deterministic compartmental model formulated as a system of ordinary 
differential equations. The ordinary differential equations track the number of MSM in South 
Australia over time in each possible state of HIV disease stage: uninfected, infected but not 
yet diagnosed, diagnosed infection but not on treatment and on ART. All HIV-infected 
individuals are classified according to their stage of HIV disease, based on CD4 count: CD4 
count higher than 500 cells per μl; between 350 cells and 500 cells per μl; from 200 cells to 
350 cells per μl; or a CD4 count of less than 200 cells per μl. A schematic diagram of this 
natural history described in the model is presented in Figure 1. The equations used in the 
model are shown in Chapter 3 Appendix.  
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The model accounts for differences in behaviour between men who are engaged with the gay 
community and men who are not, as sexual mixing and risk behaviour influence the risk of 
disease acquisition for an individual.  
We define gay social-engagement to be determined by what degree the social component of a 
person’s life is lived in the company of gay men and if they can be reached through gay male 
networks. Indicators used include the amount of free time spent in gay-specific venues, 
number of gay male friends, the amount of free time spent with them and the number of 
different places men go out with gay male friends. According to the E-Male survey, using a 
set of scales derived by Kippax et al.[24], approximately 47% of MSM in South Australia are 
gay socially engaged [22]. These populations are distinct in identity and behaviour. Men 
interviewed at the 2007 Gay Community Periodic Survey (socially-engaged MSM) self-
reported sexual identities were 86.4% gay/homosexual/queer, 9.5% bisexual, 2.6% 
heterosexual/straight, and 1.6% other [23]. In comparison, for men who participated in the E-
male survey (both non-engaged and socially engaged) the corresponding proportions of 
 
Figure 1: Schematic diagram of HIV natural history and structure of mathematical model 
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responses for sexual identity were 76.5%, 20.8%, 1.5% and 1.2%. As these two groups have 
different behaviours when it comes to number of partners acquired, condom use and HIV 
testing, we model them as distinct groups up until the point of diagnosis. This enables us to 
track how many of each group becomes infected each year and enables forecasting the impact 
of interventions that reach different proportions of each group.  
The model was also informed by behavioural inputs such as changing testing rates over time, 
probability of disclosure of serostatus, sexual positioning and assortativity of partners across 
the two groups. Biomedical inputs into the model included rates of circumcision, 
infectiousness due to disease stage, infectivity due to sexual position, effectiveness of 
treatment, effectiveness of condoms and rate of death due to HIV. All parameter values used 
in the model are shown in Table 1. Crucial to this modelling study is the assumption that HIV 
transmission due to penile-anal sex among MSM is reduced by 92% if the HIV-infected 
partner is on ART, the same relative reduction observed in studied among heterosexual 
couples. However, since there are no data on the relative reduction in infectiousness for 
homosexual partnerships we also conduct a second analysis where we assume an uncertainty 
range of 50-99% reduction in infectiousness.  
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Table 1: Parameter inputs for the mathematical model 
Paramete
r Symbol 
Description Value Reference 
SE
regc  
Average number of regular partners for 
socially engaged MSM (proportion of men 
with a regular sexual partner) 
0.728 [25-27] 
OM
regc  
Average number of regular partners for other 
MSM (proportion of men with a regular sexual 
partner) 
0.518 [25, 27] 
SE
casc  
Average number of casual partners per year for 
socially engaged MSM 
11.504 [25, 27] 
OM
casc  
Average number of casual partners per year for 
other MSM 
8.736 [25, 27] 
SE
regn
OM
regn  
Average number of anal intercourse acts per 
regular partnership per year 
10-50 [25, 27] 
SE
casn
OM
casn  
Average number of anal intercourse acts per 
casual partnership  
1 Assumption  
SE
regr  
Condom use with regular partners 
for socially engaged MSM 
2001 69.09% [25-27] 
2003 69.91% 
2005 68.09% 
2007 65.52% 
OM
regr  
Condom use with regular partners 
for  other MSM 
2001 0.69.22% [25-27] 
2003 70.04% 
2005 68.22% 
2007 65.65% 
SE
casr  
Condom use with casual partners for 
socially engaged MSM 
2001 88.83% [25-27] 
2003 88.23% 
2005 88.71% 
2007 84.63% 
OM
casr  
Condom use with casual partners for 
other MSM 
2001 80.17%    [25-27] 
2003 79.63% 
2005 80.06% 
2007 76.37% 
d   
Probability  that seropositive MSM 
will disclose serostatus in casual acts 
2001 43.2% [25-27] 
2003 39.5% 
2005 48.3% 
2007 36.6% 
d   
Probability  that seronegative MSM 
will disclose serostatus in casual acts 
2001 0.3575 [25-27] 
2003 0.355 
100 
 
2005 0.378 
2007 0.3205 
H  Efficacy of condom protection per act 90-99% [28-32] 
AIDSc  
Multiplying factor for the reduction in number 
of sexual partners for men in AIDS stage 
disease 
0.1 – 0.4 
[33] 
f  
Multiplying factor for the change in number of 
sexual partners post diagnoses of HIV 
infection  
0.4 – 0.9 [34-42] 
SP  
Average time for individuals to ‘retire’ out of 
sexually active population (no longer obtaining 
new partners) 
30-70 years [43] 
SEJ  
Percentage of socially engaged 
MSM that test for HIV infection 
each year 
2001 57% [25-27] 
2003 61% 
2005 60% 
2007 65% 
OMJ  
Percentage of other MSM that test 
for HIV infection each year 
2001 38% [25-27] 
2003 41% 
2005 40% 
2007 43% 
SE
lt
200/1 J
OM
lt
200/1 J  
Average time from the beginning of AIDS 
before individual is likely to be diagnosed with 
infection 
2-4 months [33] 
500/1 Z  
Average time (without ART) for HIV-infected 
individuals to progress from CD4 count >500 
to CD4 count 350-500 
2.95 (1.79-
4.42) years 
 
[44] a  
500350/1 Z  
Average time (without ART) for HIV-infected 
individuals to progress from CD4 count of 
350-500 to CD4 count of 200-350  
1.96 (1.81-
2.13) years 
 
[44] a  
350200/1 Z  
Average time (without ART) for HIV-infected 
individuals to progress from CD4 count of 
200-350 to CD4 count <200  
1.96 (1.81-
2.13) years 
 
[44] a  
500G  
HIV-related death rate for patients with CD4 
count >500 cells per μL and detectable viral 
load 
0.051% 
(0.035-
0.068%) 
[45] 
500350G  
HIV-related death rate for patients with CD4 
count 350-500 cells per μL and detectable viral 
load 
0.128% 
(0.092-
0.164%) 
[45] 
350200G  
HIV-related death rate per 100 person-years 
for patients with CD4 count 200-350 cells per 
μL and detectable viral load 
1.0% (0.2-
2.0)% 
[45, 46] 
200G  
HIV-related death rate per 100 person-years 
for patients with CD4 count <200 cells per μL 
and detectable viral load 
4.08 (0.30-
7.86)% 
[45, 46] 
TG  
HIV-related death rate per 100 person-years 
for patients with CD4 count <200 cells per μL 
and detectable viral load 
1.0% (0.2-
2.0)% 
Experimental 
variable  
TFG  HIV-related death rate per 100 person-years for patients with CD4 count <200 cells per μL 
4.08 (0.30-
7.86)% 
Experimental 
variable  
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and detectable viral load 
500K  
Rate at which individuals with CD4 
count >500 that commence treatment for HIV 
each year 
0.2 Assumption  
500350K  
Rate at which individuals with CD4 count 350-
500 that commence treatment for HIV each 
year  
0.5 Assumption 
350200K  
Rate at which individuals with CD4 count 200-
350 that commence treatment for HIV each 
year  
0.75-0.85 Experimental 
variable  
200K  
Rate at which individuals with CD4 count 
<200 that commence treatment for HIV each 
year  
0.85-0.95 Experimental 
variable  
Q  Percentage of individuals on ART who cease therapy each year 
1-5%  b  
U  
The percentage of times a negative man will 
take each role in a sex act based on disclosure 
of partner’s serostatus (positive +, negative -, 
unknown ?) 
See footnote
c  
[47]  
rD  Per-contact risk of transmission when negative partner takes receptive role 
0.48-1.52% [48] 
wD  
Per-contact risk of transmission when negative 
partner takes receptive role with withdrawal 
prior to ejaculation 
0.15-1.53% [48] 
uncirc
iD  
Per-contact risk of transmission when negative 
partner is uncircumcised and takes insertive 
role 
0.07-1.68% [48] 
circ
iD  Per-contact risk of transmission when negative partner is circumcised and takes insertive  role 
0.02-0.24% [48] 
/ multp a  
Multiplicative factor for transmission 
probability for people in primary/acute 
infection or in AIDS stage infection (due to 
higher viral load) 
14.7 [49, 50] 
multt  
Relative reduction in HIV transmission 
probability for people on antiretroviral therapy 
92% [7, 8, 49] 
effART  
Proportion of people on antiretroviral therapy 
with undetectable viral load 
See footnote 
d  
[51] 
mixSE  
Average percentage of sex acts a socially 
engaged MSM will have with a non-socially 
engaged MSM 
43% [25, 27] 
mixOM  
Average percentage of sex acts a non-socially 
engaged MSM will have with a socially 
engaged MSM 
55% [25, 27] 
a  A summary of the relation between HIV-1 RNA concentration and decline in 
CD4+ count from the prospective study by Mellors et al. [44] is given below: 
Plasma HIV-1 RNA 
concentration (copies/mL) 
Mean decrease in CD4+ T cell 
count per year (cells/μL) 
≤ 500 -36.  (-30.4,-42.3) 
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501-3,000 -44.8 (-39.1,-50.5) 
3,001-10,000 -55.2 (-50.7,-59.8) 
10,001-30,000 -64.8 (-59.6,-70.0) 
> 30,000 -76.5 (-70.5,-82.9) 
 
With this data, and assuming that the average viral load is ~104.87 copies per mL 
for people without treatment, the CD4+ T cell count decreases by an average of 
76.5 (70.5, 82.9) every year. 
To progress through the >500 CD4 cell category, we assume that the average 
CD4 count is 800 cells/μL after the 2-month acute phase of HIV infection and 
then declines at the constant rate of 76.5 (70.5, 82.9) cells/μL each year. Then 
the average time to progress through this compartment is 2/12 + 300/(76.5 (70.5, 
82.9)) years; that is 4.09 (3.79, 4.42) years. 
To progress through the 350-500 and 200-350 CD4 cell categories, we assume 
an average loss of 150 CD4 cells. Then the average time to progress through this 
compartment is 150/(76.5 (70.5, 82.9)) years; that is 1.96 (1.81, 2.13) years. 
b  15.4/100 person years is the average rate of stopping one regime due to toxicity 
but the vast majority usually start another regime [52]. Very few people who 
commence ART stop altogether (expert opinion). Therefore, we take the absolute 
rate of completely stopping therapy to range from 1-5% per year as an 
experimental variable. 
c  
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d  
 
 
 
 
In order to model the future we need to ensure the model can accurately represent the past. 
Latin Hypercube sampling was used for variable parameter values and the parameter sets that 
led to the 100 (of 100,000) simulations that best fit all available epidemiological 
data/indicators were used for further analysis. Once these best parameter sets were 
determined, the model simulated the expected number of HIV transmissions and disease 
progression of HIV-infected people over the years 2010 to 2015 with all current conditions 
remaining the same over this period (referred to as ‘status quo’). Once the results of the status 
quo run were established the model was re-run to simulate the outcome if different targeted 
interventions were achieved. The scenarios considered included increasing HIV testing rates 
from 55-65% testing once per year to: (i) testing 80% of socially engaged MSM, (ii) 
increasing HIV testing rates such that 80% of all MSM test once per year, (iii) testing 70% of 
all MSM twice per year. These testing scenarios were each simulated according to: (i) current 
treatment uptake rates, (ii) increased treatment such that all HIV diagnosed men receive ART 
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immediately, (iii) increased treatment such that all HIV diagnosed men who have a CD4 
count less than 500 receive ART immediately. The criterion of a CD4 count of less than 500 
per μL is used as this is the current requirement for those to obtain subsidised HIV 
antiretroviral medication under the Australian Pharmaceutical Benefits Scheme. 
 
Results 
 
The mathematical model was used to project the future epidemic course according to the 
status quo, that is, if current behavioural, testing and clinical practices remain unchanged 
(Figure 2). The infection time courses as predicted by the model suggest that South Australia 
has most likely passed the peak of its epidemic of HIV in MSM. Incidence of infection 
should have a modest decline from approximately 30 cases per year in 2009 to ~24 by 2015 if 
current conditions remain the same. The model-estimated cumulative number of new HIV 
infections from 2010 to 2015 is 124.76 (median, 116.78-131.68 IQR). 
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Figure 2: Model-projections of the expected number of HIV diagnoses among MSM in 
South Australia to 2015 according to current conditions from 100 simulations (median 
in black; dots represent HIV diagnoses data) 
 
The model was then used to simulate over the same time period the expected disease 
trajectories if conditions change due to systematic increases in testing and/or treatment. By 
definition of the sub-population, socially engaged MSM would be easier to seek and recruit 
through their connections to the gay community. Consequently, for all interventions explored, 
targeting only socially-engaged MSM was compared against targeting all MSM. 
Approximately 60-65% of MSM that are socially engaged with the gay community report 
receiving an HIV test within the last 12 months. In order to assess the impact of an 
intervention that increases HIV testing rates, we simulated 80% of socially engaged gay men 
and 80% of all MSM testing for HIV each year (Figure 3, top row, left and centre).  To 
investigate the impact of frequency rather than coverage, we also modelled 70% of all MSM 
testing twice per year (Figure 3, top row, right).The model predicts the median cumulative 
number of HIV infections, 2010-2015, for the three interventions would be 123.59, 122.90 
and 119.99 respectively. The corresponding median reduction in new infections compared to 
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simulation under current conditions would be 1.17, 1.86 and 4.77. Thus, increases in testing 
rates alone are likely to reduce the risk of transmission; however, expected reductions in 
population incidence would likely be very modest. 
We simulated ‘test and treat’ scenarios according to variations in testing frequencies and with 
all HIV-diagnosed men initiating ART if their CD4 count is less than 500 cells per μl (Figure 
3, centre row). The estimated median cumulative number of HIV infections, 2010-2015, as 
calculated by the model is 91.26 if 70% of socially engaged MSM test once per year, 90.92 if 
70% of all MSM test once per year, and 86.32 if 70% of all MSM test twice per year. This 
represents reductions of 33.50, 33.84 and 38.44 infections when compared to the status quo. 
Thus, under the assumption that infectiousness is reduced by 92% among treated MSM, 
earlier initiation of ART is expected to have a substantial population-level impact. 
If HIV-infected people with CD4 counts greater than 500 cells per μl also initiated ART from 
the time of diagnosis, then an even greater reduction in incidence could be expected. The 
resultant median cumulative HIV infections from 2010 to 2015 are estimated to be 51.01 if 
70% of socially engaged MSM test once per year, 48.52 if 70% of all MSM test once per year, 
and 39.41 if all MSM test twice per year (Figure 3, bottom row). The median reductions 
when compared to the status quo corresponding to these outcomes are 73.74, 76.24 and 85.35. 
Thus, removing the Australian Pharmaceutical Benefits Scheme criteria for subsidised 
antiretrovirals and providing ART to all HIV-diagnosed MSM regardless of CD4 count could 
lead to very substantial public health benefits. 
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Figure 3: Top row, left to right: testing 80% of socially engaged MSM, testing 80% all 
MSM and testing 70% all MSM twice yearly with current treatment uptake rate. 
Middle row left to right: the same testing regime as the top row with treatment taken up 
by all of those diagnosed and with a CD4 count <500. Bottom row, left to right: same 
testing regime as the top row but with all of those diagnosed being treated. The dashed 
blue line shows the expected number of diagnoses in the future under the current status 
quo. 
 
 
A summary of the effectiveness of each of the public health interventions modelled is shown 
in Figure 4. In this figure we present the percentage of new infections averted by each of the 
schemes compared to the status quo of current conditions remaining unchanged. Not 
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unexpectedly, the most significant and substantial savings in infections averted are made 
when all diagnosed HIV-positive MSM receive antiretroviral medication, with 68% reduction 
in infections that would otherwise be expected under current conditions for the period 2010 to 
2015. The summary presented in Figure 4 is based on assumption of a 92% reduction in 
infectiousness once ART has been commenced. We reproduce the results for the same 
intervention scenarios, allowing infectiousness reduction to vary between 50 and 99% (Figure 
5). We see that even with an allowance for variation in the effectiveness of treatment, there 
are still substantial savings to be made (51% less infections than otherwise expected) when 
70% of all MSM test every 6 months and receive ART upon diagnosis. 
Whilst it is clear from the Figures 4 & 5 that an increase in treatment results in greater 
reductions in expected incidence than testing alone, it is useful to investigate the impact of 
treatment relative to a fixed testing rate. In Figure 6 we present the expected reduction in HIV 
infections due to treatment alone for two scenarios: the first where testing remains at current 
levels, and in for the second scenario previously presented where all men test 70% each year. 
In the first scenario, the reduction in infections due to treatment are compared against a 
baseline of the current status quo – that being no change in testing or treatment. In the second 
scenario, the reduction in infections is compared against a baseline where all men who have 
sex with men are tested once per year. As expected, due to already  high testing levels in the 
majority socially-engaged population, the results for change in treatment regimens reflect 
very closely the outcomes seen in our “test and treat” interventions. 
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Figure 4: Expected number of HIV infections averted among MSM in South Australia, 
2010-2015, according to a number of interventions assuming a 92% reduction in 
infectiousness for people on ART 
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Figure 5: Expected median number of HIV infections averted among MSM in South 
Australia, 2010-2015, according to a number of interventions, allowing for variance of 
50-99% in infectiousness reduction for people on ART (that is, these results roughly 
correspond to an assumption of 75% reduction in infectiousness) 
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Figure 6:  Expected number of HIV infections averted among MSM in South Australia, 
2010-2015, according to a change in treatment relative to a fixed testing rate assuming a 
92% reduction in infectiousness for people on ART 
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Discussion 
 
Increases in HIV testing have numerous benefits: for the HIV-infected individual to receive 
care and management of infection; for public health surveillance systems to monitor 
epidemics; and potentially for the uninfected population as diagnosed individuals may change 
behaviour or receive ART to reduce transmission risks. A previous study has demonstrated 
the expected relationship between testing rates and HIV incidence in Australian MSM 
populations [53]. The relative benefit of increased testing decreases with higher testing 
coverage. Men who have sex with men in South Australia already have a high rate of testing 
for HIV with approximately 65% of men testing annually. Our results suggest that increases 
in HIV testing in the context of South Australian MSM are likely to have a very modest 
epidemiological impact.  
The health care system and infrastructure in South Australia is well-equipped to conduct 
screening for HIV. However, there are individuals who are not regularly tested for HIV. 
Campaigns in South Australia have promoted regular HIV testing among MSM. However, as 
it is much easier to target those who are socially engaged with the gay community through 
gay venues or via gay-targeted events such as Adelaide’s ‘Picnic in the Park’, innovative 
internet-based and offline measures would be required to reach all MSM in need of testing. 
For the ‘e-male survey’ Rawstorne et al. [22] advertised for participants using e-mail 
distribution lists of HIV organisations, advertisements on social networking sites, male to 
male hook-up sites and in local newspapers in order to reach MSM that are not directly 
connected to the gay community. The extra benefit gained by targeting all MSM should be 
evaluated against the extra expenditure of resources required in order to reach those who are 
not socially engaged. This is highlighted by our results that suggest only a very minor 
113 
 
epidemiological improvement when targeting all MSM compared with reaching just men 
who are socially engaged with the gay community. In order to increase coverage and 
frequency of HIV testing it may be necessary to extend hours of operation of sexual health 
clinics or to provide alternative testing mechanisms such as rapid HIV tests. If testing is not 
easy and convenient for those who are targeted, then it will be difficult to increase the 
number of people that test and the frequency thereof. MSM in Australia who have higher 
HIV risk exposure tend to test more frequently [54] but there may be a saturation level to the 
attainable frequency of testing. The levels of HIV testing among MSM in South Australia are 
already high and this may facilitate the relatively early detection of HIV infection, on average, 
and allow for the potential early initiation of ART. 
Available evidence suggests that treatment reduces transmission (among discordant 
heterosexual couples) and modelling studies suggest that this strategy could result in 
significant population-level reductions in incidence [1, 53, 55-58]. A recent detailed 
modelling study has also indicated that treatment for prevention is likely to be a highly cost-
effective public health strategy [59]. There is little evidence of the effect of ART on 
transmission risk among MSM. However, assuming that the same relative reduction in 
infectiousness found among heterosexual couples applies to MSM we have evaluated the 
potential population impact of increasing treatment rates among MSM in South Australia. 
Similar to other modelling studies, we found that expanding uptake of ART among HIV-
infected people is likely to result in a substantial reduction in incidence in the population. 
In Australia, people living with HIV are eligible for subsidised antiretrovirals if their CD4 
count is less than 500 cells per μl. We found that if all HIV-diagnosed people with CD4 
count less than 500 cells per μl are on ART then approximately 25% of infections would be 
averted. If testing rates increase such that 70% of MSM in South Australia are tested for HIV 
twice per year then ~30% of infections would be averted. However, if the Australian 
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Pharmaceutical Benefits Scheme restrictions were lifted and all HIV-diagnosed people 
received ART then HIV incidence could be expected to decrease by ~60%, most of which 
would be achieved if only men engaged with the gay community were reached. The 
proportion of potential infections averted would increase to almost 70% if all undiagnosed 
individuals are tested twice per year. 
Our model has limitations due to the data sourced for its construction. As no detailed 
behavioural data for serosorting and sexual positioning is available for MSM in South 
Australia, this was informed by research conducted on MSM in Sydney, New South Wales 
[47].  Gay Community Periodic surveys are conducted only biennially in Adelaide; this is due 
to be increased to annual as of 2010. For non-socially engaged MSM data was obtained using 
the recently conducted PASH survey [60]. As this survey has only been conducted once, back 
projections based on behavioural trends from the Adelaide surveys were used. The rate at 
which MSM would switch between the socially and not-socially engaged groups post sexual 
debut is difficult to quantify and there are no data available to derive such a rate. Assuming 
the proportions of the groups remains fairly constant, by using a per-capita force of infection 
term that incorporates both groups, we account for switching between groups. This model 
was a deterministic population-level model and the large heterogeneities that exist in the 
population were not captured but only average behaviours and clinical outcomes were 
described. Lastly, the largest limitation is the absence of data on the effect of treatment on 
infectiousness for penile-anal intercourse. Consequently, we applied the best evidence 
available from heterosexual studies. This assumption may not be valid. It is actually 
paradoxical that in most resource-rich settings in which the majority of HIV transmissions 
occur among MSM, HIV diagnosis rates have been increasing over the last decade [14-16] 
coincidentally with increases in coverage and effectiveness of ART. 
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Challenges for implementation for any intervention scheme include access, adherence and 
choice, as well as policy and clinical opinion on what is best for the patient. Any intervention 
to be truly effective would need to be adopted by the majority of the targeted population for a 
long period of time. Whilst initial adherence may be successful, there is a risk of fatigue 
when it comes to maintaining any gains in testing participation and frequency. Adherence to 
ART is also an issue when more patients are being medicated and for longer, which also 
raises concerns for the development of drug resistance. Lastly, some MSM will choose not to 
test and others, once diagnosed, will choose not to have antiretroviral therapy. The right to 
choose whether to seek medical treatment is a right held by all of those that are infected; it is 
an important ethical issue to consider removing this right as part of a prevention program. 
This strategy raises numerous ethical concerns around the concepts of individualism versus 
utilitarianism [9]. 
Treatment of HIV-infected people with antiretroviral drugs for the purpose of prevention of 
new infections is a shift away from the normal paradigm of using ART for the sole purpose 
of keeping HIV-infected people alive, reversing AIDS-defining diseases and improving their 
health. The objective of early treatment is to preserve immune function and enhance viral 
control in order to attenuate long-term clinical outcomes. A randomised controlled trial of 
early initiation of treatment demonstrated beneficial clinical outcomes for patients receiving 
monotherapy with AZT for 6 months [61]. However, currently there are no data addressing 
the impact of early initiation of combination ART on long-term clinical outcomes. Although 
the World Health Organisation has changed its recommendations on when to initiate ART, 
from a CD4 count of 200 to 350 cells per μl, this is still a long way from treating all HIV-
diagnosed individuals, many of whom are asymptomatic and generally quite healthy. Most 
treatment guidelines do not recommend early use of ART due to the lack of clinical trial 
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evidence, along with drug toxicities, the risk of selecting for drug-resistant strains of HIV, 
and financial implications [62]. 
As is true of any setting, any reduction in new infections of HIV in MSM of South Australia 
would not only benefit those in that population, but also indirectly benefits the broader 
general population also. As noted by the self-identification of sexuality and route of 
transmission, not all MSM participate in exclusively homosexual intercourse (especially 
those who are not classed as socially-engaged to the gay community). Six percent of HIV-
infected MSM in South Australia identified their infection event as injecting drug use. It is 
plausible to consider that a reduced incidence of HIV in the most-at-risk population would 
have a carry on effect to others connected to this population group. Putting aside ethical 
debates and difficulties associated with implementation and continuation, a public health 
strategy based on expanded uptake of antiretroviral therapy in a highly tested population 
would likely be highly effective at reducing HIV incidence in an MSM population and 
warrants consideration.  
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Abstract 
 
Background: As financial constraints can be a barrier to accessing HIV antiretroviral therapy 
(ART), we argue for the removal of co-payment requirements from HIV medications in 
South Australia.  
Methods: Using a simple mathematical model informed by available behavioural and 
biological data and reflecting the HIV epidemiology in South Australia, we calculated the 
expected number of new HIV transmissions caused by persons who are not currently on ART 
compared with transmissions for people on ART. The extra financial investment required to 
cover the co-payments to prevent an HIV infection was compared to the treatment costs 
saved due to averting HIV infections. 
Results: It was estimated that one HIV infection is prevented per year for every 31.4 (median, 
24.0-42.7 IQR) persons who receive treatment. By considering the incremental change in 
costs and outcomes of a change in program from the current status quo it would cost the 
health sector $17,860 (median, $13,651–24,287 IQR) per infection averted if ART is 
provided as a three-dose, three-drug combination without requirements for user-pay 
copayments.  
Conclusions: The costs of removing co-payment fees for ART are less than the costs of 
treating extra HIV-infections that would result under current conditions. Removing the co-
payment requirement for HIV medication would be cost-effective from a governmental 
perspective. 
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Introduction 
 
In South Australia, there are an estimated 750 people living with HIV that are aware of their 
infection [1]. Approximately 76% of these diagnosed cases are receiving antiretroviral 
therapy (ART) to delay or reverse disease progression and improve survival [2].Whilst it is 
not necessarily optimal for all patients diagnosed with HIV to be on ART, there remain a 
proportion of HIV-infected people who are aware of their positive serostatus, are eligible for 
treatment, but are not yet receiving antiretrovirals. It is an important health issue to remove 
barriers to treatment uptake to ensure that all in need of life-sustaining ART have access. One 
of the objectives in the South Australian HIV Action Plan [3] is to increase the appropriate 
uptake of ART. A suggested strategy to achieve this objective is to implement mechanisms 
overcoming any possible cost barriers to the use of ART. 
In Australia, the Pharmaceutical Benefits Scheme (PBS) provides subsidised prescription 
drugs to Australian residents. Patients are required to contribute a co-payment for their 
prescription medication when purchasing under the PBS. Those who receive government 
pensions, are low-income earners or hold a Health Care Card (HCC) are entitled to pay a 
reduced "concession" co-payment amount. The co-payment for clients with a HCC is $5.30 
per drug prescription and $26.30 for people without a HCC, up to an annual family threshold 
(inclusive of same sex couples) of $1,200. Approximately 50% of co-payments for HIV 
medication are at the concession level. A recent increase in co-payment costs has led to 
concern about patients’ abilities to afford essential medications [4]. According to the HIV 
Futures survey, and before an increase in co-payments, 28.3% of people with HIV in 
Australia were living below the poverty line and over 40% of patients reported the co-
payments for antiretroviral medications to be either ‘a little difficult’ or ‘very difficult’ to 
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afford [5]. Additionally, anecdotal reports from tertiary treatment centres affirm that due to 
financial reasons some patients are postponing, interrupting or even ceasing treatment [51]. 
Not only does this impact on the health of HIV-infected people but on the spread of the virus 
through the population.  
Antiretroviral medications are available from public hospital pharmacies in all Australian 
States and Territories. Unlike other Australian states, South Australia has an additional 
community pharmacy agreement for dispensing HIV medications whereby the pharmacy acts 
as an agent for the Royal Adelaide Hospital for dispensation of Highly Specialised Drugs for 
HIV treatment. Previously, Centre Pharmacy charged one co-payment for a three month-
supply of an HIV medication in contrast to the one co-payment per month supply charged by 
SA public hospital pharmacies.  More recently, Centre Pharmacy has been required to charge 
one patient co-payment per one month supply. The increase in costs is due to the 
implementation of increased PBS requirements to comply with the administrative agreement 
between the Commonwealth and the State for the Highly Specialised Drugs Program.  
The outcomes of antiretroviral treatment are of benefit at both the population and individual 
level.  Clinical outcomes such as a slow-down or reversal of disease progression [6] benefits 
the patient. Furthermore, effective treatment results in successful viral suppression  (reducing 
plasma viral load to undetectable levels, less than 50 copies per ml) in approximately 90% of 
cases [2]. International research (among heterosexual couples) has demonstrated that such 
reductions in viral load results in an average of 90-95% reduction in the infectiousness of 
HIV-infected people on ART compared with those not on ART [7-9]. Consequently, there 
has been a recent call among the HIV/AIDS global health community to substantially 
increase rates of treatment uptake for the purposes of preventing new infections [10]. 
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In this study we consider the notion of providing free access to HIV medications in South 
Australia. We evaluate the costs associated with such a strategy and the likely treatment costs 
saved through averting infections due to reductions in viral load. The analysis is conducted 
from a health sector (government as third party payer) perspective. Specifically, a simple 
mathematical model based on risk equations is used to calculate the expected average number 
of new HIV infections caused by persons who are not currently on ART compared with the 
average number expected from those who are on ART. The model reflects the HIV 
epidemiology in South Australia and is informed by available behavioural and biological data. 
We compare the extra financial investment required to remove the current co-payment 
requirement with the total medication costs saved due to preventing HIV infections with 
increased treatment uptake. We then conduct a simple cost-effectiveness analysis to 
determine if the provision of antiretrovirals would be an appropriate healthcare intervention 
from a governmental perspective. 
 
Methods 
 
In South Australia from 2004 to 2008, 93.1% of HIV diagnoses were attributed to three 
dominant routes of exposure: intercourse between men who have sex with men (MSM, 60%), 
heterosexual sex (25.3%) and transmission via injecting drug use (IDU, 7.8 %). We 
developed equations that estimate HIV transmission risk for each of these transmission routes. 
Specifically, the risk equations conservatively calculate the average number of new HIV 
infections that could be attributed to one infected person each year. They are conservative 
because the number of secondary infections averted from ongoing chains of transmission is 
not estimated by our model. 
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The equations incorporated the risk of HIV transmission per act for each type of sexual or 
injecting act and the prevalence of HIV in the relevant partnership groups. The rate of 
circumcision among the male population and the reduction in infectiousness due to 
antiretroviral medication were included in the equations. To account for sexual behaviour, the 
model includes the average annual number of casual and regular sexual partners each person 
has and the frequency of sex with these partners. Similarly, for IDUs the model included the 
average yearly number of injecting events. HIV protection measures depicted in the model 
include the rate of condom use in each partnership type (with the efficacy of condoms) and 
the proportion of acts/partnerships in which a person discloses their HIV serostatus (and the 
resultant sexual position they generally perform as a consequence). In the context of 
transmission via injection, the rates of sharing injections and cleaning of injecting equipment 
(with the efficacy of cleaning) are included. Mathematically, the average number of new HIV 
transmissions per HIV-infected MSM per year can be expressed according to these factors as 
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where C is the average number of partners for each relationship type (casual or regular), P is 
the prevalence of the relevant partnership group, r is the rate of condom use, β is the 
transmission risk for each act type, δ is the rate of disclosure of serostatus (+ denotes 
disclosed positive, - denotes disclosed negative and ? denotes unknown serostatus), c is the 
proportion of men that are circumcised, n is the number of acts per relationship type per year 
and ε is the efficacy of condoms/ cleaning of injecting equipment. The risk of male-to-female 
transmission (MtoF), female-to-male transmission (FtoM) and transmission via injecting drug 
use (IDU) have the following similar expressions:
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These model equations are first used to calculate the risk of each exposure type prior to 
treatment and then recalculated with an allowance for the reduction in infectiousness ( tH , 
where treatt re reH E E ) due to treatment. The difference between the resultant risk calculations 
is the expected number of new infections averted per person, per year, due to initiation of 
treatment. From this relationship we calculated the number of people needed to treat (NNT) 
in order to avert one HIV infection each year and thus, the financial cost per infection averted 
in the immediate-to-short term.  The costs of covering the required number of co-payments 
were then evaluated in comparison with the costs of treating the infection that would 
otherwise have been expected. All parameter values used in the analyses are provided in 
Table 1. Ethical approval was not required for this study. 
Table 1: Parameters used in our mathematical model 
Parameter definition Range of values a 
Reduction in transmission risk per risk event due to treatment compared to no treatment 
( tH , where treatt re reH E E ) 
90.02 (81.13-
98.72)% [7, 11]  
Transmission risk per act of unprotected receptive anal act (with ejaculation) ( reE ) 1.43 (0.48-2.85)% 
[12] 
Transmission risk per act of unprotected receptive anal act (without ejaculation)( wiE ) 0.65 (0.15 - 1.53)% 
[12]  
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Transmission risk per act of unprotected insertive anal act (with circumcision)( cinE ) 0.11 (0.02 - 0.24)% 
[12]  
Transmission risk per act of unprotected insertive anal act (without circumcision)( ncinE ) 0.62 (0.07-1.68)% 
[12]  
Transmission risk per act of unprotected receptive vaginal act ( mfE ) 0.1(0.05-0.17)%[13-
21]  
Transmission risk per act of unprotected insertive vaginal act (w/out 
circumcision)( fmE ) 
0.05 (0.025-0.085)% 
[13-21]  
Proportion of men that are circumcised ( c ) 65 (50.3-82.6)% 
[22]  
Efficacy of condoms ( cH ) 95 (80-99)%  
[23-27] 
Rate of disclosure of HIV status by HIV-positive MSM (G ) 45.9 (30-60)% [28]  
Estimated population size of gay men in South Australia 12,500  
[29, 30] 
Condom use among heterosexual couples in which discordant HIV status is known 
( hetr ) 
75 (69-80)% [5]  
Prevalence of HIV among heterosexual population ( ,mal femP P ) 0.1(0.098 - 
0.148%)% [31] 
Average number of regular sexual partners per year for heterosexuals  
( hetregc )  
1 (0.8-1.2) 
assumption 
Transmission probability of HIV per injection with a contaminated syringe ( iduE ) 0.7 (0.56-0.84)% 
[32, 33]  
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Weighted average annual injecting frequency for IDUs in South Australia ( injn ) 300 (256-384) [34]  
Proportion of injections that are shared in South Australia (V ) 16 (10-22%)% [35]  
Prevalence of HIV among IDUs in South Australia ( iduP ) 0.86 (0.5-1)% [34]  
Average number of acts per year  in regular MSM partnership  
( msmregn ) 
100 (80-120) [36]  
Average number of casual partners of HIV-positive MSM  
( msmcasc ) 
14 (10-16) [37] (b) 
Average number of regular partners MSM ( msmregC ) 0.65 (0.5-0.7)% [38]  
Average number of acts per casual MSM partnership ( msmcasn ) 1 [36] 
Condom use in casual partnerships MSM ( msmcasr )  75 (60-90)% [38]  
Condom use in regular partnerships MSM ( msmregr ) 48 (30-65%)[38]  
Prevalence of HIV in partners of positive MSM ( msmpartP ) 0.398 (0.35-0.45) 
[38]  
Prevalence of HIV in general MSM ( msmgenP ) 0.1 (0.08-0.12) [2, 
31]  
Number of acts per regular heterosexual partnership per year  
( hetregn ) 
100 (80-120) 
assumption 
Rate of needle cleaning ( q )  0.75 (0.6-0.9) [34]  
Efficacy of cleaning syringes ( qH ) 0.675 (0.6-0.75) 
[34]  
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Proportion of acts in which the negative partner will 
take role when partner is known to be positive 
Receptive with ejaculation 
( re ) 
0.11[37] 
Receptive with withdrawal 
prior to ejaculation ( wi ) 
0.33 [37] 
Insertive ( in ) 0.56 [37] 
Proportion of acts in which the negative partner will 
take role when partner’s serostatus is unknown 
Receptive with ejaculation 
( ?re ) 
0.21 [37] 
Receptive with withdrawal 
prior to ejaculation ( ?wi ) 
0.33 [37] 
Insertive ( ?in ) 0.46 [37] 
 
Explanatory footnotes 
a Mean (95% Confidence Bounds) reported. A uniform 
distribution is applied across the 95% CBs for input 
into model. 
b  
 
Distribution of the number of casual partners of gay 
men per 6 months (percentage of men in each 
category) used in the calculation of msmcasC [37] 
1-1.5 26% 
2-5 21% 
6-10 16% 
11-50 30% 
51-60 7% 
 
 
130 
 
 
Uncertainty and sensitivity analysis 
Uncertainty analysis was conducted by defining a probability distribution for each of the 
input parameters that covers the plausible range of values based on the published literature. 
Using Latin hypercube sampling, the distributions were sampled 10,000 times generating the 
equivalent number of unique parameter sets. The expected numbers of transmissions, with 
and without additional provision of treatment due to removal of the copayment requirements, 
were then calculated for each parameter set. Due to the variability in the inputs to the model 
there was a subsequent range of outcomes for each of the model output variables. Sensitivity 
analyses were conducted through the method of factor prioritization by reduction of variance 
and by calculating partial rank correlation coefficients (PRCCs) to determine the importance 
of uncertainty in input estimates to the range in outcome variable measures.  
Cost-effectiveness analysis 
We calculated a simple incremental cost per quality-adjusted life year (QALY) gained in 
order to determine if the free provision of antiretroviral medication is an efficient healthcare 
interventional in an economic sense. An intervention is determined to be cost-effective if the 
cost per QALY saved is below a pre-determined willingness-to-pay (WTP) threshold. In 
Australia, the WTP threshold is approximately AU$64,000 [39] and in a resource-rich setting 
such as South Australia, an estimated 7.5 QALYs are lost per HIV infection [40]. 
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Results 
 
According to the model, the expected number of new transmissions resulting from each 
infected person per year is much less than one, for all transmission routes even without 
consideration of reduction in infectiousness due to antiretroviral treatment. Men who have 
sex with men have the highest average transmission rate, with an average of 0.1772 (median, 
0.1419 – 0.2135 IQR) new infections per year without treatment, which is equivalent to one 
transmission every 5.6 (median, 4.7-7 IQR) years. In comparison, without treatment one 
transmission would occur after an average of 5.9 (median, 4.8 – 7.4 IQR) years per IDU,  35 
(median, 25.6 – 49.4 IQR) years for heterosexual males, and 115 (median, 84 – 164.9 
IQR)years for heterosexual females (or equivalently, an average of one infection would occur 
per year for every 115 HIV-infected females). With treatment, the transmission rates are 
substantially reduced across the population. The model was used to estimate the per-capita 
rate of HIV transmission for each transmission route due to initiation of treatment for one 
year, adjusting for the cumulative number of exposure events and average behaviours of each 
population group. It was conservatively estimated that the number needed to treat in one year 
to prevent an HIV infection in the appropriate susceptible group is: 6.4 (median, 5.5-7.7 IQR) 
MSM, 38.5 (median, 28.7-53.1 IQR) heterosexual males, 126.5 (median, 94.2 – 177.2 IQR) 
heterosexual females, or 11.5 (median, 10.4 – 13 IQR) IDUs (Figure 1). Over the five years 
of reported data in South Australia (2004-2008), 60% of HIV diagnoses were among MSM, 
16.7% among heterosexual males, 8.6% among heterosexual females, and 7.8% among IDUs 
(and 6.9% were among other categorisations).  Adjusting for the proportion of diagnoses 
associated with each risk group as a weighted average, one HIV infection is prevented per 
year for every 31.4 (median, 24 – 42.7 IQR) people (Figure 1) who receive treatment in 
South Australia.   
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Figure 1: The number needed to treat to avert an HIV infection by infective group and 
weighted overall population 
 
 
Currently, annual HIV medication costs per person in South Australia are approximately 
$14,000, [41-44] with an estimated average lifetime cost of the order of $400,000 [44] 
(assuming approximately 30 years of treatment). By providing treatment to 31.4 people each 
year in order to prevent one new infection, the cost of averting that infection would be 31.4 x 
$14,000 = $439,600. Hence, in terms of medication costs only, the expenditure currently 
required to prevent an infection is roughly of the same magnitude but likely only marginally 
more than what would be required to provide lifelong treatment to the infected person that 
would have resulted. Simplistically, an averted infection leads to approximately 7.5 QALYs 
gained. Therefore, the approximate cost per QALY is $58,613 (=$439,600/7.5), which is 
below the WTP threshold. Conservatively, this does not include other costs associated with 
healthcare services that would also be saved. Therefore, if a treatment program enables 
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access for people who would not have otherwise received therapy, then from a purely 
economic perspective, provision of full treatment is cost-effective.  
As the cost of HIV medications are already partially subsidised by the government, a change 
in program to free access should also be considered purely in terms of the incremental cost of 
removing the patient co-payment requirement and not full ART costs. If ART was provided 
as a three-drug, three-dose regimen, it would cost just an additional $17,860 to cover current 
co-payment expenses in order to avert one infection. However, according to current treatment 
patterns, two-thirds of patients receive their three-drug regimen as a two-pill dose. This 
reduces the incremental cost per infection averted to $13,891. 
The incremental cost to the government to remove the co-payment requirement for all 750 
people currently diagnosed with HIV infection in South Australia would be approximately 
$331,800, of which, $79,632 would be for those (approximately 180) people who are not 
currently receiving treatment. This incremental cost to remove copayments for all patients is 
less than the estimated lifetime treatment cost of one new infection. If all of those who are 
currently diagnosed but not receiving ART (approximately 24%) were to uptake treatment, 
this would avert an expected additional 5.73 new infections each year. The annual cost in 
terms of medication for this sub-population would be $2,520,000, but by averting 5.73 
infections, saves lifetime medication costs of $2,292,000. Therefore, in terms of co-payments 
costs and in terms of medicinal costs to the government, the removal of co-payments for all 
HIV-infected patients would likely be less than treating the additional infections that would 
otherwise be expected.  
By conducting sensitivity analyses on the outcomes of the model, we are able to determine 
which of the input parameters are the most important in the calculation of transmission risk 
and to what extent they influence the variability in the outputs. Based on our PRCC analysis 
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we found that for each of the scenarios where sexual intercourse is the route of transmission, 
the most important parameter is the per-act risk of transmission. For people who inject drugs, 
the most influential parameter is the average proportion of injection acts that are shared per 
year. For untreated MSM, the per insertive-act risk accounts for 48.6% of the variability in 
the expected number of annual transmissions. For heterosexual people not on ART, the 
applicable gender-to-gender per-act risks caused approximately 50% of the outcome variation. 
For people receiving ART the effectiveness of treatment in reducing infectiousness was 
found to be the most influential parameter associated with sexual transmission. For MSM, 
male-to-female and female-to-male transmission, the effectiveness of ART caused 63.6%, 
57.5% and 56.4% of variability in the expected number of transmissions respectively. In 
IDUs receiving antiretrovirals, the rate of needle cleaning was the parameter most influential, 
accounting for 62.3% of the variation in the model outputs. 
 
Discussion  
 
Our calculations have some potential limitations due to the data sources used. There are no 
data available for the South Australian MSM population for any changes in sexual risk 
behaviour post-commencement of treatment, only post-diagnosis. However, as shown in 
Chapter 3, even a small change in treatment rates alone in a subpopulation averts infections in 
the greater population of interest.  Recently there has been discussion regarding viral load 
being used to negotiate condom use in serodiscordant partnerships [45]. By using post-
diagnosis behaviours, we essentially take the conservative estimate for expected infections as 
we do not allow for an increase in unprotected acts due to belief about viral loads. In fact, it 
has been found that HIV-positive men who have a detectable viral load are as likely to 
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engage in serodiscordant unprotected anal intercourse and no less likely to restrict themselves 
to the receptive position as those who reported their viral load as undetectable [45]. We used 
the best data available to inform our calculations from comparable settings, e.g. behavioural 
distributions for some parameters were obtained from studies of MSM in Sydney and 
international studies on biological transmission rates were used, and different values may 
apply to South Australia. However, we used South Australian data sources wherever possible. 
It is possible that other STIs may act as biological cofactors to increase transmission 
probabilities. The average transmission probabilities used in the model were based on studies 
which estimated transmission rates among populations of people whilst attempting to control 
for numerous factors including behaviour and background rates of other STIs. Therefore, we 
believe it is appropriate for us to directly apply the average transmission rates without 
explicitly included expressions for STI factors. We assumed that treatment reduced 
infectiousness by 92% per exposure event, based on two recent studies conducted among 
heterosexual discordant couples [7, 46]. It is not known whether the same relative reduction 
in transmission is appropriate for transmission routes of higher risk such as sharing injecting 
equipment and penile-anal sex [47]. Further, although the average annual costs of 
antiretrovirals are known, lifetime costs of medications can only be estimated based on rough 
extrapolations, as have been done elsewhere. This model is static, and therefore cannot be 
used for the long term projection of disease progression or capture the dynamic features of 
infections averted. Nor could we therefore, evaluate the cumulative cost savings over time, 
and as such, our cost estimates have not been discounted. As the question of whether the 
removal of copayments would be an efficient distribution of resources is relatively simple, 
and with the data available, this model type is reasonable and appropriate to provide a simple 
and transparent assessment. 
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In this study we provided a simple economic argument in support of the South Australian 
government covering the financial cost of co-payments for HIV antiretroviral drugs. We 
showed that such a policy would be cost-effective. Our results are relativey conservative and 
directly applicable to the epidemiological context of South Australia. The quantitative 
outcomes of our analysis would be different for other settings but the qualitative conclusions 
of our analysis are likely to be broadly applicable to other similar contexts. Our mathematical 
framework can easily be extended to other contexts by applying appropriate epidemiological 
and behavioural data. Numerous economic studies carried out in a variety of different 
international settings have also shown provision of antiretroviral therapy to be cost-effective 
or cost-saving [48-50]. 
Financial policies and practices for provision of antiretrovirals differ across Australia. Policy 
in South Australia requires that the State pay for the co-payments of each one month supply 
of antiretrovirals dispensed, regardless of whether it is recouped from the patient. This is 
similar to the policy in New South Wales, Queensland, Australian Capital Territory and 
Tasmania, although some of these jurisdictions have no community pharmacy dispensation. 
In Victoria, antiretrovirals are dispensed for free from the Melbourne Sexual Health Centre; 
otherwise a co-payment is required from all other Victorian public hospital pharmacy outlets. 
In Western Australian and the Northern Territory, antiretrovirals for HIV treatment are 
supplied free of charge. It would not be an extreme step for South Australian policy on costs 
for HIV treatment to be aligned with that in Western Australia and the Northern Territory. 
There also exist precedents in South Australia for provision of free treatment and/or 
immunisation for diseases that present a public health risk. In South Australia, treatment 
and/or immunisation for tuberculosis, hepatitis B, seasonal influenza and sexually transmitted 
infections other than HIV are available without cost to the patient.  
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The inability for some people to access consistent treatment for HIV not only impacts upon 
the individual, but also the health system and the general population. By delaying treatment 
uptake or ceasing it altogether due to inability to finance co-payment costs, HIV-infected 
individuals can experience persistently increased viral load. This can have a damaging effect 
on the general health of individuals and the population. At a macro level, increased average 
viral loads in the population will lead to increased incidence of HIV. Ultimately this will lead 
to increased costs associated with ART, as well as more hospital admissions and outpatient 
appointments.  
Facilitating increases in treatment rates by removing the co-payment requirement for HIV 
medication is likely to result in numerous beneficial outcomes including reductions in HIV 
transmissions and less resistance to antiretrovirals, improved health outcomes for HIV-
infected individuals, and a reduced burden on public health resources. Recent discussions and 
recommendations about novel prevention strategies are also promoting increased treatment 
rates among all HIV-infected people [10]. There is strong clinical and epidemiological 
support for increasing treatment rates in addition to the financial benefits. We carried out a 
simple health economics analysis from a governmental perspective of covering co-payments 
for HIV antiretroviral drugs and found that this initiative is cost-effective, and we therefore 
recommend its implementation.  
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Abstract 
 
Objectives: Commercial sex is licensed in Victoria, Australia such that sex workers are 
required to have regular tests for sexually transmitted infections (STIs). However, the 
incidence and prevalence of STIs in sex workers is very low, especially since there is almost 
universal condom use at work. We aimed to conduct a cost-effectiveness analysis of the 
financial cost of the testing policy versus the health benefits of averting the transmission of 
HIV, syphilis, chlamydia, and gonorrhoea to clients.  
Methods: We developed a simple mathematical transmission model, informed by 
conservative parameter estimates from all available data, linked to a cost-effectiveness 
analysis. 
Results: We estimated that under current testing rates it costs over AU$90,000 in screening 
costs for every chlamydia infection averted (and AU$600,000 in screening costs for each 
quality adjusted life year (QALY) saved) and over AU$4,000,000 for every HIV infection 
averted (AU$10,000,000 in screening costs for each QALY saved). At an assumed 
willingness to pay of AU$50,000 per QALY gained, HIV testing should not be conducted 
less than approximately every 40 weeks and chlamydia testing approximately once per year; 
in comparison, current requirements are testing every 12 weeks for HIV and every 4 weeks 
for chlamydia.  
Conclusions: Mandatory screening of female sex workers at current testing frequencies is not 
cost-effective for the prevention of disease in their male clients. The current testing rate 
required of sex workers in Victoria is excessive. Screening intervals for sex workers should 
be based on local STI epidemiology and not locked by legislation. 
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Introduction 
 
Sex work in the state of Victoria, Australia, is decriminalised but regulated through a 
licensing system. Sex workers in Victoria are required to provide evidence of having regular 
sexual health check-ups for Chlamydia trachomatis, Neisseria gonorrhoeae, and 
Trichomonas vaginalis and to be examined for genital warts or active herpes lesions every 
month, plus serology for HIV and syphilis every three months [1]. Sex workers may be 
prosecuted for knowingly having sex with clients while carrying a sexually transmissible 
infection (STI) or for not having the prescribed STI tests. The financial cost of consultations 
and testing for these STIs is usually covered by the government healthcare system. However, 
it is known that many sex workers have almost universal condom use at work and a low 
incidence of STIs [2]. The few STIs that they do acquire are usually attributable to private 
sexual partners [2]. Although it is a hallmark of public health campaigns to promote STI 
testing among groups with relatively large numbers of sexual partners, we postulated that the 
current testing rates required of sex workers in Victoria may be excessive. We conducted a 
simple analysis on the cost-effectiveness of these regulations and evaluated the cost-
effectiveness of alternative testing frequencies. To assess the cost-effectiveness of regular 
STI testing we used a mathematical model to estimate the expected number of STI 
transmissions from sex workers to their clients based on available behavioural, biological, 
and epidemiological data. We used the model to explore how the expected number of sex 
worker-to-client transmissions of HIV, syphilis, chlamydia, and gonorrhoea changes with the 
frequency of STI testing and the cost of that testing. We took a health sector perspective with 
3% discounting of costs and outcomes according to standard methods [3]. We only included 
the costs and outcomes of diseases in male clients.  
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Methods 
 
If a sex worker has an STI then the expected number of transmissions of the infection to 
clients (per sex worker per week) can be estimated as the product of the number of clients 
each sex worker has per week, n , and the probability of transmission per sexual encounter 
with a client, E . The probability of transmission per encounter can be modelled by
  ^ `1 1 1p b b pE H Ec     ª º¬ ¼  for a condom usage rate of p , condom efficacy of H , 
condom breakage rate of b, and baseline probability of transmission per unprotected act of 
E c . In a population of N sex workers, if the incidence rate (per week) of a sex worker 
acquiring an infection is O  then the expected prevalence of infected sex workers at any time 
is approximately NOW , where W  denotes the average number of weeks between tests. The 
total expected number of infections caused by all infected sex workers per week is 
I N nOW E .          (1) 
That is, the modelled number of transmissions is a function of the average sexual activity 
level of sex workers (in terms of number of acts and condom use), the biological transmission 
efficiency of the organism in question (in terms of both incidence to sex workers and 
secondary transmissions from sex workers to clients), and the testing frequency.  
The total number of infections caused by all infected sex workers per week (equation 1) can 
be expressed in terms of the total number of tests per week: 
2
Total number of tests per week
n NI O E ,      (2) 
or the total cost of conducting all tests: 
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2
Total cost
c n NI O E ,        (3) 
where c is the cost per test. The expected weekly cost of testing all sex workers every W  
weeks on average is Nc W . Then, the cost per infection averted, for any given testing 
frequency, can be calculated from taking the gradient of equation (3): 
2
2 2CostPerIA
c n N c
I n
O E
O EW  .      (4) 
If each infection results in a loss of q quality-adjusted life years (QALYs) for the infected 
person, then the cost outlaid for each QALY saved is  
 2CostPerQALY q
c
nO EW .       (5) 
We also used estimates of the cost to treat infections to calculate the expected total financial 
loss/saving (net monetary benefit) for the health system (total savings is calculated as the cost 
saved on treatment from averting infections minus the cost of screening, assuming a 
willingness to pay of AU$50,000 per QALY gained). We also calculated the marginal cost 
effectiveness ratio by dividing the net monetary benefit by the net health benefit (net QALYs 
gained was calculated by the product of the number of infections averted and the QALYs lost 
per infection). 
In Table 1 we present values and costs for the parameters of this model based on behavioural, 
biological, epidemiological, and screening cost data and literature associated with HIV [4-8], 
syphilis [9-18], chlamydia [19-21], and gonorrhoea [22-26] for Victoria, Australia. We 
estimate STI incidence in sex workers from sexual health clinic databases and recently 
reported estimates of incidence in Victorian sex workers [2]. But we conservatively use the 
upper 95% confidence bound of incidence as the mean value in our model. Specifically, we 
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take incidence to be 0.1/100 person-years for HIV, 0.1/100 person-years for syphilis, 3.3/100 
person-years for chlamydia, and 0.7/100 person-years for gonorrhoea. Notably, no confirmed 
cases of HIV transmission to or from a sex worker in Australia have ever been reported. We 
take the efficacy of condoms to be 95% [27-31] and assume that they break or slip 2.5% of 
the time [32], even though an Australian prospective study suggested that 0.6% may be a 
more accurate measure for sex workers [33]. We also conservatively assume that a broken or 
slipped condom equated to unprotected sex. The actual number of sex workers in Victoria is 
not precisely known but we base our analysis on an estimated 2000 sex workers. This 
estimate is derived from studies showing that the proportion of men that access sex workers 
in Victoria is similar to that in the State of New South Wales [2, 34, 35] and an estimation of 
the size of the sex industry in New South Wales [36]. This is also in agreement with estimates 
based on the number of registered brothels and average number of women working from each 
brothel and consistent with expert opinion [37]. 
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Table 1: Definitions and values of parameters used in our analysis 
 
Parameter Definition Value 
O  Incidence of infection (per year)* HIV 0.1 /100py 
syphilis 0.1 /100py 
chlamydia 3.3 /100py 
gonorrhoea 0.7 /100py 
E c  Probability of transmission from an infected SW 
to a male client per unprotected penetrative 
penile-vaginal exposure  
Primary HIV 0.003 
syphilis 0.15 
chlamydia 0.35 
gonorrhoea 0.22 
p  Proportion of penetrative penile-vaginal exposures in which 
condoms are used 
99% 
H  Efficacy of condoms  95% 
b  Proportion of penetrative penile-vaginal acts using condoms 
where breakage or slippage of condom occurs 
2.5% 
n  Average number of clients per sex worker per week 15 
q  Quality-adjusted life years (QALYs) lost due to 
an infection 
HIV 7.5 
chlamydia  (3 days) 
c  Cost per test(s) chlamydia + gonorrhoea AU$57.35** 
chlamydia + gonorrhoea + HIV + 
syphilis 
AU$82.65** 
 
* Using upper bounds of 95% confidence intervals 
** Based on Australian MBS data 
 
Screening costs 
We used costs reported under the Australian Medicare health system for consultation and STI 
testing (October 2008). Costs for each clinical consultation for a sexual health check-up are 
AU$32.80 (assuming level B on the Medicare scheme). In addition, it costs AU$24.55 to 
conduct a chlamydia and/or gonorrhoea polymerase chain reaction assay (item 69316). If 
both HIV and syphilis testing are carried out together (item 69387) then the extra testing cost 
is AU$25.30, but if the tests are carried out on separate occasions then the syphilis testing 
cost (item 69384) is AU$13.40 and the HIV ab/ag testing cost (item 69384) is AU$13.40. For 
consultations in which multiple STIs are screened we apportioned the consultation costs 
equally across each STI.  
148 
 
Treatment costs  
If a screening test detects an infection then we consider the treatment costs for chlamydia and 
gonorrhoea as the cost of one consultation for screening tests (MBS item 23) plus the cost of 
the relevant medication required to clear the infection (using costs under the Pharmaceutical 
Benefits Scheme). Similarly for syphilis, the treatment cost is composed of three 
consultations, one for providing medication and two follow-up serological tests.  
Costs of Disease in male clients 
Costs associated with each infection in male clients were estimated. There are no recent 
estimates of the costs of people living with HIV or experiencing complications related to 
chlamydia, gonorrhoea and syphilis in Australia. Therefore we used the lifetime costs of HIV 
infection in 2004 derived from data in the USA [38]; inflated to 2007 prices with the medical 
component of the US Consumer Price Index [39] and converted to Australian dollars using 
the Purchasing Power Parity [40]; this estimate was AU$490,370 discounted at 3%. We used 
an expected value analysis of the complications of chlamydia and gonorrhoea to estimate the 
costs of infection (Chapter 5 Appendix). Data from Australia and expert opinion on the 
frequency and treatment of disease (and complications including arthritis, epididymitis and 
infertility) are used to estimate a cost per chlamydia infection of AU$57 and cost per 
gonorrhoea infection of AU$82. We did not calculate the cost associated with complications 
of syphilis infection because of a lack of data and uncertainty.  
Utility of Disease 
We estimated a loss of 7.5 QALYs from the time of HIV infection, discounted at 3%, as used 
in an recent systematic review of economic evaluations of HIV interventions [41]. For the 
utility loss associated with complications of chlamydia and gonorrhoea in men, we used the 
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expected value analysis discussed above to calculate a utility loss of 0.0085 per infection over 
12 months, undiscounted. We did not calculate a utility loss for syphilis. 
 
Results 
 
 
The implementation of current STI screening guidelines for 2000 female sex workers in 
Victoria costs over AU$3,750,000 per year at the current screening frequency of every 12 
weeks for HIV and syphilis and every 4 weeks for chlamydia and gonorrhoea. The cost of 
screening for chlamydia and gonorrhoea is AU$1,490,000; the cost of screening for HIV is 
AU$400,400 (Fig. 1).  
The expected number of STI transmissions from sex workers to male clients per year is low 
with less than 0.1 HIV cases, ~3.6 syphilis cases, ~16.4 chlamydia cases, and ~2.8 
gonorrhoea cases (Fig. 1) even if the STI incidence rate to sex workers is conservatively high. 
This is because the population prevalence (and incidence) of STIs in sex workers is low and 
condom usage rates are very high.  
If testing frequency was increased then screening costs would increase sharply. But not 
surprisingly, if the testing frequency was decreased then screening costs would decrease but 
the number of infections to clients would increase (Fig. 1). Even if testing frequency was 
decreased to just once per year, if the incidence rate to sex workers remained unchanged then 
less than 1 HIV transmission, ~16 syphilis transmissions, ~36 gonorrhoea transmissions, and 
~210 chlamydia transmissions could be expected to male clients. 
To ascertain the degree to which investment in frequent testing leads to the low incidence we 
calculated the cost outlaid (for screening) per infection averted in clients. In Figure 2a we 
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present the modelled relationship between the screening costs per infection averted and the 
number of weeks between tests for HIV, syphilis, chlamydia, and gonorrhoea. Under current 
testing rates, for example, it costs over AU$90,000 in screening costs for every chlamydia 
infection averted and over AU$4,000,000 for every HIV infection averted (Fig. 2a). To assess 
the value of this testing schedule we extended this relationship to estimate the cost per QALY 
saved (Fig. 2b). We calculated that under current testing rates, it costs almost AU$600,000 in 
screening costs for each QALY saved due to the burden of chlamydial infections and it costs 
over AU$10,000,000 in screening costs for each QALY saved from HIV infection.  
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We determined the incidence levels that would be required in order for the current testing rates to 
become cost-effective. We found that current frequencies of STI testing would only be cost-effective if 
incidence increases substantially (Table 2). Incidence would need to increase by 12-fold for HIV, 67-
fold for syphilis, 213-fold for chlamydia, and 53-fold for gonorrhoea from the conservatively high 
incidence already assumed. 
Table 2: Comparison between current conditions and increased risk scenarios in order to satisfy cost 
effectiveness of no more than $50,000 per QALY saved. 
 
  Current condom 
use (99%) 
Decrease in 
condom use (to 
90%) 
Incidence rate 
required for current 
testing frequency to 
be cost-effective 
HIV 1.2/100py 0.6/100py 
Syphilis 6.7/100py 3.3/100py 
Chlamydia 704.4/100py 351.5/100py 
Gonorrhoea 37.4/100py 18.7/100py 
Minimum time 
between tests 
(weeks) for cost 
effectiveness (at 
current incidence) 
HIV 41.41 29.25 
Syphilis 56.71 40.06 
Chlamydia 58.44 41.28 
Gonorrhoea 29.25 20.66 
Minimum time 
between tests 
(weeks) for cost-
effectiveness (if 
incidence increases 
3-fold) 
HIV 23.91 16.89 
Syphilis 32.74 23.13 
Chlamydia 33.74 23.83 
Gonorrhoea 16.89 11.93 
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 We then determined the frequency of testing that would be cost-effective (cost per QALY saved less 
than $50,000) under conservative assumptions about the present and if condom use declines and/or STI 
incidence increases. In Table 2 we show the minimum time between tests that is cost-effective under 
current conditions and for the scenarios of condom use decreasing from 99% to 90% and/or incidence 
increases by 3-fold. Even under the extreme (and unrealistic) scenario of a substantial change in both 
condom use and incidence, the minimum time between tests that is cost-effective is over 16 weeks for 
HIV, approximately 24 weeks for syphilis and chlamydia, and almost 12 weeks for gonorrhoea. This is 
still markedly longer than current practice. 
We also estimated the marginal (incremental) cost-effectiveness ratio of each screening frequency. 
Screening at the current recommended frequency costs over AU$500,000 per QALY saved for HIV, and 
over AU$10 million per QALY saved for Chlamydia (Fig. 3a). The Net Monetary Benefit (NMB) of 
screening at current frequencies is  calculated using an assumed willingness to pay of AU$60,000 per 
QALY gained (or US$50,000 per QALY) [42].  The NMB was a loss of AU$356,000 per year for HIV 
and a loss of almost AU$1.5 million for chlamydia (Fig. 3b); that is, none are cost-effective at current 
screening frequencies. Based on our model analysis, HIV testing should not be conducted less than 
approximately every 40 weeks for the cost per QALY saved to be less than AU$50,000 and the 
frequency of chlamydia testing should not be less than approximately once per year. Indeed, just in 
terms of financial aspects, screening costs are almost AU$1,500,000 more expensive than the treatment 
costs saved by preventing chlamydia infections and screening costs are over AU$350,000 more 
expensive than the treatment costs saved by preventing HIV infections (Fig. 3). In order to break-even 
financially, such that the cost of screening is not less than the costs saved on treatment (when the curves 
on Fig. 3 cross zero), based on our model we calculated that testing should not be less than every 36 
weeks for HIV, 295 weeks for syphilis, 160 weeks for chlamydia, and 446 weeks for gonorrhoea. These 
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estimates are independent of the number of sex workers. Thus, if the incidence of STIs in sex workers 
remains low then there is a strong argument for relaxing regulations to less frequent testing, if not 
abandoning mandatory testing entirely.  Notably, among representative population-based samples of 
female sex workers, more of the women in the voluntary testing environment in Sydney (53%) attended 
public sexual health clinics than in the mandatory testing environment in Melbourne (29%, p<0.001)) 
[43].  
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Discussion 
 
Some previous studies have attempted to estimate the costs averted by STI prevention 
programs in various settings (e.g. [2, 44, 45]). Our study used a novel mathematical 
transmission model and conservative parameters, linked to a cost-effectiveness analysis, to 
examine current testing rates among commercial sex workers in Victoria. We show, for the 
first time, that the current testing rates are not cost-effective. Mandatory screening of sex 
workers as legislated in Victoria is not cost-effective for the prevention of disease in their 
male clients at current test frequencies. If screening occurs much less frequently it may be 
cost-effective although the benefit is still very limited. Expenditure on screening at the 
current frequency could be spent on more effective and cost-effective prevention programs to 
produce more benefit for individuals and the health sector. Female sex workers have one of 
the lowest prevalences of HIV (and other STIs) in Australia, compared with levels in other 
groups of the general sexually active population [2, 46, 47]. Legal climates and STI testing 
regulations for sex workers varies across Australian jurisdictions. Despite much more 
frequent testing of the women in Victoria, STI (gonorrhoea, chlamydia, trichomoniasis, and 
Mycoplasma genitalium infection) prevalences have been found to be uniformly low (0%-
3.6%) in representative samples of sex workers tested in brothels in Melbourne, Sydney, and 
Perth [43]. In Sydney and Perth, STI screening is voluntary and the appropriate screening 
interval is negotiated between the woman and her clinician on an individual basis. This also 
suggests that relaxing STI screening requirements in Victoria may not result in a noticeable 
change in STI transmission rates. Since STI screening varies between jurisdictions but 
epidemiology of STIs and client behaviour is relatively similar, change in policy in Victoria 
could have little change in social perceptions or spread of STIs but could save considerable 
financial and time resources. Our study suggests that the current laws mandating regular 
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screening in Victoria may be using valuable resources in ways that are not cost-effective and 
should be reviewed.  
Mandatory testing was introduced when the sex industry was decriminalised in Victoria in 
1984 in the context of a general fear of the emerging AIDS epidemic and limited knowledge 
about transmission. However, sex workers have significant personal incentives to avoid the 
acquisition of STIs so consistent condom use has been an industry norm since the 1980s. The 
majority of STIs that are transmitted to sex workers are now from their regular non-
commercial partners and not from their commercial sexual partners [2].  
There are also legal and ethical dimensions of STI screening of sex workers that require 
consideration.  Regulation is carried out in other industries of goods and services in order to 
protect the public (e.g., food/restaurants, medical devices, consumer products, health status of 
healthcare personnel etc.). There may be obligations and responsibilities for the government 
to ensure that sex workers do not have STIs. If clients acquire STIs from sex workers and 
then infect their regular partners, marital disruption (and attendant costs) could be 
significant. The acquisition of infections may produce psychological problems and cause 
other harm. Such outcomes could be grounds for awarding punitive damages in legal cases. 
Reviewing current regulations for screening in Victoria should consider the potential for such 
legal and ethical liabilities (and corresponding financial liabilities) as well as screening 
practices in similar settings where frequent testing is not mandatory.  
Our study has a number of limitations. First, we only considered the health sector costs and 
outcomes related to mandatory screening for STIs. One could argue that there is a value 
related to reassurance for sex workers, clients and the wider community in regular STI testing. 
It is not clear whether or not the decision by a client to visit a sex worker is affected by 
knowledge that the sex worker has been screened for STIs in the last 4 weeks. Second, we 
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used costs and outcomes of infections that were derived from the literature and an expected 
value analysis. This approach allows comparisons between our results and the cost-
effectiveness of other interventions for HIV prevention such as antenatal testing of pregnant 
women. Third, we only included the infections occurring in the commercial sexual partners 
of sex workers, but not infections in the sex workers themselves or their non-commercial 
partners. However, such infections are personal health issues unrelated to the women’s 
occupation. Similarly, secondary infections from clients to non-commercial partners are not 
considered. As incidence and prevalence of STIs in the general female population is much 
higher than that of sex workers, there is no evidence to focus on this particular group. Fourth, 
our model simply investigated infections that remain between testing periods and did not 
consider other dynamic features associated with disease transmission such as possible 
clearance of bacterial infections due to the host immune response or background antibiotic 
use. Our simple static model does not take into account onward transmission in the 
population. This method is appropriate for analysis of low incidence settings but if the 
methods were to be applied elsewhere to a location of high incidence then this simple 
transmission model would underestimate the contribution to control, and therefore 
overestimate the cost per case averted. However, this model would be appropriate for other 
settings of relatively low incidence. Fifth, there may be some sex workers that are not tested 
as frequently as required by law, or not test at all. These women may have greater levels of 
infection which is not accounted for in our analysis. However, the number of such women is 
believed to be small. Lastly, we did not carry out a detailed multivariate sensitivity analysis, 
although we did explore the impact of changes in STI incidence and condom use (Table 2). 
We also determined that the most important factor in the model is the average time between 
tests. The influence of this parameter on the annual cost of screening, cost per infection 
averted, cost per QALY saved, marginal cost-effectiveness ratio, and total savings was shown 
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in Figures 1-3. It is also important to note that if the screening program were removed or if 
there were long intervals between testing then it may be difficult to ascertain whether STI 
incidence changes. If there were outbreaks or local epidemics then the cost-benefit estimates 
could also change substantially. Such changes may go undetected without a frequent 
screening program; however, it is also possible that screening less frequently allows more sex 
workers to be screened. 
However, our simple model has been useful to provide insight into the magnitude of the 
expenditure and effectiveness in preventing infections in male clients with respect to the 
frequency of testing for STIs in female sex workers. In conclusion, we show that mandatory 
regular screening of sex workers for STIs and HIV is not cost-effective. We propose that 
resources could be better spent on more cost-effective interventions instead. Furthermore, 
screening intervals for sex workers in any jurisdiction around the world should be based on 
local STI epidemiology. Specifically, the cost-effectiveness of screening for STIs in any 
setting is highly dependent on the incidence of the infections which are likely to be 
geographically specific and the behaviour of sex workers in that setting.  
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Key messages  
x Commercial sex is licensed in Victoria, Australia such that sex workers are required 
to test regularly for STIs despite very low incidence and prevalence. 
x It was determined that mandatory screening of sex workers at current frequencies is 
not cost-effective and costs are well-beyond normal willingness to pay thresholds.  
x Screening intervals for sex workers should be based on local STI epidemiology and 
not locked by legislation.  
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Abstract 
 
Background: Serosorting, the practice of seeking to engage in unprotected anal intercourse 
with partners of the same HIV status as oneself, has been increasing among men who have 
sex with men (MSM). However, the effectiveness of serosorting as a strategy to reduce HIV 
risk is unclear, especially since it depends on the frequency of HIV testing.  
Methods: We estimated the relative risk of HIV acquisition associated with serosorting 
compared with not serosorting by using a mathematical model, informed by detailed 
behavioral data from a highly studied cohort of gay men.  
Results: We demonstrate that serosorting is unlikely to be highly beneficial in many 
populations of MSM, especially where the prevalence of undiagnosed HIV infections is 
relatively high. We find that serosorting is only beneficial in reducing the relative risk of HIV 
transmission if the prevalence of undiagnosed HIV infections is less than ~20% and ~40%, in 
populations of high (70%) and low (20%) treatment rates, respectively, even though 
treatment reduces the absolute risk of HIV transmission. Serosorting can be expected to lead 
to increased risk of HIV acquisition in many settings. In settings with low HIV testing rates 
serosorting can more than double the risk of HIV acquisition.  
Conclusions: Therefore caution should be taken before endorsing the practice of serosorting. 
It is very important to continue promotion of frequent HIV testing and condom use, 
particularly among people at high risk. 
 
Summary: In this paper we calculated the relative risk of acquiring HIV associated with 
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serosorting and determine that serosorting is only beneficial in settings with very high testing 
rates. 
 
Introduction 
 
Serosorting is the practice of choosing sexual partners thought to be of concordant HIV 
serostatus in order to reduce the risk of HIV transmission during unprotected intercourse [1-
3].  There is strong evidence to suggest that in various populations of men who have sex with 
men (MSM) around the world the formation of casual sexual partnerships and behavior 
within such partnerships has been increasingly influenced by the disclosure of HIV serostatus 
[1, 4-9]. But the extent to which the practice of serosorting protects HIV-uninfected MSM 
from acquiring HIV is unclear. In this study we aim to quantify the relative effectiveness of 
serosorting across a wide spectrum of contexts related to the prevalence of undiagnosed 
infections. The effectiveness of serosorting for reducing the risk of HIV acquisition is highly 
dependent on other population-specific parameters, in particular, the coverage and frequency 
of HIV testing. Serosorting may in fact lead to increased risk [10] if a partner’s HIV 
serostatus is unintentionally misreported because it is unknown. Consequently, the proportion 
of the sexually active population that is HIV-infected but undiagnosed is a crucial 
determinant of the effectiveness of serosorting. In the ideal scenario of 100% accurate 
knowledge and no misreporting of serostatus, serosorting is 100% effective at preventing 
HIV acquisition by HIV-negative people who practice it. Conversely, serosorting may result 
in substantially increased risk of HIV acquisition if a large proportion of the HIV-infected 
population is undiagnosed and serosorting thereby leads to the formation of discordant 
partnerships and more unprotected sex. Here we present the results of a mathematical 
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modeling analysis that demonstrate the importance of context, especially the prevalence of 
undiagnosed HIV infection, in determining the effectiveness of serosorting in reducing the 
risk of HIV acquisition. We estimate thresholds for the prevalence of undiagnosed HIV 
infections in a population for which serosorting increases risk. 
 
Methods 
 
We developed a mathematical model to investigate the relationship between the proportion of 
the HIV-infected population that is undiagnosed and the relative risk of serosorting, which 
refers to the risk of HIV acquisition for MSM who practice serosorting relative to the risk of 
HIV acquisition for those who do not practice serosorting. A full description of the 
mathematical formulation of the model is given in the Appendix. Briefly, the relative risk of 
serosorting is determined by calculating the probability that a casual partnership is 
serodiscordant (a prerequisite for HIV transmission) when serosorting does and does not 
occur, and the probability that HIV transmission will occur in both cases. The probability of 
any casual partnership being serodiscordant will, be dependent on the proportion of the 
population that has undiagnosed infection and the prevalence of HIV in the population. The 
probability of transmission in a serodiscordant partnership is taken to be dependent on the 
proportion of acts that are insertive, receptive with withdrawal and receptive with ejaculation, 
and the proportion of partners with diagnosed HIV infection that are on antiretroviral 
treatment (ART). We assume different rates of transmission from cases on ART than from 
cases not on ART but we did not consider heterogeneity in transmission rates throughout the 
natural course of infection. We use detailed behavioral data from the Health in Men (HIM) 
cohort [11, 12], a highly studied cohort of gay men, to inform the expected proportion of acts 
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that are insertive, receptive with withdrawal or receptive with ejaculation based on 
knowledge of the partner’s HIV status (see Figure A1 in the Appendix). The modeled 
formulation yields theoretical maximum and minimum relative risks of serosorting of: ~2.15 
when all HIV-infected people are undiagnosed, and 0 when everyone knows their true HIV 
serostatus, respectively. 
 
To evaluate the relative risk of serosorting in specific settings we chose parameters from 5 
representative locations. (1) In Sydney, Australia, the percentage of HIV infections that are 
undiagnosed has been estimated from a modeling study to be ~10% [13] and this is consistent 
with data from a community-based study that recruited gay men [14]. In Australia, ~70% of 
diagnosed cases are on ART [15]. (2) It is widely cited that in the United States ~48% of all 
infections are undiagnosed [16]. However, there is very large heterogeneity between cities 
and other demographic variables, particularly age and ethnicity. (3) Other estimates suggest 
that ~25% of HIV infections in the United States are undiagnosed [17-19]. We assume 
treatment rates are between 50% and 70% among diagnosed cases in the United States. (4) It 
has been estimated that ~44% of HIV infections in London, England are yet to be diagnosed 
[20]. We also assume that treatment rates are around 50% of all diagnosed infections in this 
population [21]. (5) We assume that in many sub-Saharan countries ~80-90% of all HIV 
infections are undiagnosed and HIV treatment rates are low (20%). 
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Results 
 
In Figure 1 we present the modeled relationship between the relative risk of HIV acquisition 
due to serosorting compared with not serosorting, versus the proportion of the HIV-infected 
MSM population that are undiagnosed, for various treatment rates. As the proportion of 
undiagnosed infections increases there is a corresponding increase in the risk associated with 
serosorting. Whilst it is theoretically possible for serosorting to achieve 100% effectiveness 
(if everyone knows and discloses their true serostatus), in a worst case scenario the relative 
risk of practicing serosorting is more than double the risk of not serosorting (Fig. 1); this 
value is informed by the average proportion of acts that are insertive or receptive with or 
without withdrawal and the average transmission rates for each type of sex act (see Chapter 6 
Appendix). The relative risk of serosorting was not found to be highly sensitive to HIV 
prevalence but it was moderately sensitive to HIV treatment rates. We estimate that 
serosorting is only of any benefit at all for reducing HIV risk when the proportion of men 
with HIV who are undiagnosed is less than ~20% in the case of high treatment rates (70%) 
and less than ~40% for low treatment rates (20%)(Fig. 1), assuming treatment reduces 
transmission rates by 95%.  
 
In resource-rich countries where there are often high rates of testing for HIV amongst MSM, 
serosorting may be an effective means of reducing the incidence of HIV infections. For 
example, we estimate that the relative risk of serosorting in Sydney, Australia (where 
approximately 10% of HIV infections are undiagnosed) is ~0.57 (i.e., 43% effectiveness)(Fig. 
1). Using commonly cited estimates of the percentage of undiagnosed infections in the United 
States (of 48%), our model indicates that practicing serosorting in the United States is likely 
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to increase risk by almost 50% (Fig. 1). If just 25% of HIV infections in the United States 
were undiagnosed then it is unclear whether practicing serosorting would increase or decrease 
the risk of HIV acquisition (Fig. 1). We estimate that practicing serosorting in London (44% 
undiagnosed) is likely to increase the risk of acquiring HIV by over 30%. In comparison, in 
resource-constrained countries where the prevalence of undiagnosed infections is high, 
serosorting would not be effective even at low treatment rates and could increase HIV risk by 
~90% (Fig. 1). However, these thresholds would be altered if sexual positioning preferences 
among gay men were considerably different in other settings than they are for gay men in 
Sydney. 
 
Figure 1: Modeled relationship between the relative risk of serosorting and the proportion of 
HIV-infected MSM who have not been diagnosed with their infection, for varying treatment 
rates. 
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In Figure 2 we present the relative risk of serosorting for different combinations of treatment 
rates and prevalence of undiagnosed HIV infections. It can be seen that if treatment rates 
increase then the relative risk associated with serosorting worsens. This finding may seem 
counter-intuitive but it is important to note that the absolute risk of HIV transmission in the 
population decreases with increases in treatment rates. But the effectiveness of serosorting is 
calculated by the ratio of the chance of transmission when serosorting to the chance of 
transmission when not serosorting in a particular setting. Treatment rates do not influence the 
risk of acquiring HIV when serosorting and only choosing partners who are thought to be 
HIV-negative. However, when serosorting does not take place sexual partners of any 
serostatus could be chosen and could include partners who are HIV-positive and on ART. 
Consequently, the relative risk of serosorting compared with not serosorting is calculated 
using a term that is independent of treatment divided by a term that decreases with increasing 
treatment rates; the result is a relative risk statistic that increases with treatment rates. 
Therefore, high treatment rates in a population are likely to decrease overall incidence levels, 
however, serosorting has a reduced relative benefit compared with not serosorting because 
the risks of transmissions are less. Serosorting can still be of additional value in high-
treatment settings if there are significant increases in testing rates which reduce the 
prevalence of undiagnosed infections. For example, in London the prevalence of undiagnosed 
HIV infections would need to decrease from 44% to ~30% for serosorting not to increase risk. 
But if treatment rates increased from 50% to 70% then the prevalence of undiagnosed 
infections would need to decrease to ~20% for the practice of serosorting to have the same 
risk as not serosorting. 
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Figure 2 Contour plot of the relative risk of serosorting versus the percentage of diagnosed 
cases on treatment and the prevalence of undiagnosed infections. Bands of color represent 
intervals of relative risk: 0-0.5 (light green), 0.5-1 (green), 1-1.5 (orange), 1.5-2(light red), 2-
2.5 (dark red). 
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Discussion 
 
Serosorting is unlikely to be highly beneficial in many populations of MSM, especially when 
the proportion of undiagnosed HIV infections is relatively high. Indeed serosorting with 
casual partners will likely increase HIV risk in settings where the percentage of infections 
that are undiagnosed is greater than approximately 40%. This percentage is likely to be 
exceeded in most resource-constrained countries and also in many resource-rich settings. 
However, our calculations suggest that serosorting can lead to effective reduction in risk in 
those locations where the proportion of undiagnosed HIV infections is relatively low.  
 
 Our mathematical modeling analysis of HIV transmission incorporates detailed data of 
sexual positioning and risk reduction strategies in MSM. A limitation of our analysis is that it 
is based on behavioral data of gay men in Sydney, Australia and this may not be 
representative of practices of MSM in other locations. However, similar trends in serosorting 
and strategic positioning have been observed in MSM throughout the industrialized world [1, 
5, 6, 9]. Another limitation is that we used average transmission levels across all stages of 
HIV infection. We assumed that ART reduces transmission by 95%, however, the actual 
reduction in transmission rates due to ART is not yet well established. 
 
The effectiveness of serosorting depends on accurate disclosure of HIV serostatus. Some 
HIV-infected people may mistakenly believe that they are not infected and thus disclose as 
HIV-negative to sexual partners [22]. Disclosure of HIV status in sexual partnerships may 
also lead to other strategies to reduce the risk of HIV transmission, such as strategic 
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positioning and negotiated safety [23-26].  But disclosing HIV status may be associated with 
substantial stigma, so that even if a man knows he is HIV-infected, he may not disclose his 
HIV status or may even disclose false information (although this is thought to be relatively 
rare). However, even if truthful disclosure always occurs, serosorting is a potentially risky 
strategy and its effectiveness for an individual uninfected man also depends on the frequency 
of testing of his sexual partner and the partner’s previous risk exposure. At a population level, 
the effectiveness of serosorting is specific to each context because it depends on the average 
HIV testing coverage and frequency in the population, and the rate of treatment. Different 
testing and treatment patterns exist between different populations.  
 
Serosorting is safer than having unprotected anal intercourse with a serodiscordant partner 
but our model-based estimates suggest that it is not as safe as consistent condom use. Here, 
we only considered unprotected sex and not sex where a condom is used. If condoms are only 
used with partners of known discordant status, then it is imperative to know the true HIV 
status of partners. Our analysis suggests that unless the surrounding population has a small 
proportion of undiagnosed infections, serosorting is likely to increase the risk of HIV 
acquisition in practice. Therefore, it is not appropriate to suggest that serosorting may offer 
partial protection from HIV. The available evidence suggests that HIV-uninfected men who 
serosort remain at risk of acquiring HIV infection, and quite possibly at significantly 
increased risk compared with not serosorting.  
 
Encouraging frequent testing for HIV, particularly among people at high risk, is a very 
important public health strategy. In addition to greater accuracy in serosorting, the benefits of 
undiagnosed HIV-infected individuals becoming aware of their serostatus include the 
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tendency for sexual behavior to decrease and treatment can be sought. Both of these lower the 
risk of HIV transmission. Various behavioral studies provide evidence that risky sexual 
behavior decreases after HIV diagnosis [27-35]. Increasing HIV diagnoses requires educating 
susceptible populations to seek HIV testing on the basis of indicators such as a known 
exposure to HIV or early recognition of symptoms. The practice of serosorting is increasing 
among MSM in various settings. In order for this practice to be beneficial, public health 
campaigns must continue to promote frequent HIV testing among groups at high risk. This 
message is of even greater importance in regions where current testing rates are relatively low. 
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Available evidence does not support serosorting as an HIV risk 
reduction strategy 
 
Serosorting is an increasingly common practice among gay men whereby the selection of 
sexual partners is based on concordance of HIV serostatus [1-3]. Serosorting occurs in order 
to facilitate unprotected anal intercourse without risk of HIV transmission. Evidence suggests 
that disclosure of HIV serostatus is increasingly influential not only on the formation of 
casual partnerships among gay men (serosorting) but also on the sexual position that each 
man is likely to take in a coital act (known as strategic positioning) and the likelihood of 
using a condom (known as negotiated safety) [3-9].  Although these inter-related strategies 
appear to be sophisticated measures for reducing risk, in some circumstances they may lead 
to increased risk of HIV transmission in a population [10, 11].  Serosorting, when coupled 
with actual positioning and condom behavior, may result in increased risk of HIV acquisition 
if a moderate proportion of the HIV-infected population is undiagnosed. This undiagnosed 
proportion may lead to the formation of partnerships that are thought to be concordant but are 
actually discordant. In partnerships that are thought to be concordant, HIV-negative men are 
more likely to take a receptive role (which is more risky in a discordant partnership) and less 
likely to use condoms. 
Cassels et al. developed a detailed compartmental mathematical transmission model in order 
to demonstrate that ‘under realistic scenarios of sexual behavior and testing for men who 
have sex with men (MSM) in the United States, serosorting can be an effective harm 
reduction strategy’ [12]. However, they failed to consider how strategic positioning and 
negotiated safety behaviors change with or without disclosure of HIV status and therefore 
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their assertions about the benefits of serosorting are overstated. Additionally, they assumed 
that all men test for HIV 1-2 times per year. This is much greater than the best available data 
on actual testing rates in the United States [13]. It is estimated that between 25% [14-16] and 
48% [17] of all HIV infections in the United States are undiagnosed which implies that 
testing rates are considerably lower than 1-2 times per year for all men. If Cassel’s et al. used 
more conservative testing rates in line with rates that are consistent with levels of 
undiagnosed infections then based on their model-derived Figure 4, serosorting would have 
been shown to result in higher equilibrium prevalence. The authors also state that with 
serosorting, 22% of contacts are apparently serodiscordant, and 50% without. With a 
prevalence of 16% their model would require partner acquisition rates among HIV-positive 
men to be much greater than among HIV-negative men. Lastly, we question the relevance of 
using equilibrium prevalence (that is, no epidemiological or behavioral change) to gain 
insight into the effect of a recent phenomenon on an epidemic where there is increasing 
incidence. 
Using more realistic assumptions the model of Cassel et al. would yield very different 
conclusions, such that serosorting is not likely to reduce risk of HIV acquisition among gay 
men in the United States but in fact is likely to increase risk in most contexts. Serosorting, 
strategic positioning and negotiated safety cannot be decoupled. It has been demonstrated that 
accounting for behavior change is integral, as the risk reduction strategies adopted by 
negative men vary with the level of knowledge of their partner’s serostatus [11, 18].  There is 
not sufficient evidence to measure the true effectiveness of serosorting as a harm-reduction 
strategy. Modeling can be useful to inform our understanding when realistic behavioral inputs 
are used. The benefit of serosorting is highly context specific and depends upon the 
frequency of testing, accurate disclosure of serostatus and behavior. Our position, based on 
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this study and others in the literature, is that serosorting has a real potential to increase risk 
and should not be promoted as a public health strategy. 
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Conclusion 
 
In Chapter 1, the Cambodian HIV Epidemic Model (CHEM) was presented. The 
accompanying software to the model has been designed so that users can define and assess 
different targeted scenario combinations of past and future epidemic patterns and programs. 
Results from our model demonstrate that past public health programs in Cambodia were 
effective in reducing HIV incidence. The 100% Condom Use Program (100% CUP) was an 
intervention promoting 100% condom use for transactional sex in direct sex workers. For the 
years 2000 -2010, using the CHEM it was estimated that the 100% CUP intervention averted 
almost 70% of HIV infections in female sex workers that would have otherwise been 
expected had it not been put into place. As an added benefit, the flow on effect of this 
program was such that it also averted approximately 40% of infections in their male clients 
and led to a 5-10% reduction in the overall incidence of HIV in Cambodia. The introduction 
of antiretroviral therapy was of even greater benefit to the overall population. Overall, the 
implementation of access to ART was estimated to avert 10-15% of infections with a 
reduction in incidence across all population groups.  
In order to mitigate future epidemic trends, combinations of interventions should cover all 
populations at risk of HIV infection. In addition to those with high-risk behaviours, such as 
female sex workers and men who have sex with men, it is important to ensure any future 
public health policy include strategies which protect those who have lower-risk behaviours 
but remain at risk of infection due to their relationship type. Interventions such as increasing 
testing rates, scaling-up the provision of ART and promoting condom use in combination 
provide the most benefit for the majority of people at risk of HIV, including women who are 
spouses of men who participate in transactional sex and injecting drug users. Results from the 
model predict that in comparison to projections under current conditions, that almost one-
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third of infections expected in 2011-2020 could be averted with a health policy that results in: 
10% condom use in heterosexual non-transactional sex; a testing rate of 20% in the general 
lower-risk population; and a reduction in the rate of needle sharing for injecting drug users to 
30%. This combination of interventions is thought to be feasible in the Cambodian context 
and this study showed that it would have a substantial impact on the HIV epidemic in 
Cambodia. 
The impact of the Global Economic Crisis on HIV epidemics in Papua New Guinea and 
Cambodia was assessed in Chapter 2. The GEC likely had a greater effect in PNG than in 
Cambodia. Increases of up to 17% in HIV incidence and 11% in diagnoses could be expected 
in PNG over the following 3 years. It was found that for Cambodia, due to existing funding, 
infrastructure, and surveillance systems, it would not be expected for the total number of 
diagnoses to be largely effected. Due to possible behaviour changes however, an estimated 
increase in incident cases of HIV of up to 10% may not be observed under the surveillance 
system currently in place. The number of AIDS-related deaths could be increased by a 
reduction in antiretroviral therapy. In terms of epidemic mitigation, a decrease in education 
programs and voluntary counseling and testing services are the key areas of concern for both 
settings. These findings are consistent with the findings from CHEM in Chapter 1. 
A model exploring the expected epidemiological impact of adopting a strategy that increases 
HIV testing and initiates earlier use of antiretroviral therapy as a method of reducing HIV 
transmission was presented in Chapter 3. The rationale for this study is the large international 
movement towards treatment as prevention for HIV and it was important to assess whether 
this strategy may be of benefit in a local concentrated epidemic. This study focused on the 
population of men who have sex with men in South Australia, a group to which HIV 
transmission in that location is predominantly confined. What made this model unique is the 
classification of MSM into two behavioural groups, men that are socially engaged with the 
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gay community and those whom are not. This division of MSM is unique to the location, and 
those who do not identify as socially-engaged are also more likely to participate in 
heterosexual intercourse. The mathematical model used in the study found that in a 
population that already has high testing rates, a further increase in testing rates alone is 
unlikely to have a substantial impact upon expected future incidence. However, if a strategy 
combines increases in treatment coverage and testing rates, a 60-70% reduction in incidence 
over the next 5 years could be expected. The model found that the majority of potential 
reductions in incidence were achieved by targeting men who are socially engaged. As this 
population is easier to reach through the use of gay community networks, investing in such a 
strategy would be highly effective in reducing the incidence in that population. Due to the 
stratification of behavioural groups, any reduction in HIV transmission in those who do not 
identify as socially-engaged could have a positive carry-on effect to the greater community as 
it would reduce risk for their heterosexual partners also. 
Also in the setting of South Australia, an argument for the provision of free antiretroviral 
medication is given in Chapter 4. The concern that financial constraints could be providing a 
barrier to accessing ART motivated the analysis of the cost-effectiveness of removing the co-
payment requirement by the Australian government. By calculating the expected number of 
new HIV transmissions caused by persons who are currently on ART compared with those 
who are not on ART, it is possible to determine the extra financial investment required to 
cover the co-payments to prevent an HIV infection. The cost of this investment was then 
compared to the costs saved by not requiring provision of treatment for the HIV infections 
averted. The model found that one HIV infection is averted for approximately every 31.4 
persons who receive treatment. In terms of removing the co-payment requirement, the cost to 
the government to prevent an infection is less than how much would cost in order to treat the 
person for their HIV infection. Facilitating access and adherence to treatment can have 
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numerous beneficial outcomes in addition to a reduction in transmissions. Community viral 
load is decreased, as the number of infected persons delaying or ceasing treatment due to 
financial constraints is reduced. Improved adherence reduces the likelihood of resistance to 
antiretrovirals. The improved health outcomes for HIV-infected individuals also reduce the 
burden on public health resources. Via this simple health economic analysis, we find that 
covering co-payments for HIV antiretroviral drugs is cost-effective from a governmental 
perspective. This study has been presented to South Australia Health and has been 
recommended for implementation. 
In Chapter 5 a cost-effectiveness analysis was conducted of the financial cost of the sexual 
health screening policy on female sex workers in Victoria. The cost of regular testing of 
licensed commercial sex workers in Victoria were compared with health benefits gained in 
averting transmission of HIV, syphilis, chlamydia, and gonorrhoea to clients. Results from 
the transmission model found that each year the expected number of transmissions from sex 
workers to clients of HIV, syphilis, chlamydia and gonorrhoea would be extremely low, due 
mainly to their low STI prevalence level and almost 100% condom use.  Licensed workers 
are required to test for Chlamydia and gonorrhoea every 4 weeks and every 12 weeks for HIV 
and syphilis. With current incidence rates, in order to make testing cost-effective, it would be 
required to reduce the minimum time between tests for HIV, syphilis, chlamydia, and 
gonorrhoea to 41.4, 56.7, 58.4 and 29.3 weeks respectively. This study highlights that whilst 
female sex workers are traditionally a high-risk group for HIV transmission, it is location 
dependant and that it should not be assumed that they are a driver behind an epidemic. It is 
important to ensure that when public-health interventions are implemented that they are 
epidemiologically appropriate, as the impact they may have may not be effective in terms of 
reducing infections or financially. This study was presented to the Health Department of the 
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Victorian government and has been a key piece of evidence in the controversial debate about 
revising current policy. 
The practice of serosorting and its impact on the likelihood of HIV transmission is presented 
in Chapter 6. Serosorting is a risk-reduction strategy growing in the gay male community that 
is not based on promotion or education from health or governmental authorities. Evidence 
presented in Chapter 6 suggests that especially where the prevalence of undiagnosed HIV 
infections is relatively high, serosorting is unlikely to be highly beneficial in many 
populations of men who have sex with men. The benefit of serosorting depends upon the 
frequency of testing, accurate disclosure of serostatus and behaviour and is therefore highly 
context-specific. In settings with low HIV testing rates we found serosorting can more than 
double the risk of HIV acquisition and in general can be expected to lead to increased risk in 
most settings even with high treatment rates. This modelling exercise highlights the 
importance of education and regular HIV testing. The crucial factor in safety of this practice 
is the accurate disclosure of serostatus. Whilst this may intuitively seem to be a good practice, 
based on our findings, serosorting has a real potential to increase risk and should not be 
promoted as a public health strategy. 
In this thesis mathematical modelling is used in a number of different ways. Modelling was 
used to measure how effective the implementation of a public health policy was in mitigating 
the HIV epidemic in Cambodia in the past (Chapter 1). We then used modelling to project 
possible epidemic trajectories and calculate risk in two very different settings: Cambodia, a 
low income country where the majority of infections occur due to heterosexual intercourse 
and Australia, a high-income country with an epidemic predominantly based in the MSM 
population (Chapters 1, 2, 3 & 6). What can be learned from both settings is: the importance 
of ensuring that any intervention put into place is contextually appropriate; sentinel and 
behavioural surveillance are conducted routinely, are maintained and any deficiencies 
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identified and addressed; and educating those who are at risk about how they are at risk and 
how to minimise that risk through behaviour change is important. 
Mathematical modelling was then used as an economic tool to evaluate the cost-effectiveness 
of potential changes to public health strategies (Chapters 4 & 5). What was learnt in these 
studies is that again, it is important to ensure that any intervention is appropriate for the 
setting for where it is to be implemented. In the case of Victoria, whilst some sub-populations, 
such as female sex workers, may often display higher-risk behaviour and be a crucial part of 
the driving force behind an epidemic, this cannot be assumed to be always true. The high-
frequency testing policy was implemented at great cost to the government with negligible 
return fiscally or epidemiologically. It also results in substantial amounts of time wasted by 
clinicians, which diverts attention from other people in need of services. Through the study in 
South Australia, we learned that a policy of spending money to remove obstacles for infected 
persons to benefit from existing interventions in place can avert infections and save money in 
the long term. 
All of the studies presented in this thesis utilised behavioural data in addition to other, more 
easily quantifiable inputs such as viral load, length of infection, etc. What has been learned 
from this work is that there is a need for modellers to interact with social researchers in the 
design of surveys, such that the outputs are directly aligned for modelling and other 
quantitative evaluation. Number, gender split and frequency of encounters with sexual and 
injecting partners, condom use at last – sex, and frequency of role taken in homosexual sex 
are examples of quantities that are crucial to the examination of the spread of STIs. Whilst 
this data is sometimes collected by social researchers, it is often grouped: for example sexual 
partners could be 0, 1 -5, 6-10, 11+. For condom use, it is often reported as “rarely”, 
“sometimes”, “often”, “always” – which is subjective to the interviewee and is difficult to 
translate to percentages. Small changes in survey design achieved by collaboration with 
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social researchers could only improve model outcomes. Additionally, the impact of modelled 
interventions could be more easily globally compared and communicated if outcomes are 
aligned with UNGASS /UNAIDS indicators. 
Since the Global Economic Crisis, a reduction in HIV spending has been seen not just in the 
developing and middle-income countries discussed in Chapter 2, but universally. The 
optimum allocation of scarce resources is topical and relevant in various funding 
environments: be it the assessment of the most effective intervention strategies in resources 
limited countries in South-East Asia, the economic arguments for the  provision of free 
access to ART, and how best to implement test and treat strategies in both generalised and 
localised epidemics.  As social contexts change it pertinent to ensure that resource allocation 
adapts to the epidemic faced to remain relevant and maximally beneficial. 
Currently, there is no viable vaccine or cure for HIV. Overall, the recurring theme throughout 
our studies was testing and treatment, and showed time and again the positive outcomes such 
a scheme provides. Diagnosis benefits the person infected with HIV, in allowing him/her to 
access support and treatment. The community is benefited with the behavioural changes 
made by those diagnosed in order to minimise the risk of further transmissions and the 
reduced community viral load achieved through treatment. For those countries that cannot 
afford it, it is crucial that they receive the funding to put the required infrastructure into place 
and for those who can afford scaling up treatment, it is important to remove any barriers to 
access for those who require it. 
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Appendix 
 
Acronyms 
100% CUP 100% Condom Use Program 
AEM Asian Epidemic Model 
AIDS Acquired Immune Deficiency Syndrome 
ART Antiretroviral Therapy 
CHEM Cambodian HIV Epidemic Model 
DALY Disability Adjusted Life Year 
DSW Direct Sex Worker (Brothel- Based) 
EPP Estimation and Projection Packahe 
FSW Female Sex Worker 
GEC Global Economic Crisis 
HAART Highly Active Antiretroviral Therapy 
HIV Human Immunodeficiency Virus 
IDU Injecting Drug User 
IQR Inter-Quartile Range 
ISW Indirect Sex Worker 
MSM Men who have Sex with Men 
MSMW Men who have Sex with Men and Women 
NMB Net Monetary Benefit 
NSP Needle and Syringe Program 
ODE Ordinary Differential Equation 
PBS Pharmaceutical Benefits Scheme 
PPT Periodic Presumptive Treatment 
PRCC Partial Rank Correlation Coefficients 
QALY Quality Adjusted Life Year 
RNA Ribonucleic Acid 
STD Sexually Transmitted Disease 
STI Sexually Transmitted Infection 
VCCT Voluntary Confidential Counselling and Testing 
WTP Willingness To Pay 
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Appendix for Chapter 3 
 
The mathematical transmission model is described by a series of ordinary differential 
equations (ODES), one for each compartment/disease stage for each population group. The 
model ODEs are as follows: 
 
Here, the force of infection for socially engaged MSM is given by 
 
where 
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An equivalent mathematical construct for the force of infection applies to non-socially 
engaged MSM. 
The population sizes in each disease state are defined by: 
 
 
The per-partnership and per-act transmission probabilities are mathematically described by 
the following equations, which are terms in the force of infection expression: 
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Executive summary 
Background 
Over the period 1985-2008, 1155 HIV infections were detected in South Australia 
and over 300 of these people have died from AIDS or HIV-related illnesses. 
Historically, after following a typical infectious disease epidemic trajectory until 1999 
there has since been a moderate but important increase in the number of HIV 
diagnoses, reflecting what is believed to be a rise in underlying incidence. From 
2004 to 2008, 93.1% of South Australian HIV diagnoses were attributed to three 
predominant routes of exposure: intercourse between men who have sex with men 
(MSM, 60%), heterosexual sex (25.3%) and transmission via injecting drug use (IDU, 
7.8 %). Approximately 76% of the diagnosed cases are receiving antiretroviral 
therapy[1]. HIV-infected men who have sex with men (MSM) in South Australia have 
also disproportionately been affected by the emergence of a syphilis epidemic over 
the last decade. 
This report evaluated the patterns of HIV infections among MSM in South Australia 
in order to determine the key drivers of past trends, evaluate past and present 
programs, and to forecast epidemic trajectories in the future according to current 
conditions or due to implementation of public health interventions. The primary 
method for investigation was the development and analysis of a mathematical 
transmission model. The deterministic compartmental model used behavioural, 
clinical and biological data to track the number of MSM in South Australia over time 
that are in each state of HIV disease stage and HIV transmission to MSM who are 
socially engaged with the gay community or to other MSM. The model was calibrated 
to reflect the past and present epidemiology of HIV in South Australia. 
 
Evaluating the past 
The rate of HIV diagnoses in South Australia has increased significantly over the 
past decade but over the past few years it has stabilised or even started to decline. 
Over the same period of increased HIV diagnoses there has been reported decrease 
in condom use, first declining among regular partners (from around 2003) and then 
with casual partners (from around 2005). A rise in unprotected anal intercourse with 
casual partners has been attributed as the major reason for the rise in HIV 
diagnoses in other Australian jurisdictions; however, it is not clear to what extent the 
change in condom use contributed to the rise in diagnoses in South Australia since 
reported changes in rates of unprotected anal intercourse occurred after the 
observed increase in HIV cases.  
Changes in conditions and implementation of public health interventions were 
analysed. According to the South Australian HIV model for MSM: 
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x  If the 2008 Testing-Testing-123 campaign was not implemented and testing rates 
continued on the previous trend then there would have been 0.18 extra HIV infections 
in the following year; that is, one infection would be averted for every five years of 
implementation of this campaign.  
x Without the increase in testing reported over the past decade, an additional 2.87 HIV 
infections would have occurred in South Australia. 
x Had condom use not declined in recent years there would have been 12.46 less HIV 
infections. 
x If rates of disclosure of HIV serostatus to casual partners over this period had 
remained the same there would have been 0.48 less HIV infections 
x Without the increase in effectiveness of ART over this period, an additional 2.20 HIV 
infections would have occurred. 
In addition, an estimated 122 HIV infections were averted due to Clean Needle 
Programs in South Australia over the decade, 1999-2009. 
 
Epidemic projections 
The South Australian HIV model for MSM was used to forecast epidemic trajectories 
according to a number of different scenarios.  The model suggests that if conditions 
do not change, incidence should decline moderately from about 30 cases per year to 
about 24 cases per year by 2015. However, if conditions change there would be a 
different number of observed HIV cases over the next 5 years (2010-2015): 
x An intervention that results in halving the number of sexual partners for a period of 
one year would result in a median reduction of 2.63 (2%) HIV infections. 
x If condom use was increased to 100% with all casual partners for a period of one 
year there would be a median reduction of 3.84 (3%) infections. 
x By increasing HIV testing rates among men socially engaged with the gay community 
to 80% testing each year a median of 1.17 (1%) infections would be averted. 
x If 70% or 80% of all MSM receive an annual test for HIV this would result in median 
reductions of 0.72 (0.6%) and 1.86 (1.5%) infections respectively. 
x An intervention that results in twice yearly testing among 70% of MSM who are 
socially engaged with the gay community or 70% of all MSM testing result in median 
reductions of 4.53 (3.6%) and 4.77 (3.8%) infections.  
x ‘Test and treat’ strategies could potentially lead to substantial decreases in the 
number of HIV infections. If 70% of MSM are tested each year and all HIV-diagnosed 
men receive antiretroviral therapies then there would be a median reduction of 76.24 
(61%) infections. If twice-yearly testing was carried out and all diagnosed cases 
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receive antiretroviral therapies then the median infections averted would raise to 
85.35 (68%). 
o If only HIV-diagnosed cases with a CD4 count less than 500 cells per μl 
receive treatment upon diagnosis, and 70% of all MSM are tested each year, 
then 33.84 (27%) of infections would be averted. 
 
Summary 
South Australia has responded successfully to contain and minimise the spread of 
HIV such that the prevalence of infection among all South Australians has remained 
at or below 0.1%. The success of South Australia’s past response to HIV is in part 
due to the coordination of HIV prevention programs and partnership approach 
between government, NGOs, researchers, clinicians and community representatives. 
However, the rate of HIV diagnoses in South Australia has increased significantly 
over the past decade particularly among MSM. If preventative changes in risk-related 
behaviour could be sustained for the long-term then it is likely to substantially reduce 
the number of new infections but if only short-term changes are feasible then there 
will be very modest impacts. Promotion of testing among MSM in South Australia 
has been successful to lead to very high rates. Whilst testing is a cornerstone of HIV 
prevention and is highly important, it is unlikely that further increases in testing rates 
will have a substantial impact on HIV trajectories, but if testing rates decrease then 
incidence could be expected to increase. However, if early treatment was 
commenced for diagnosed individuals then it could have a substantial public health 
impact by reducing community-level viral load and average infectiousness of HIV-
infected people. Implementation of wide-scale ‘test and treat’ campaigns may be 
worth considering. Eliminating barriers to accessing treatment, such as removing the 
requirement of patients to cover financial co-payments, would be cost-effective for 
reducing HIV transmissions and benefit people living with HIV.   
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Introduction 
Australia’s response to HIV has generally 
been very effective in minimising the 
spread of HIV such that the prevalence 
of infection among all Australians has 
remained at or below 0.1%. Despite this, 
the burden of HIV is high for the people 
infected with this virus and certain 
population groups are at particularly high 
risk of acquiring HIV. South Australia has 
had similar, if not even better, success 
compared with the rest of Australia with 
regards to containing the spread of HIV. 
South Australia has a strong and 
successful commitment to the partnership approach to HIV/AIDS with shared 
responsibility and cooperation between the Federal and State governments, affected 
communities, non-government organisations, medical professionals and research 
bodies. Stemming from this partnership, and led by the South Australian Department 
of Health, an HIV Action Plan 2009-2012 was developed and it was launched in 
2009 [2]. It describes strategies and activities to: 
x Reshape the prevention response to stem rises in new infections of HIV; 
x Improve the coordination of care for people with HIV; 
x Connect people isolated from HIV education, prevention and care services to 
appropriate supports. 
The plan identifies new key priority actions to be accomplished by 2012 in South 
Australia’s response to HIV/AIDS.  
The current report supports the HIV Action Plan by evaluating past responses, 
determining the key drivers of change in trends and numbers of new infections, 
examining the current epidemiological patterns of HIV infection, and projecting the 
future HIV trajectories according to scenarios whereby there is no change in 
behaviour or practice or according to effective implementation of a host of potential 
intervention strategies. Therefore, this report specifically supports the reshaping of 
the prevention response to HIV. 
Epidemiology of HIV in South Australia 
 
Over the period 1985-2008, 1155 HIV infections were detected in South Australia 
and over 300 of these people have died from AIDS or HIV-related illnesses. The 
epidemic curve in South Australia of numbers of HIV diagnoses followed a typical 
pattern of infectious disease epidemic trajectories until around 1999 (Figure 1). From 
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the year 2000 there has been a moderate but important increase in the number of 
HIV cases detected in South Australia (Figure 1). 
 
Figure 1: HIV diagnoses in South Australia, 1985-2008, by gender and year of diagnosis (three-
year moving averages included) 
It is evident from the HIV epidemic curve (Figure 1) that HIV has disproportionately 
affected males compared to females. This is due to HIV infection predominantly 
contained within the population of men who have sex with men (MSM) (Figure 2, 3); 
in the five-year period 2004-2008 162, or 60%, of the 269 new diagnoses were 
among MSM. A significant number of newly infected people (68 people, 25%) 
reported acquiring HIV through heterosexual contact. Women represent 
approximately 10% of all HIV cases in South Australia and 13% of the notifications in 
2004-2008. In South Australia from 2004 to 2008, 93.1% of HIV diagnoses were 
attributed to three predominant routes of exposure: intercourse between men who 
have sex with men (MSM, 60%), heterosexual sex (25.3%) and transmission via 
injecting drug use (IDU, 7.8 %). The increase in HIV diagnoses since 2000 has 
largely been due to male homosexual sex (Figure 3), but there has also been an 
increase in reported heterosexual transmission of HIV. 
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Figure 2: HIV diagnoses in South Australia over the five-year period, 2004-2008, by gender and 
route of exposure 
 
 
Figure 3: Trend in HIV diagnoses in South Australia, 1999-2008, by route of exposure 
The overall per-capita rate of HIV diagnosis in South Australia has increased 
significantly over the past decade (Figure 4). The rate of HIV diagnoses is roughly at 
a median level when compared with other Australian States and Territories (Figure 
4).  
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Figure 4: Age standardised rate of HIV diagnosis, 1999-2008, by jurisdiction 
Priority populations 
Based on the epidemiology of HIV in South Australia the HIV Action Plan [2] 
identified four populations of South Australians to receive the highest priority for 
education, prevention and health promotion initiatives:  
x Gay and other men who have sex with men; 
x People living with HIV/AIDS; 
x Aboriginal and Torres Strait Islander people; 
x People with diverse cultural and linguistic backgrounds who are from countries in 
which HIV/AIDS is highly prevalent. 
Other priority populations include:  
x People who inject drugs; 
x People in custodial settings; 
x Sex workers. 
Gay and other men who have sex with men (MSM) 
Clearly gay and other men who have sex with men are the priority group most 
affected by HIV in South Australia. Since the beginning of the HIV epidemic in the 
early 1980s men who have sex with men account for approximately 70% of all HIV 
diagnoses in South Australia.  Of all HIV diagnoses among these men, 86% can be 
attributed solely to male homosexual sex, 6% of reported cases indicated injecting 
drug use and 8% of reported cases indicated sex with both men and women. Over 
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the past five years these proportions have changed slightly to 76%, 15%, and 9%, 
respectively, suggesting that although male homosexual exposure remains the most 
dominant route of transmission, the epidemic has become moderately more 
generalised.  
Based on the Australian Study of Health and Relationships and Australian Census 
data, it is estimated that there are approximately 12,000 homosexual and bisexual 
men in South Australia [3]. This suggests that the prevalence of HIV among gay and 
other men who have sex with men is approximately 5%; this is considerably lower 
than HIV prevalence levels in the Eastern States of Australia [3]. However, the 
prevalence of HIV among men who have sex with men is substantially higher than in 
the rest of the population in South Australia (where it is about 0.1%). 
The population of men who have sex with men is not homogeneous in behaviour or 
in the burden of HIV. For example, some men attach themselves to the gay 
community whilst others do not. According to the e-male survey in South Australia, 
approximately 47% of men who have sex with men are gay socially engaged (as 
determined by whether men know other gay men and can be reached through gay 
male networks)[4]. Further, 76.5% of respondents in South Australia identified as 
gay/homosexual/queer, 20.8% as bisexual, 1.5% as heterosexual/straight, and 1.2% 
as other [4]. In comparison, the respective proportions of participants of the 2007 
Adelaide Gay Community Periodic Survey self-reporting each sexual identity were 
86.4%, 9.5%, 2.6%, and 1.6% [5]. 
People living with HIV/AIDS 
In South Australia around 750-800 people are currently living with HIV and 
diagnosed with their infection [6]. It is likely that there is a further 80-140 people (10-
15%) who are currently infected with HIV and undiagnosed with their infection based 
on testing rates and estimated diagnosis levels in other Australian jurisdictions [7-8]. 
Approximately 76% of the diagnosed cases are receiving antiretroviral therapy [1]. 
Aboriginal and Torres Strait Islander people 
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Figure 5: HIV diagnoses by route of exposure across all Australian jurisdictions, 2004-2008, 
among Aboriginal and Torres Strait Islanders and non-Indigenous Australians 
 
The number of Aboriginal people diagnosed with HIV in South Australia is small (28 
notifications by the end of 2008) but the risk of increasing infections among this 
population remains unless prevention efforts continue. Given the higher rate of HIV 
transmission due to injecting drug use in this population compared with the non-
Indigenous population (Figure 5) and the link between some sexually transmissible 
infections (STIs) and the transmission of HIV as well as the national upward trend in 
STI infections in the Aboriginal population, prevention work with Aboriginal 
organisations and communities is highly important. 
Location/travel associated with HIV including people from overseas  
The majority of HIV diagnoses in South Australia were likely due to transmissions 
that occurred in South Australia. However, data on the new diagnoses in the five-
year period 2004-2008 indicate that 26% of new notifications in South Australia were 
likely to have been acquired overseas; of these, approximately 28% of cases were 
known to be HIV-positive before entering Australia. HIV was likely acquired interstate 
for 7.5% of cases.  
Heterosexually acquired HIV has been increasing in importance in recent years 
(Figure 3). Over the past 10 years, 1999-2008, 39/105 (37%) of reported 
heterosexually acquired cases were in people from a high prevalence country with 
approximately equal numbers of males and females (Figure 6); 40% were reportedly 
female-to-male heterosexually acquired and 23% male-to-female heterosexually 
acquired. The increased reported number of female-to-male transmissions compared 
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with male-to-female, with relative rate of 1.74, suggests that some cases may be 
homosexually acquired but reported as heterosexual exposure.  
 
Figure 6: Reported heterosexually acquired diagnoses in South Australia, 1999-2008 
People who inject drugs 
It is well established that injecting drug use has been a major driver of the spread of 
HIV in Asia whereby epidemics have typically followed a chain of transmission 
starting from spread among injecting drug users to the rest of the general population 
[9]. Thus, it is always important that people who inject drugs are a priority population 
to ensure effective prevention measures are in place. In South Australia HIV has 
largely been contained outside of the population of injecting drug users, primarily due 
to needle and syringe programs (see evaluation of the past section). The number of 
injecting drug users in South Australia is estimated to be approximately 15,000 
people [10] (Figure 7). Over the 10-year period, 1999-2008, 31 HIV diagnoses in 
South Australia were attributed solely to injecting drug use, accounting for 5.8% of 
diagnoses. The prevalence of HIV among people who inject drugs in South Australia 
is estimated to be 0.86% [10].  
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Figure 7: Estimated number of injecting drug users in South Australia [10] 
Despite the availability of needle and syringe programs in South Australia, sharing of 
injecting equipment is still relatively common (Figure 8); coupled with relatively high 
frequencies of injecting (Figure 9) suggests that populations of people who inject 
drugs should remain a priority population for HIV in South Australia. 
 
Figure 8: Proportion of injecting drug users in South Australia participating in the Australian 
Needle and Syringe Program Survey to report sharing syringes in the last month [11] 
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Figure 9: Frequency of injecting by participants of the Australian Needle and Syringe Program 
Survey in South Australia [11] 
 
People in custodial settings 
Over the five-year period, 2004-2008, 17,716 people were received into South 
Australian prisons [12]. Of these people, 26.4% were tested for HIV antibody. Twenty 
cases were found to be HIV-positive, representing 0.4% prevalence [12]. 
Sex workers 
Sex workers are generally population groups of priority due to the large number of 
exposure events and high potential for the acquisition and spread of HIV and other 
sexually transmissible infections. Sex work is prohibited in South Australia (like in 
Western Australia and the Northern Territory). There are limited data on sex workers 
in South Australia. However, all surveillance activities, primarily through Adelaide’s 
Clinic 275, have not documented any case of HIV among sex workers in South 
Australia [12]. This is likely due to almost universal condom usage [13]. Furthermore, 
South Australian men are the least frequent consumers of commercial sex services 
in Australia [14]. 
 
Testing rates and CD4 counts 
South Australia has consistently collected CD4+ T cell counts of HIV-infected 
individuals at diagnosis and completion rates are greater than in any other Australian 
jurisdiction, at over 90%. However, HIV cases in South Australia (and the Northern 
Territory) have a significantly greater likelihood of presenting with infection with 
advanced disease (CD4 count < 200 cells per μl) compared with all other Australian 
jurisdictions. Late presentation is associated with exposure other than male 
homosexual sex and increasing age (based on multivariate logistic regression 
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analysis). CD4 counts at diagnosis have generally increased over time in South 
Australia (Figure 10a). As expected, CD4 count at diagnosis is strongly associated 
with the frequency of testing (Figure 10b). 
 
Figure 10: CD4 distribution at HIV diagnosis for cases detected in South Australia (a) by 
calendar year, (b) by years since last HIV-negative test 
 
The degree of HIV disease progression from the time of infection until diagnosis 
among cases in South Australia is shown by comparison of CD4 distributions in 
Figure 11. There is clearly a large distribution in disease progression by the time of 
diagnosis, with reductions from a mean of approximately 900 CD4 cells per μl in 
uninfected people to a bimodal distribution with peaks at approximately 500 and 100 
CD4 cells per μl. Testing rates are crucial for detecting earlier infection.  
 
Figure 11: CD4 distribution at HIV diagnosis in South Australia compared with uninfected 
controls 
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HIV testing among the priority group of men who have sex with men is relatively high. 
Among men recruited to the Adelaide Gay Community Periodic Survey in 2007, 8.7% 
did not know their HIV status and 10.4% had not been tested for HIV [5]. This is 
comparable to the 7% of men in the e-male survey who report being gay socially 
engaged but have not had an HIV test [4]. However, 32% of men living in South 
Australia who are not socially engaged with gay networks in South Australia did not 
know their HIV status. Men who have received an HIV test generally test for HIV 
relatively frequently (Figure 12) [4-5]. Testing rates have also been increasing 
(Figure 13).  
HIV testing among MSM is relatively high, but it may be important to improve access 
to mechanisms that facilitate HIV screening for non-MSM populations in South 
Australia. 
 
 
Figure 12: HIV testing rates among MSM in South Australia who have received an HIV test 
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Figure 13: HIV testing rates among gay men recruited to the Gay Community Periodic Surveys 
in South Australia (excluding those recruited from sexual health clinics) who have received an 
HIV test 
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Association between HIV and syphilis 
Over the last decade syphilis has re-emerged in numerous industrialized countries 
including Australia [15-19], particularly among gay men [20-23]. Infectious syphilis 
diagnoses in Australian men have increased from approximately 1 per 100,000 in the 
year 2000 to 10-15 per 100,000 in 2008, with increasing trends in diagnoses of 
infectious syphilis occurring in each Australian state and territory including South 
Australia. Among gay and other homosexually active men, rates of sexually 
transmissible infections (STIs), and particularly syphilis have increased significantly 
in all major Australian cities since the late 1990s, with at least half the cases being 
among HIV-positive gay men. These epidemics are concerning since syphilis 
infections are accompanied by significant health burdens as untreated cases may 
progress to tertiary syphilis [24-25], and the presence of syphilis lesions facilitate HIV 
transmission [26].  
South Australia has experienced a relatively unique switch in the pattern of syphilis 
infections. During the 1990s syphilis infections were predominantly (91.7%) affecting 
Aboriginal and Torres Strait Islander populations, with roughly equal diagnoses 
among males and females (Figure 14). The number of syphilis cases declined over 
the 1990s. There was a re-emergence of syphilis in the 2000s. However, the 
epidemic shifted to predominantly affect non-Indigenous males (Figure 14). 
 
Figure 14: Syphilis diagnoses in South Australia by gender and Aboriginal and Torres Strait 
Islander status 
 
In the five-year period, 2004-2008, there were 162 syphilis diagnoses in South 
Australia; 125 (77%) of which were among non-Indigenous Australians and 136 
(84%) were among males. The emergent syphilis epidemic over the last decade has 
mainly affected gay and other men who have sex with men. More specifically, 
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syphilis has disproportionately affected HIV-positive gay men (Figure 15). In South 
Australia’s surveillance mechanisms syphilis diagnoses have been linked to HIV 
status. During 2004-2008, 50% of all syphilis diagnoses were among HIV-positive 
men. The average age at syphilis diagnosis was 37.1 years. These summary 
statistics are not significantly different if data are limited to infectious syphilis (primary 
or secondary stages).  
  
 
Figure 15: Syphilis diagnoses in South Australia among non-Indigenous males by reported 
sexual orientation 
 
Health promotion activities across Australia have had little impact on the resurgence 
of syphilis among gay men and rates continue to rise [27-28]. During the period of 
late 2008 to end 2009, the National Gay Men’s Syphilis Action Plan (NGMSAP) was 
developed [29]. This plan was initiated by the Blood Borne Virus and STIs 
Subcommittee (BBVSS) of the Australian Population Health Development Principal 
Committee and its development, along with underlying research, was carried out by 
the authors of the current report at the National Centre in HIV Epidemiology and 
Clinical Research [29]. The priorities of the NGMSAP are summarised as:  
x Priority 1 
o Gay men are encouraged to test for syphilis as it pertains to their level of risk: The 
more sexually active the individual gay man then the more often he should be tested. 
For sexually-active gay men in general, testing for syphilis should be linked to other 
routine testing. Ongoing screening for syphilis should be routine with HIV 
management and testing (as opt-out strategies): Sexually-active HIV-infected men 
should be tested for syphilis during routine check-up, usually every 3 
months; Screening for syphilis should also be conducted alongside every HIV test for 
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sexually-active gay men not previously diagnosed with HIV. In addition, as a 
minimum, men who have more than 20 partners per 6 months should be tested 
for syphilis at least twice per year. Testing sexually active gay men who have 
never previously been tested is also important. 
x Priority 2 
o Easier ways for notifying sexual partners discreetly should be created. The goal 
is to quantifiably observe an increase in the rate of partner notification. To 
decrease stigma, increased education about syphilis is required. Mechanisms for 
partner notification should consider patient-led, clinician-led, and centralised 
notification models that use a variety of means and technologies. 
x Priority 3 
o There is general agreement that the proposed syphilis chemoprophylaxis 
(‘syphilaxis’) trial should proceed as soon as is practical. It is recommended that 
possible Australian funding sources for the trial be investigated. 
x Supporting priority 
o Promoting condom use to maintain current high usage levels remains critical. 
Condom use and number of sexual partners are also important concepts in education 
for gay men in assessing their level of risk and relative need for, and frequency of, 
testing. 
o Consideration should be given to locating highly sexually active gay men, who 
have greater than 20 partners per 6 months, for the purposes of targeting 
interventions. Care should be taken for protecting the confidentiality of the venues 
and men involved. 
The priorities recommended in the NGMSAP are consistent with the priority action 
areas from the last National Sexually Transmissible Infections Strategy (2005-2008) 
and the next National Sexually Transmissible Infections Strategy to be released in 
2010. Implementation of the NGMSAP priorities has commenced in 2010. 
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Modelling evaluation methods 
Mathematical models can provide useful insights into the complex dynamics of 
disease transmission [30]. In this report a mathematical model is developed to 
describe the HIV epidemic among men who have sex with men (MSM) in South 
Australia. The model is informed by South Australian behavioural and clinical data 
along with biological data from the international literature and it is calibrated to reflect 
the past and present epidemiology of HIV in South Australia. The model is used to 
determine the key drivers of past trends, evaluate past and present programs, and to 
forecast epidemic trajectories in the future according to current conditions or due to 
implementation of public health interventions. 
 
A deterministic compartmental model was constructed and formulated as a system 
of ordinary differential equations to track the number of MSM in South Australia over 
time that are in each state of HIV disease stage: whether uninfected with HIV or HIV-
infected and undiagnosed, diagnosed, or on antiretroviral treatment. All MSM are 
classified according to whether they belong to a population that is socially engaged 
to the gay community or not. All HIV-infected individuals are classified according to 
their stage of HIV disease, based on CD4 count: CD4 count > 500 cells per μl; 350 
cells per μl < CD4 count < 500 cells per μl; 200 cells per μl < CD4 count < 350 cells 
per μl; or CD4 count < 200 cells per μl. A schematic diagram of this natural history 
described in the model is presented in Figure 16. The ordinary differential equations 
used in the model are shown in Appendix A. 
 
 
Figure 16: Schematic diagram of HIV natural history and structure of mathematical model 
 
Force of infection 
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The force of infection is the dynamic rate at which susceptible individuals become 
infected with HIV. Typically the force of infection is calculated as the average number 
of sexual partners each susceptible person has per year, multiplied by the probability 
that each new partner is HIV-positive, multiplied by the probability of HIV 
transmission occurring per partnership per year. Each of these factors will change 
continuously over time. A number of variables contribute to each of these 
components. 
Number of sexual partners 
The model incorporates the average numbers of casual sexual partners and the 
average numbers of regular partners MSM have each year. Stratified data of partner 
acquisition rates [4, 31-33] that demonstrate the heterogeneity in the population are 
used to obtain weighted average partner rates for the population; differences 
between men who identify as socially engaged to the gay community and men who 
are not socially engaged with the gay community are included. The degree of 
assortativity of partners (i.e., like with like – e.g., gay community attached men 
choosing only partners who are also attached to the gay community) [34] was 
determined by examination of the frequency distributions of the locations where 
community engaged and community non-engaged men report obtaining their sexual 
partners (Figure 17).  These frequencies were balanced to determine the rate of 
mixing between the two population groups. 
 
 
Figure 17: Locations where men who have sex with men, who participated in the e-male survey, 
reported looking for male sex partners in South Australia: (a) reported gay community 
engaged; (b) reported not gay community engaged. 
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Probability that new sexual partner is HIV-positive 
If there was homogeneous non-differential mixing and no change in sexual 
behaviour between any categories of MSM, then the probability that a new partner is 
HIV-positive is simply the ratio of the number of HIV-infected men to the total number 
of men in the population. There is evidence of change in behaviour upon diagnosis 
and men who have late-stage disease are likely to have reduced numbers of 
partners. Also, due to different assortative mixing rates (e.g. different groups of men 
acquire partners from different types of locations) the probability of new partners 
being HIV-positive must be calculated dynamically based on the prevalence of HIV in 
the pool of potential partners of the specific group of men. Furthermore, the 
probability of a discordant partnership depends on the rate of serosorting. 
Serosorting is the practice of choosing sexual partners thought to be of concordant 
HIV serostatus in order to reduce the risk of HIV transmission during unprotected 
intercourse [35-37]. There is strong evidence to suggest that in various populations 
of MSM around the world the formation of casual sexual partnerships and behaviour 
within such partnerships has been increasingly influenced by the disclosure of HIV 
serostatus [35, 38-43]. Serosorting is not as common in South Australia as in other 
locations in Australia [44] and is less common among HIV-negative MSM. However, 
serosorting has still been an increasing phenomenon in South Australia which has 
undoubtedly influenced the dynamics of partnership formation.  
 
Probability of HIV transmission per discordant partnership per year 
The probability of HIV transmission in a discordant partnership depends on the 
number and type of risk exposure events. Engaging in unprotected anal intercourse 
(UAI) is the most common risk-related event associated with HIV transmission 
among South Australian men. However, the actual per-exposure risk of acquiring 
HIV differs between insertive and receptive roles of penile-anal intercourse [45]. 
Further, transmission risk is less for receptive sex involving withdrawal compared 
with receptive sex involving ejaculation inside the rectum and transmission risk is 
less for circumcised men partaking in the insertive role [45]. According to knowledge 
of partners’ serostatus an HIV-negative man may choose which sexual position they 
are willing to take (known as strategic positioning). It has been established that 
disclosure of HIV status influences sexual positioning of gay men in Australia [46]. If 
a condom is used during sex, then transmission risk decreases substantially. Also, if 
the HIV-infected partner is on effective antiretroviral therapy with suppressed viral 
load then transmission risk is also reduced [47]. The risk of transmission associated 
with each of these combinations differs and must be calculated to accurately 
estimate the risk per exposure event. Finally, the probability of transmission in a 
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discordant partnership must calculate the cumulative risk over all exposure events 
that occur over time (where there are likely to be numerous exposures to different 
types of risk events). The mathematical expression for the force of infection used in 
the mathematical model is presented in Appendix A. 
Input data and assumptions 
The model is based on available behavioural, clinical, biological and epidemiological 
data. All model inputs are presented in Table 1. The symbols correspond to rates 
used in the model equations presented in Appendix A. 
Table 1: Inputs and assumptions for mathematical model 
Parameter 
Symbol 
Description Value Referenc
e 
reg
SEc  
Average number regular partners for socially 
engaged MSM (proportion of men with a regular 
sexual partner) 
0.728 [48-50] 
reg
OMc  
Average number regular partners for other MSM 
(proportion of men with a regular sexual partner) 
0.518 [48, 50] 
cas
SEc  
Average number casual partners per year for 
socially engaged MSM 
11.504 [48, 50] 
cas
OMc  
Average number casual partners per year for 
other MSM 
8.736 [48, 50] 
reg
SEn
reg
OMn  
Average number of anal intercourse acts per 
regular partnership per year 
10-50 [48, 50] 
cas
SEn
cas
OMn  
Average number of anal intercourse acts per 
casual partnership  
1  
SE
regcondom  
Condom use with regular partners 
for socially engaged MSM 
2001 69.09% [48-50] 
2003 69.91% 
2005 68.09% 
2007 65.52% 
OM
regcondom  
Condom use with regular partners 
for  other MSM 
2001 0.69.22% [48-50] 
2003 70.04% 
2005 68.22% 
2007 65.65% 
SE
cascondom  
Condom use with casual partners for 
socially engaged MSM 
2001 88.83% [48-50] 
2003 88.23% 
2005 88.71% 
2007 84.63% 
OM
cascondom  
Condom use with casual partners for 
other MSM 
2001 80.17%    [48-50] 
2003 79.63% 
2005 80.06% 
2007 76.37% 
posdisclose  Probability  seropositive MSM will 2001 43.2% [48-50] 
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disclose serostatus in casual act 2003 39.5% 
2005 48.3% 
2007 36.6% 
negdisclose  
Probability  seronegative MSM will 
disclose serostatus in casual act 
2001 0.3575 [48-50] 
2003 0.355 
2005 0.378 
2007 0.3205 
H  Efficacy of condom protection per act 90-99% [51-55] 
AIDSc  
Multiplying factor for the reduction in number of 
sexual partners for men in AIDS stage disease 0.1 – 0.4 
[56] 
f  Multiplying factor for the change in number of sexual partners post diagnoses of HIV infection  0.4 – 0.9 [57-65] 
SP  
Average time for individuals to ‘retire’ out of 
sexually active population (no longer obtaining 
new partners) 
30-70 years [66] 
SEJ  
Percentage of socially engaged 
MSM that test for HIV infection each 
year 
2001 57% [48-50] 
2003 61% 
2005 60% 
2007 65% 
OMJ  
Percentage of other MSM that test 
for HIV infection each year 
2001 38% [48-50] 
2003 41% 
2005 40% 
2007 43% 
SE
lt
200/1 J
OM
lt
200/1 J  
Average time from the beginning of AIDS before 
individual is likely to be diagnosed with infection 
2-4 months [56] 
500/1 Z  Average time (without ART) for HIV-infected individuals to progress from CD4 count >500 to 
CD4 count 350-500 
2.95 (1.79-
4.42) years 
 
[67] a  
500350/1 Z  Average time (without ART) for HIV-infected individuals to progress from CD4 count of 350-
500 to CD4 count of 200-350  
1.96 (1.81-
2.13) years 
 
[67] a  
350200/1 Z  Average time (without ART) for HIV-infected individuals to progress from CD4 count of 200-
350 to CD4 count <200  
1.96 (1.81-
2.13) years 
 
[67] a  
500G  HIV-related death rate for patients with CD4 count >500 cells per μL and detectable viral load 0.051% (0.035-
0.068%) 
[68] 
500350G  HIV-related death rate for patients with CD4 count 350-500 cells per μL and detectable viral load 0.128% (0.092-
0.164%) 
[68] 
350200G  HIV-related death rate per 100 person-years for patients with CD4 count 200-350 cells per μL and 
detectable viral load 
1.0% (0.2-
2.0)% 
[68-69] 
200G  HIV-related death rate per 100 person-years for patients with CD4 count <200 cells per μL and 
detectable viral load 
4.08 (0.30-
7.86)% 
[68-69] 
TG  HIV-related death rate per 100 person-years for patients with CD4 count <200 cells per μL and 
detectable viral load 
1.0% (0.2-
2.0)% 
Experimental 
variable  
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TFG  HIV-related death rate per 100 person-years for patients with CD4 count <200 cells per μL and 
detectable viral load 
4.08 (0.30-
7.86)% 
Experimental 
variable  
500K  Proportion of individuals with CD4 count >500 that commence treatment for HIV each year 0.2 
Experimental 
variable  
500350K  Proportion of individuals with CD4 count 350-500 that commence treatment for HIV each year  0.5 
Experimental 
variable  
350200K  Proportion of individuals with CD4 count 200-350 that commence treatment for HIV each year  0.75-0.85 
Experimental 
variable  
200K  Proportion of individuals with CD4 count <200 that commence treatment for HIV each year  0.85-0.95 
Experimental 
variable  
Q  Percentage of individuals on ART who cease therapy each year 
1-5%  b  
posn  
The percentage of times a negative man will take 
each role in a sex act based on disclosure of 
partner’s serostatus 
See 
footnotec  
[46]  
rE  Per-contact risk of transmission when negative partner takes receptive role 0.48-1.52% [70] 
wE  
Per-contact risk of transmission when negative 
partner takes receptive role with withdrawal prior 
to ejaculation 
0.15-1.53% [70] 
uncirc
iE  Per-contact risk of transmission when negative partner is uncircumcised and takes insertive role 
0.07-1.68% [70] 
circ
iE  Per-contact risk of transmission when negative partner is circumcised and takes insertive  role 
0.02-0.24% [70] 
multpa  
Multiplicative factor for transmission probability for 
people in primary/acute infection or in AIDS stage 
infection (due to higher viral load) 
14.7 [71-72] 
multt  
Relative reduction in HIV transmission probability 
for people on antiretroviral therapy 
92% [47] 
effART  
Proportion of people on antiretroviral therapy with 
undetectable viral load 
See 
footnote d  
[73] 
mixSE  
Average percentage of sex acts a socially 
engaged MSM will have with a non-socially 
engaged MSM 
43% [48, 50] 
mixOM  
Average percentage of sex acts a non-socially 
engaged MSM will have with a socially engaged 
MSM 
55% [48, 50] 
a  A summary of the relation between HIV-1 RNA concentration and decline in CD4+ count 
from the prospective study by Mellors et al. [67] is given below: 
Plasma HIV-1 RNA 
concentration (copies/mL) 
Mean decrease in CD4+ T cell 
count per year (cells/μL) 
≤ 500 -36.3 (-30.4,-42.3) 
501-3,000 -44.8 (-39.1,-50.5) 
3,001-10,000 -55.2 (-50.7,-59.8) 
10,001-30,000 -64.8 (-59.6,-70.0) 
> 30,000 -76.5 (-70.5,-82.9) 
 
With this data, and assuming that the average viral load is ~104.87 copies per mL for 
people without treatment, the CD4+ T cell count decreases by an average of 76.5 (70.5, 
82.9) every year. 
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To progress through the >500 CD4 cell category, we assume that the average CD4 
count is 800 cells/μL after the 2-month acute phase of HIV infection and then declines 
at the constant rate of 76.5 (70.5, 82.9) cells/μL each year. Then the average time to 
progress through this compartment is 2/12 + 300/(76.5 (70.5, 82.9)) years; that is 4.09 
(3.79, 4.42) years. 
To progress through the 350-500 and 200-350 CD4 cell categories, we assume an 
average loss of 150 CD4 cells. Then the average time to progress through this 
compartment is 150/(76.5 (70.5, 82.9)) years; that is 1.96 (1.81, 2.13) years. 
b  15.4/100 person years is the average rate of stopping one regime due to toxicity 
but the vast majority usually start another regime [74]. Very few people who 
commence ART stop altogether (expert opinion). Therefore, we take the 
absolute rate of completely stopping therapy to range from 1-5% per year as an 
experimental variable. 
c  
 
d
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The key time-dependent behavioural parameters used in the model are provided in 
Figures 18-21.  
 
Figure 18: Reported condom usage in regular relationships from the Adelaide Gay Community 
Periodic Surveys 
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Figure 19: Reported condom usage in casual relationships from the Adelaide Gay Community 
Periodic Surveys 
 
 
Figure 20: Reported disclosure of HIV status to casual partners from the Adelaide Gay 
Community Periodic Surveys 
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Figure 21: Reported HIV testing rates from the Adelaide Gay Community Periodic Surveys 
 
Sampling and sensitivity analysis 
Parameters used in the model were assigned a range of plausible values based on 
available data (Table 1). Latin Hypercube Sampling [75] generated 10,000 samples 
from each distribution. These parameter sets became input values for the 
mathematical model which was run 10,000 times. The sum of squares of the 
difference between the model simulated number of HIV diagnoses and the actual 
number of HIV diagnoses in South Australia over the period 2003-2008 was 
calculated for each simulation and Monte Carlo filtering was used to arrive at 100 
parameter sets that best describe the past epidemiology. It was ensured that the 
model also accurately represents other epidemiological features in the population 
such as HIV prevalence, rates of undiagnosed infections, and antiretroviral treatment 
rates. Sensitivity analyses were performed to determine important factors associated 
with epidemic patterns.  The SaSAT software package [76] was used to sample input 
parameters. The mathematical model was implemented in computer programming 
code using Matlab software. 
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Model fit to surveillance data 
 
Using the established input data, the South Australian HIV mathematical model was 
run over the time period 2002 to 2008. In Figure 22 the model-generated simulated 
expected number of HIV diagnoses is plotted with the actual number of HIV 
diagnoses in South Australia. The model accurately reflected the epidemic trends in 
diagnoses (Figure 22). The model also estimated that 13.68% (median, 13.41-14.10% IQR) of HIV-
infected people in South Australia are undiagnosed and 79.40% (median, 78.42-80.21% IQR) of 
diagnosed people are on antiretroviral treatment. 
 
The model estimated the expected number of incident infections over the period 
2002-2008 that must have occurred in order to lead to the observed number of 
diagnoses (Figure 23). This suggests that incidence was relatively high at the 
beginning of the last decade, giving rise to an emergence of HIV (as indicated in 
Figure 4). However, the number of incident cases very closely aligns with the 
number of diagnoses over the past 4-5 years (Figure 23). This is attributable to the 
high testing rates among MSM in South Australia. Furthermore, the number of 
diagnoses approximately mirrors the incident cases approximately 18 months earlier 
(distance between roughly parallel curves) (Figure 23).  
 
Figure 22: Model simulated number of HIV diagnoses over the period 2002- 2008 from 100 
simulations (median in black); actual HIV diagnoses are also indicated  
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Figure 23: Model simulated number of HIV diagnoses over the period 2002- 2008 from 100 
simulations (median is black solid curve) compared with simulated number of incident cases 
(dashed curve)  
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Evaluating the past  
The rate of HIV diagnoses in South Australia has increased significantly over the past 
decade but over the past few years it has stabilised or even started to decline (Figure 4). Over the 
same period of increased HIV diagnoses there has been an increase in unprotected anal intercourse, 
as indicated by a reported decrease in condom use (Figures 18 and 19). As expected, condom use is 
higher among casual partners (Figure 19) than among regular partners (Figure 18). However, it was 
among regular partners that condom use appears to have declined first, from around 2003) and later 
followed by a decline in condom use among casual partners, from around 2005 (Figures 18 and 19). It 
is not clear to what extent the change in condom use contributed to the rise in HIV diagnoses in South 
Australia since the rise in HIV cases (Figure 4) occurred before the reported changes in condom use.  
In most populations of MSM in Western countries, including in most Australian 
jurisdictions, disclosure of HIV serostatus between casual sexual partners has 
become increasingly common (in addition to commonly disclosing to regular partners) 
[35, 38-43]. Disclosure of HIV status facilitates decisions around partnership 
formation, sexual positioning within partnerships and negotiations around condom 
use. These risk reduction strategies based on knowledge of HIV status is becoming 
more common. However, in contrast to most settings, in South Australia disclosure 
of HIV status has not increased but remained relatively constant or even decreasing. 
Disclosure of HIV status occurs in approximately 40% of partnerships for both HIV-
seronegative and HIV-seropositive gay men (Figure 20). 
Testing rates among gay men in South Australia are relatively high and increasing 
(Figure 21). High rates of HIV testing are valuable for effective surveillance but more 
importantly high testing rates benefit the individuals at risk of HIV in order to provide 
appropriate clinical care, management and treatment but increasing testing rates is 
also beneficial at the population-level as a public health prevention strategy [77]. 
This is because HIV-infected people who are aware of their HIV status tend to 
change their behaviour in order to reduce secondary transmission to others. 
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TT123 campaign 
 
The Reducing Rising Rates of HIV Infection in South Australia working party first met 
in mid May 2008. It was charged with the responsibility of developing a health 
promotion response to the rising rates of HIV infection amongst gay men and men 
who have sex with men in South Australia. Group membership comprised 
representatives of service organisations responsible for HIV prevention in South 
Australia. The Adelaide 2008 Feast Festival was identified as an opportunity in which 
to promote messages about HIV prevention to gay men.  After considerable cross-
sector collaboration the TESTING - TESTING - 1 - 2 – 3 campaign was developed. 
The campaign’s aims and objectives were to: 
x Make gay men aware of the rise in HIV infections in South Australia and to 
encourage behaviours that would assist to reduce the risk of HIV transmission; 
x Make gay men aware of the rising rates of sexually transmitted infections such as 
Chlamydia, syphilis and gonorrhoea and their association with HIV transmission; 
x Reduce levels of STIs in the gay community by encouraging men to test for STIs and 
HIV, and especially if they have had unprotected sex; 
x Reduce HIV transmission by encouraging gay men to test for HIV and to know their 
HIV status. 
The campaign’s messages focussed on:  
x The importance of testing regularly for HIV and for gay men to know their HIV status; 
x The importance of testing regularly for STIs as one way for gay men to reduce their 
risk of getting or passing on HIV. 
These key messages were placed on print press advertisements, posters, condoms, 
websites, and pride march placards. Other campaign activities also promoted the 
increase in testing. 
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Did the TT123 campaign influence testing rates? 
 
Impact assessment of interventions attempts to translate investment into estimates 
of impact. The impact of a campaign can be measured by the degree of awareness 
of the interventions among the targeted groups in the public. But the primary impact 
of this campaign is in the measurement of HIV testing rates among gay men. The 
potential effectiveness of the intervention can then be estimated by comparing 
observed epidemiological outcomes with what would have been expected had the 
campaign not been implemented. In order to assess the impact of an intervention it 
is essential to compare data before and after it took place. The Adelaide Gay 
Community Periodic Surveys are serial cross-sectional surveys and the best source 
for independently measuring general trends in testing rates. Data on reported HIV 
testing rates from the Adelaide Gay Community Periodic Surveys are shown in Table 
2.  
 
Table 2: Proportion of non HIV positive men who reported to have had HIV test excluding men 
recruited from sexual health clinics (Note: before 2005, answer option did not include “never 
tested”) 
  1998 
n (%) 
1999 
n (%) 
2001 
n (%) 
2003 
n (%) 
2005 
n (%) 
2007 
n (%) 
2009 
n (%) 
Never tested - - - - 79 (14.2) 
39 
(9.11) 
109 
(14.2) 
Less than 6 months 195 
(46.4) 
161 
(44.2) 
202 
(45.3) 
344 
(49.5) 
238 
(43.3) 
202 
(47.2) 
342 
(44.6) 
7 – 12 months 71 
(16.9) 
69 
(19.0) 
90 
(20.2) 
132 
(19.0) 
102 
(18.3) 
78 
(18.2) 
144 
(18.8) 
1 -2 years 77 
(18.3) 
65 
(17.9) 
59 
(13.2) 
102 
(14.7) 
62 
(11.1) 
56 
(13.1) 
70 
(9.1) 
More than 2 years 77 
(18.3) 
69 
(19.0) 
95 
(21.3) 
117 
(16.8) 
77 
(13.8) 
53 
(12.4) 
102 
(13.3) 
Total 420 
(100) 
364 
(100) 
446 
(100) 
695 
(100) 
558 
(100) 
428 
(100) 
767 
(100) 
 
To evaluate whether the TT123 campaign had a noticeable impact on testing rates, 
the data from 2009 should be compared with the trend in testing data from previous 
years. It should be noted, however, that because different samples of individuals 
participate in each survey sampling biases may exist. For example, the percentage 
of gay men who report never testing for HIV was 14.2% in 2005, 9.1% in 2007 and 
14.2% in 2009 which is unlikely reflective of the actual changes in numbers of gay 
men who have not had an HIV test. When all testing data are included, the 
distribution of testing rates in 2009 appears to be almost identical to the reported 
data from 2005 (Figure 23). These data suggest that the TT123 did not have an 
impact on decreasing the proportion of gay men who have not received an HIV test. 
In order to assess potential changes in testing practices among gay men who have 
previously received an HIV test the non-testing respondents should be excluded. In 
Figure 24 it is shown that the proportion of gay men who have tested for HIV in the 
last 12 months has modestly increased over the last few years: from 71.79% in 2005, 
to 71.96% in 2007, to 73.89% in 2009. That is, there was a relative increase in 
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testing rates among gay men who have been tested of 0.22% from 2005 to 2007 but 
the relative increase in testing rates from 2007 to 2009 was 2.69%. Therefore, it is 
reasonable to infer that the TT123 campaign did marginally increase testing among 
gay men who had previously been tested. 
  
 
Figure 23: Reported HIV testing rates from the Adelaide Gay Community Periodic Surveys, 
2005-2009 
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Figure 24: Reported HIV testing rates from the Adelaide Gay Community Periodic Surveys, 
2005-2009, excluding men who report never testing for HIV 
 
According to the South Australian HIV model, if the TT123 campaign was not 
implemented and testing rates continued on the previous trend then there would 
have been 0.18 (median, 0.14-0.22 IQR) extra HIV infections in the following year. 
That is, if the intervention was implemented every year for 10 years then 
approximately 2 infections could be expected to be averted that are directly 
attributable to TT123. 
 
The influence of testing patterns 
Over the last decade there has been a steady increase in the rate of testing for HIV 
among gay men in South Australia (Figure 21). If the increase in testing over this 
period had not occurred then, according to the model, an additional 2.87 (median, 
0.99-1.81 IQR) HIV infections would have occurred among men who have sex with 
men in South Australia (Figure 25). 
 
Figure 25: Cumulative number of HIV incident infections among men who have sex with men in 
South Australia (solid curve) compared with expected cumulative number of incident HIV 
infections if testing rates had not changed (dashed curve) 
 
Epidemiological impact of changes in behaviour and treatment 
 
The influence of changes in condom usage 
Although there are differences between Australian States in the reported usage of 
condoms, overall the trend in the data is towards an increase in levels of unprotected 
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anal intercourse [31] (Table A.1). Condom use has declined in recent years in South 
Australia (Figures 18, 19). If the change in condom use over this period had not 
occurred then, according to the model, there would have been 12.46 (median, 13.48-
14.82 IQR) less HIV infections among men who have sex with men in South 
Australia (Figure 26). 
 
Figure 26: Cumulative number of HIV incident infections among men who have sex with men in 
South Australia (solid curve) compared with expected cumulative number of incident HIV 
infections if rates of condom use had not changed (dashed curve) 
 
The influence of serosorting and disclosing serostatus 
Serosorting refers to the practice of seeking sex with partners of the same HIV 
serostatus, usually in order to negotiate unprotected anal sex with that partner. 
Among men believed to be in HIV-negative seroconcordant relationships there is a 
presumed lower risk of HIV transmission; or in the case of HIV-infected men 
serosorting for seroconcordant HIV positive men, no risk of HIV transmission. 
Disclosure of HIV serostatus has been increasing in many settings but has not 
changed markedly in South Australia (Figure 20). If the change in rates of disclosure 
of HIV serostatus to casual partners over this period had not occurred then, 
according to the model, there would have been 0.48 (median, 0.51-0.27 IQR) less 
HIV infections among men who have sex with men in South Australia (Figure 27). 
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Figure 27: Cumulative number of HIV incident infections among men who have sex with men in 
South Australia (solid curve) compared with expected cumulative number of incident HIV 
infections if rates of disclosure of HIV serostatus had not changed (dashed curve) 
 
 
 
The influence of the effectiveness of ART 
Clinical surveillance data has indicated an increase in the proportion of patients 
treated with combination antiretroviral therapy (ART) that have undetectable viral 
load (Table A.1). If the increase in effectiveness of ART over this period had not 
occurred then, according to the model, an additional 2.20 (median, 2.12-2.40 IQR) 
HIV infections would have occurred among men who have sex with men in South 
Australia (Figure 28). 
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Figure 28: Cumulative number of HIV incident infections among men who have sex with men in 
South Australia (solid curve) compared with expected cumulative number of incident HIV 
infections if change in the effectiveness of ART had not changed (dashed curve) 
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Clean needle program 
The evaluation of needle and syringe programs in South Australia is based on the 
2009 Return on Investment 2 study [10]. 
The ‘Clean Needle Program’ (CNP) in South Australia, operated by the Drug and 
Alcohol Services, commenced in 1989. Pharmacy programs in South Australia for 
distributing needles and syringes commenced in the early 1990s. South Australia 
has 81 CNPs, consisting of one primary outlet, 69 secondary outlets and 11 
enhanced secondary outlets. There are over 170 pharmacies that sell needles and 
syringes on a commercial basis. Primary and secondary outlets are based in 
metropolitan Adelaide and in rural areas. Some outreach services are also provided. 
Disposal facilities are provided at all community CNP sites, most pharmacies and 
some local councils also provide disposal facilities. 
Number of CNP sites in South Australia: 81 (plus pharmacies) 
Number of syringes distributed 1999-2008 (Figure 29): 31,569,283 
Average number of syringes distributed per year: 3,156,928 
Total spending 2007/8: $1,536,115 
 
 
Figure 29: Number of needles and syringes distributed in South Australia (1999-2008) 
 
The proportion of Australian injecting drug users (IDUs) that are in South Australia 
has remained relatively steady. The number of needles and syringes distributed 
through CNPs in South Australia increased during 2002-2004 but has started to 
decline in recent years. The average frequency of injecting by IDUs in South 
Australia has remained steady but sharing rates have tended to increase slightly. 
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Despite this, the incidence of HIV has remained relatively low among South 
Australian IDUs. 
In 2007/8, 2,763,030 sterile injection equipment units were provided in South 
Australia: 20% were distributed through secondary sites with 63% of these through 
enhanced secondary sites. 241,900 needles and syringes were distributed through 
pharmacies. Pharmacists charge an average of $5-$10 per five-pack out-of-pocket 
costs. The number of CNP sites in South Australia is listed in Table 3. Table 4 
reports the spending by financial year in 2008 dollars, unadjusted and adjusted for the 
consumer price index (CPI). 
Table 3: Number of CNP sites in South Australia 
 Primary Secondary Enhanced 
secondary 
2007/8 1 69 11 
2006/7 1 67 9 
2005/6 1 65 6 
2004/5 1 64 6 
2003/4 1 66 6 
2002/3 1 66 5 
2001/2 1 65 5 
2000/1 1 63 5 
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Table 4: Summary of expenditure on CNPs in South Australia (2000/1-2007/8) 
 2000/1 2001/2 2002/3 2003/4 2004/5 2005/6 2006/7 2007/8 
Consumables ($’000)         
Sterile injecting equipment 494 456 501 504 430 489 405 401 
Disposal equipment 253 233 256 109 260 260 274 227 
sub-total 747 690 757 613 690 749 679 629 
CNP SUPPORT ($’000)         
Primary CNPs Operations  182 216 215 215 215 215 215 215 
Support for Secondary CNPs 147 309 370 322 388 661 386 637 
sub-total 329 526 585 537 603 877 601 853 
TOTAL ($’000) 
(unadjusted for CPI) 1,077 1,216 1,342 1,150 1,294 1,625 1,280 1,482 
TOTAL in 2008 ($’000) 
(CPI adjusted)  1,361 1,490 1,597 1,337 1,466 1,792 1,367 1,536 
 
Evaluating CNPs over the period 1999-2009 
The ROI mathematical epidemiological transmission model was applied to IDUs and 
CNPs specifically in South Australia. The model was used to evaluate current CNPs 
versus no program and to project likely epidemiological impacts of potential changes 
to the program. The model estimated the expected number of HIV cases in South 
Australia with and without CNP distribution of sterile injecting equipment (Figure 30). 
The estimated number of infections averted is presented in Figure 31. An estimated 
122 (89-175, IQR) HIV infections were averted due to CNPs in South Australia over 
the decade, 1999-2009. 
HIV cases with CNPs 
 
HIV cases without CNPs 
 
Figure 30: Estimated HIV incidence in South Australia with and without CNPs 
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Figure 31: Estimated cumulative number of HIV cases averted in South Australia due to CNPs 
 
Epidemic projections in South Australia 
The South Australian model was used to project the expected number of HIV cases 
in the future among IDUs, according to scenarios whereby current syringe 
distribution levels are maintained or if there are increases or decreases in the 
provision of syringes through South Australian CNPs. It was forecasted that few HIV 
transmissions were likely to occur through exposure to contaminated injecting 
equipment; however, if there are significant decreases in CNP provision of sterile 
injecting equipment then an HIV epidemic is likely to emerge (Figure 32) 
HIV cases with CNPs HIV cases without CNPs 
Figure 32: Projections of the expected number of HIV cases in South Australia according to 
current syringe distribution or no CNPs 
Economic evaluation of CNPs in South Australia 
The spending of $15m in the funding of CNPs in South Australia from year 2000-2009 
has resulted in a saving of $93m in healthcare costs, with more than 15,000 
Disability Adjusted Life Years saved with a net financial saving of $80m. However, 
these savings are attributable not only to HIV infection but also hepatitis C virus 
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infections averted. A summary of the return on investment of CNP funding in South 
Australia is shown in Table 5. The mathematical and economic modelling estimated 
that if CNPs are continued at the same level of funding in SA for the next ten years, 
$295m of net financial savings will accrue ($258m discounted at 3%) and for twenty 
years $605m ($458m discounted at 3%). The lifetime net present value of 
investment in CNPs that took account of all healthcare costs and savings (but not 
costs associated with productivity losses) would be $3.85bn ($1.26bn discounted at 
3%). 
Table 5: Return on Investment of CNP funding in South Australia (2000-2009) 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Healthcare costs 
saved $m (IQR) 
11 
(10- 
13) 
11 
(10-
14) 
10 
(9- 
13) 
9 
(8- 
12) 
9 
(8- 
11) 
9 
(7- 
11) 
8 
(7- 
10) 
8 
(7- 
10) 
9 
(7- 
10) 
9 
 (8- 
11) 
CNP funding 
 $m (median) 1 1 2 1 1 2 1 2 2 2 
Net cost savings 
$m (median) 10 9 9 8 8 7 7 7 7 8 
DALY gain 
(median) 1,369 1,573 1,643 1,641 1,611 1,560 1,493 1,427 1,387 1,382 
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Projecting future HIV trends in South Australia  
Status quo 
The long-term vision of the South Australian HIV Action Plan [2] is to minimise the 
transmission of HIV in South Australia. Mathematical modelling projections of the 
expected epidemic trends according to different conditions can inform appropriate 
public health responses to achieve this aim. The model was used to project the 
future epidemic course according to the status quo, that is, if current behavioural and 
testing and clinical practices remain unchanged (Figure 33). The model projects 
suggest that South Australia is likely past the peak of infection and incidence should 
decline moderately from about 30 cases per year to about 24 cases per year by 
2015 if conditions do not change. It is estimated that the cumulative number of HIV 
infections, 2010-2015, would be 124.76 (median, 116.78-131.68 IQR).  
 
Figure 33: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to current conditions 
 
The South Australian HIV mathematical model was also used to forecast the 
expected number of HIV cases according to changes in behavioural conditions or 
effective implementation of interventions.  
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Behaviour change 
Partner acquisition 
Rates of partner acquisition have remained relatively stable and it is probably unlikely that they will 
change substantially. But even small changes in partner numbers could have a noticeable impact on 
epidemic trends [30]. Engagement with focus groups of gay men in other Australian jurisdictions and 
with stakeholders in the HIV sector have suggested that it is highly unlikely that gay men will change 
their number of sexual partners, however, they may consider a change for a short period of time if it 
would benefit the rest of the community [29]. The impact of an intervention that results in halving the 
number of sexual partners for a period of one year before resorting back to prior behaviour was 
simulated (Figure 34). It is estimated that the cumulative number of HIV infections, 2010-
2015, would be 122.13 (median, 113.78-127.99 IQR); that is, a median reduction of 
2.63 infections compared to the status quo. 
 
Figure 34: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to a short-term (1 year, 2010) intervention involving halving the 
number of sexual partners 
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Condom use 
Rates of condom use have been declining in South Australia and have likely contributed to higher 
rates of HIV infection (Figure 26). If the current trends continue then HIV diagnoses will undoubtedly 
be higher. Similar to partner numbers, MSM are unlikely to increase condom use in the modern era of 
HIV unless it was for a relatively short time and if it would benefit the rest of the community [29]. The 
impact of an intervention that results in increasing condom use to 100% with all casual partners for a 
period of one year before resorting back to prior behaviour was simulated (Figure 35). It is 
estimated that the cumulative number of HIV infections, 2010-2015, would be 120.92 
(median, 112.17-126.92 IQR); that is, a median reduction of 3.84 infections 
compared to the status quo. 
 
Figure 35: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to a short-term (1 year, 2010) intervention involving universal 
condom use with casual sexual partners 
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Test and treat 
Increasing HIV testing rates 
One of the cornerstones of effective prevention programs is the promotion of HIV 
testing. Newly-infected people have higher viral loads (for about 3-6 months [78-80]) 
than at any other time during the course of infection and consequently have the 
greatest infectiousness per sexual encounter [72, 81]. Newly-infected people are 
generally unaware of their new serostatus and their potential to cause secondary 
HIV transmissions. Detecting newly-infected people generally only occurs if there are 
high rates of testing for HIV (in terms of coverage, i.e., the proportion of people who 
are tested, and the frequency of testing, i.e., number of times people are tested per 
year). High testing rates can also have additional epidemiological benefits. One 
benefit is that individuals who are diagnosed as HIV-positive typically change their 
behaviour in order to reduce onward transmission to others. Although some 
individuals may increase sexual activity and/or the acquisition of new sexual partners, 
most individuals diagnosed with HIV significantly decrease sexual partner acquisition 
by as much as 50% on average [57-65]. Frequent testing also benefits effectiveness 
of risk reduction strategies such as serosorting, strategic positioning and negotiated 
safety as well as facilitates the initiation of antiretroviral treatment for HIV-infected 
people detected with their infection. 
Priority Action Area 2 of the South Australian HIV Action Plan is on HIV testing [2]. 
HIV testing is critical for the prevention of HIV and to ensure that care and early 
treatment is provided to people with HIV. The objective of this action area is to 
increase the uptake of HIV testing. 
Approximately 60-65% of MSM that are socially engaged with the gay community 
report receiving an HIV tested within the last 12 months. The impact of an 
intervention that results in increasing HIV testing rates among socially engaged gay 
men to 80% testing each year was simulated (Figure 36). It is estimated that the 
cumulative number of HIV infections, 2010-2015, would be 123.59 (median, 116.04-
130.05 IQR); that is, a median reduction of 1.17 infections compared to the status 
quo. If 70% or 80% of all men who have sex with men receive an annual test for HIV 
then the cumulative number of HIV infections, 2010-2015, would be 124.04 (median, 
118.62-128.58 IQR) or 122.90 (median, 118.38-127.53 IQR) respective; that is, 
median reductions of 0.72 and 1.86 infections compared to the status quo (Figures 
37 and 38).  
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Figure 36: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to increases in HIV testing rates such that 80% of socially engaged 
MSM receive a test each year 
 
 
Figure 37: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to increases in HIV testing rates such that 70% of all MSM receive 
a test each year 
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Figure 38: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to increases in HIV testing rates such that 80% of all MSM receive 
a test each year 
 
If an intervention targeted frequency rather than coverage of testing then the 
epidemiological impact would be modest but there would be an incremental benefit. 
The impact of interventions that result in 70% of MSM who are socially engaged with 
the gay community or 70% of all MSM testing twice per year was simulated (Figure 
39, 40). It is estimated that the cumulative number of HIV infections, 2010-2015, 
would be 120.23 (median, 112.90-124.87 IQR) and 119.99 (median, 116.59-124.31 
IQR) respectively; that is, median reductions of 4.53 and 4.77 infections compared to 
the status quo. 
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Figure 39: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to increases in HIV testing rates such that 70% of socially engaged 
MSM receive two tests each year 
 
 
Figure 40: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to increases in HIV testing rates such that 70% of all MSM receive 
two tests each year 
 
Testing rates in South Australia are already relatively high. Although the health care 
system and infrastructure is well-equipped to conduct screening for HIV, increasing 
rates may not be very acceptable to most gay men. But greater efforts may be 
required to reach individuals who are not regularly tested for HIV or who are at 
higher risk, and this may include extending hours of operation of sexual health clinics 
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or providing alternative testing facilities. Persons who have higher HIV risk exposure 
tend to test more frequently [82] but there may be a saturation level to the frequency  
of testing that is attainable. It is also important to increase the uptake of testing 
among other priority populations including Aboriginal people and priority CALD 
populations. 
 
Rapid tests 
One way for facilitating an increase in HIV testing could be utilising rapid testing 
technologies. A concern around use of rapid tests in Australia is that they are 
associated with a longer window period compared with standard EIA tests and so 
they may not detect a number of infections that would otherwise be detected. A 
benefit of rapid testing is that the individual will receive their test result on the same 
day which will allay fears of uncertainty associated with waiting times (of days or 
weeks) between testing and receiving results for EIA tests. Another benefit is that 
extra days of known HIV positivity, especially if in acute infection where there is 
greater infectiousness, may lead to slightly greater duration of preventing secondary 
transmissions. Detailed distribution data from the Melbourne Sexual Health Centre 
on testing frequency and time between testing and receiving test results, along with 
data on the window period was used in a mathematical model to evaluate rapid tests 
compared to standard EIA tests. By accounting for testing frequencies and window 
periods, it was calculated that for approximately 95% (94.81%) of HIV-positive cases 
diagnosis would occur at the next test for all diagnostic tests and in 5.19% of cases 
the window period would result in a delay in diagnosis until the second HIV test for 
rapid tests (Figure 41). However, when adjusting for all cases on average rapid tests 
would reduce the number of days until diagnosis by 11.40 days (median, 7.06-16.89 
IQR) compared to the fourth generation EIA test. 
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Figure 41: Model generated results from simulation of 100,000 gay men of the 
expected distribution of the number of days of known HIV positivity due to use 
of a standard rapid test compared to use of the 4th generation EIA test 
 
Increasing treatment rates 
The introduction of combination antiretroviral therapies (ART) has had a positive 
impact for many people living with HIV/AIDS, including increasing life expectancy 
and quality of life. Priority Action Area 3 of the South Australian HIV Action Plan is on 
treatment, care and support of people living with HIV [2]. It emphasises the 
importance to increase the appropriate uptake of ART. One barrier to be overcome is 
removing financial constraints. A cost-effectiveness analysis of removing 
copayments associated with ART for treatment-eligible HIV-infected South 
Australians is presented in Appendix B. 
Recently there has been considerable discussion in the international HIV/AIDS 
community around using ART for prevention. Interest around the potential role of 
ART as a measure to reduce sexual transmission of HIV at the population level was 
stimulated by a World Health Organisation research group which reported results of 
a model showing that universal annual HIV testing with immediate ART of all those 
diagnosed (known as “test and treat”) could substantially reduce, or even eradicate, 
severe generalised heterosexual HIV epidemics [83]. Although eradication has been 
challenged (e.g. [84]), the strategy should lead to reduced HIV incidence because 
effective ART reduces average viral load levels in populations and thus also 
reducing infectiousness. Very recently, large financial investment has been 
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committed to implementing “test and treat” or “seek and treat” in British Columbia, 
Vancouver and this strategy is also being considered in other regions. Therefore, the 
expected epidemiological impact of implementing versions of this strategy in South 
Australia was investigated. 
It is likely to be more feasible to seek after and recruit men who are attached to the 
gay community than those who are not socially engaged to the gay community. Thus, 
interventions targeting socially engaged MSM compared with targeting all MSM were 
explored. The expected impact of an intervention that results in 70% testing rates among socially 
engaged MSM and all HIV-diagnosed MSM receiving antiretroviral therapies is shown in Figure 42. It 
is estimated that the cumulative number of HIV infections, 2010-2015, would be 
51.01 (median, 46.82-54.42 IQR); that is, a median reduction of 73.74 infections 
compared to the status quo. 
 
Figure 42: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to 70% testing rates among socially engaged MSM and all HIV-
diagnosed MSM receiving ART 
 
If not just socially engaged MSM but all MSM are targeted with ‘test and treat’ such 
that 70% are tested at least once per year and all diagnosed people receive ART 
regardless of their CD4 count then the estimated cumulative number of HIV 
infections, 2010-2015, would be 48.52 (median, 44.30-48.66 IQR); that is, a median 
reduction of 76.24 infections compared to the status quo (Figure 43). 
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Figure 43: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to 70% testing rates among all MSM and all HIV-diagnosed MSM 
receiving ART 
 
The impact of ‘test and treat’ interventions that test 70% of all MSM twice per year 
and provide ART for all diagnosed individuals was simulated (Figure 44). It is 
estimated that the cumulative number of HIV infections, 2010-2015, would be 39.41 
(median, 37.30-39.83 IQR); that is, a median reduction of 85.35 infections compared 
to the status quo. 
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Figure 44: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to 70% of all MSM testing twice per year and all HIV-diagnosed 
MSM receiving ART 
 
Currently, HIV-infected individuals in Australia are eligible for antiretroviral therapies 
under the s100 scheme if their CD4 count is less than 500 cells per μl. Therefore, 
‘test and treat’ interventions were investigated in which all HIV-infected men with 
CD4 counts less than 500 cells per μl initiated antiretroviral treatments but not if their 
CD4 counts were greater than 500 cells per μl. If 70% of socially engaged MSM test 
for HIV each year and all diagnosed men with CD4 counts less than 500 cells per μl 
initiate ART then the estimated median cumulative number of HIV infections, 2010-
2015, would be 91.26; that is, a median reduction of 33.50 infections compared to 
the status quo (Figure 45). If 70% of all MSM test for HIV once or twice per year and 
diagnosed men initiate ART then the estimated median cumulative number of HIV 
infections, 2010-2015, would be 90.92 and 86.32 respective; that is, reductions of 
33.84 and 38.44 infections compared to the status quo (Figure 46, 47) 
 
 
Figure 45: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to 70% of socially engaged MSM testing for HIV each year and all 
HIV-diagnosed MSM with CD4 count less than 500 cells per μl receiving ART 
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Figure 46: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to 70% of MSM testing for HIV each year and all HIV-diagnosed 
MSM with CD4 count less than 500 cells per μl receiving ART 
 
 
Figure 47: Projections of the expected number of HIV diagnoses among MSM in South 
Australia to 2015 according to 70% of MSM testing for HIV twice per year and all HIV-
diagnosed MSM with CD4 count less than 500 cells per μl receiving ART 
 
Comparison of interventions 
A comparison of expected numbers of infections averted is shown in Figure 48. 
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Figure 48: Expected number of HIV infections averted among MSM in South Australia, 2010-
2015, according to a number of interventions 
Other biomedical interventions 
PrEP 
 
Pre-exposure prophylaxis (PrEP) with antiretroviral drugs is a proposed strategy for 
reducing the risk of HIV transmission between discordant sexual partners. Animal 
studies have demonstrated encouraging results (e.g. [85-89]) but so far only one 
phase II human trial of PrEP has released (inconclusive) findings [90] after stopping 
early due to concerns about study design [91]. Other clinical trials of PrEP are 
currently being conducted or in planning stages for populations of heterosexuals or 
gay men, with results expected to be released progressively over the next few years 
[92]. If found to be efficacious in humans PrEP would be an additional option to 
barrier protection for those who are at risk of HIV acquisition. In preparation for 
public health decision-making if and when a PrEP candidate passes clinical testing, it 
is important to determine thresholds of PrEP usage, efficacy, and reduction in 
condom use that will render PrEP beneficial or detrimental for individuals and 
populations of gay men. 
There are concerns that the introduction and use of PrEP may lead people to feel 
protected against HIV and therefore less likely to use condoms; this could result in 
Replacing condoms with PrEP [93] could lead to less protection against HIV 
transmission if the efficacy of PrEP is substantially less than the high efficacy of 
condoms and in settings where condom use is currently high [94]. A mathematical 
model was used to determine thresholds for the relative effectiveness of PrEP for 
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gay men in Australia. In Figure 49 it is demonstrated that any risk disinhibition 
(swapping condoms for 70% effective PrEP) will have a more noticeable impact for 
men who currently use condoms in a higher proportion of sexual acts. If there is little 
risk disinhibition and high usage then PrEP can result in significant decreases in risk 
(Figure 49). 
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(a) 
 
(b) 
 
(c) 
 
 
 
Figure 49: Contour plots of the relative effectiveness of PrEP on the risk of HIV 
transmission versus PrEP usage and level of condom replacement 
(disinhibition) for gay men who use condoms in (a) 50%, (b) 70%, and (c) 90% 
of sexual acts. 
 
Accounting for the large heterogeneity in populations of gay men in Australia, the 
average change in population-level incidence according to average levels of PrEP 
usage and risk disinhibition is shown in Figure 50 for PrEP efficacies of 50%, 70% or 
90%. If the efficacy of PrEP is 50% then there will be little advantage to its 
introduction unless there is almost no reduction in condom use and PrEP 
supplements current condom use (Fig. 50a). In the likely best-case scenario, if high-
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efficacy (90%) PrEP is used to complement current condom usage then HIV 
incidence in the population can decrease by up to ~70% (Fig. 50c). 
(a) 
 
(b) 
 
(c) 
 
 
  
Figure 50: Contour plots of the relative effectiveness of PrEP on population-
level HIV incidence versus PrEP usage and level of condom replacement 
(disinhibition) for PrEP efficacies of (a) 50%, (b) 70% and (c) 90%. 
 
The modelling suggests that although the use of moderately effective PrEP may 
result in a reduction in the average risk of HIV infection among gay men, even small 
degrees of condom replacement can outweigh this benefit and lead to increased risk. 
The relative impact of PrEP will differ between men based on levels of risk 
disinhibition and their current levels of condom usage with greater benefit for men 
who currently use condoms less frequency and are at higher risk of HIV acquisition. 
Targeting a PrEP-based intervention at men at highest risk would have the greatest 
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preventative benefit and would lead to decreased chance of detrimental population-
level outcomes from risk disinhibition. 
Circumcision 
 
Adult male circumcision has been shown to be effective for the prevention of 
acquisition of HIV in three randomised trials in heterosexual men in Southern and 
Eastern Africa [95-97]. In 2008, a large Australian community-based cohort reported 
a significant reduced risk of HIV seroconversion among circumcised MSM who 
predominantly took the insertive role in anal intercourse with a hazard ratio of 0.11, 
(95% CI 0.03-0.80, p=0.041) after controlling for age and unprotected anal 
intercourse [98]. Recently the authors of this report co-authored a published study on 
the expected effectiveness and cost-effectiveness of introducing circumcision as an 
interventions among Australian men who have sex with men [99]. It was determined 
that under the (unrealistic) situation of large-scale implementation of circumcision 
among gay men would result in 2-5% of HIV infections being averted per year with 
initial costs ranging from $3.6m to $95.1m depending on coverage. The number of 
circumcisions needed to prevent one HIV infection was estimated to be between 118 
and 330.  Circumcision would be cost-effective but would no longer be effective if 
there was minor behavioural disinhibition and the large financial investment may be 
more effectively spent on other interventions. 
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Conclusions  
Historically South Australia has responded successfully to contain and minimise the 
spread of HIV such that the prevalence of infection among all South Australians has 
remained at or below 0.1%. The success of South Australia’s past response to HIV is 
in part due to the coordination of HIV prevention programs and partnership approach 
between government, NGOs, researchers, clinicians and community representatives. 
However, the rate of HIV diagnoses in South Australia has increased significantly over the 
past decade particularly among men who have sex with men, which is the population group greatest 
affected  by HIV in South Australia. This is similar to what has occurred in most other 
jurisdictions in Australia and in comparable settings internationally. The research of 
this study suggests that the main contributor to changes in HIV infections in South 
Australia was a decline in condom use. Over the past few years HIV diagnoses have 
stabilised or even started to decline in South Australia.  
Using the South Australian HIV mathematical model it was shown that the TT123 
campaign carried out in Adelaide likely had a small impact. It does not appear to 
have decreased the proportion of MSM who have never received an HIV test. 
However, the TT123 campaign likely had an effect of encouraging MSM who have 
received an HIV test to receive another one and thus the campaign modestly 
increased testing rates. The increase in testing rate due to the TT123 campaign 
prevented an estimated 0.2 of an infection. That is, an HIV infection would be 
averted for every five years of implementation of the campaign. 
The South Australian model was used to forecast the trajectory of HIV in South 
Australia until the end of 2015. The model estimated that if behaviour and testing 
practices do not change then the number of HIV infections would decline by about 20% 
over five years but the number of HIV diagnoses would still be higher than a decade 
ago. Changes in conditions can substantially alter the epidemic trajectory. Changes 
in sexual behaviour among men who have sex with men could have a substantial 
impact on HIV incidence in the population. However, decreases in partner acquisition 
rates and increases in condom usage are unlikely to be widely acceptable among 
populations of MSM. Short-term behavioural changes may be more feasible and will 
have a moderate impact. 
Whilst the rates of HIV testing in South Australia remain very high, a significant 
proportion of people infected with HIV in South Australia are unaware of their HIV 
status, with a significant impact on new transmission rates. To have a noticeable 
impact on HIV trends men who have not received an HIV test should be targeted and 
other men should be targeted to have an HIV test at least twice per year. 
Of all interventions considered, only one was observed to have the potential to have 
a large epidemiological impact, namely, ‘test and treat’. If a ‘test and treat’ 
intervention targeted 70% of MSM who are socially engaged with the gay community 
(i.e. a likely proportion of the main population group that can be more easily targeted) 
then ‘test and treat’ is likely to have a very small impact. However, if a significant 
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proportion (70%) of men who are not connected to gay networks can be reached 
with ‘test and treat’ then the intervention would be expected to have a very 
substantial epidemiological impact. Other interventions, such as preventative prophylaxis or 
male circumcision are less likely to be viable options for effective public health strategies.  
One particularly important aspect highlighted by the modelling is that any 
intervention has to be continued over the long term for its impact on the epidemic to 
be sustained; otherwise an HIV epidemic is likely to re-emerge. Thus the long term 
acceptability of an intervention to populations of men who have sex with men is a 
highly important consideration. 
In order to design effective and specific interventions the model was structured in a 
way to investigate the behaviour and epidemiology of men who are attached to the 
gay community compared with those who are not actively engaged in gay networks. 
The expected impact of targeting interventions at particular populations was explored. 
This is the first time any modelling analysis has incorporated this separation in 
populations for any setting. The model yielded mixed results with testing 
interventions likely to be effective by targeting men who are engaged in the social 
networks of the gay community whereas ‘test and treat’ needs to target all men. This 
result could be due to men in the gay community being at greater risk of infection 
and so they are like a core group such that targeting them would have the greatest 
preventative benefit. However, for ‘test and treat’ to be effective it would have to be 
adopted by most of the HIV-infected population in order to reduce population-level 
viral load. 
Other priority populations cannot be ignored. Prevention activities should also be 
targeted to people who arrive in South Australia from countries in which there is a 
high HIV prevalence and people who travel to these countries. There is a continuing 
risk of an accelerated epidemic among other at-risk populations that must be tracked 
over the rest of the term of the current South Australian HIV Action Plan, including 
amongst Aboriginal people, people who inject drugs, prisoners and sex workers. 
Prevention efforts must remain vigilant to the needs of these particular groups, as 
well as the priority population of men who have sex with men, with flexibility to 
respond decisively and quickly when changes to the pattern of the epidemic emerge. 
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Appendix A:  Mathematical model equations  
 
The equations of the mathematical model used in this research are described below. 
The model tracks distinct populations of men who have sex with men who are 
socially engaged to the gay community and those who are not.  The ordinary 
differential equations for uninfected and HIV-infected but undiagnosed socially 
engaged men are: 
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The ordinary differential equations for uninfected and HIV-infected but undiagnosed 
men who are not socially engaged to the gay community are: 
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The ordinary differential equations for all men who have sex with men who are HIV-
infected and diagnosed with their infection but untreated are: 
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The following ordinary differential equation represents the change in the number of 
men who have sex with men who are on antiretroviral treatment: 
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The following ordinary differential equation represents the change in the number of 
men who have sex with men who are experiencing treatment failure: 
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The most important term in this system of equations is the force of infection, 
represented byO , which denotes the per-capita rate of becoming infected. Its 
mathematical expression is: 
1 2 3 4 5 6 7 8 9 10O O O O O O O O O O O          , where: 
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Appendix B:  The case for providing free antiretroviral therapy in 
South Australia  
 
This is a paper prepared by Kelly-Jean Heymer (NCHECR), Matthias Wentzlaff-
Eggebert (SA Health), Elissa Mortimer (SA Health), and David Wilson (NCHECR).  
Introduction 
In South Australia around 750 people are currently living with HIV and diagnosed 
with their infection [6]. Approximately 76% of the diagnosed cases are receiving 
antiretroviral therapy (ART) to delay or reverse disease progression and improve 
survival [1]. Although it is not necessarily optimal for all patients diagnosed with HIV 
to be on ART, there exist a proportion of HIV-infected people who are aware of their 
positive serostatus, are eligible for treatment, but are not yet receiving antiretrovirals. 
It is an important health issue to remove barriers to treatment uptake to ensure that 
all in need of life-sustaining ART have access. One of the primary barriers could be 
financial constraints.  
In Australia, the Pharmaceutical Benefits Scheme (PBS) provides subsidised 
prescription drugs to Australian residents. Patients are required to contribute a co-
payment for their prescription medication when purchasing under the PBS. Those 
who receive government pensions, are low-income earners or hold a Health Care 
Card (HCC) are entitled to pay a reduced "concession" co-payment amount. A 
recent increase in co-payment costs has led to concern about patients’ abilities to 
afford essential medications [100]. According to the HIV Futures survey, over 40% of 
patients reported the co-payments for antiretroviral medications to be either ‘a little 
difficult’ or ‘very difficult’ to afford [33]. Therefore, it is likely that the inability to afford 
HIV antiretroviral medication has led patients to delay, cease or interrupt treatment. 
Not only does this impact on the health of HIV-infected people but on the spread of 
the virus through the population.  
Antiretroviral medications are available from public hospital pharmacies in all 
Australian States and Territories. Unlike other Australian states, South Australia has 
an additional community pharmacy agreement for dispensing HIV medications 
whereby the pharmacy acts as an agent for the Royal Adelaide Hospital for 
dispensation of Highly Specialised Drugs for HIV treatment. Previously, Centre 
Pharmacy charged one co-payment for a 3 month-supply of HIV medication in 
contrast to the one co-payment per month supply charged by SA public hospital 
pharmacies.  More recently, Centre Pharmacy has been required to charge one 
patient co-payment per one month supply. The increase in costs is due to the 
implementation of increased PBS requirements to comply with the administrative 
agreement between the Commonwealth and the State for the Highly Specialised 
Drugs Program.  
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Currently, the patient co-payment stipulations in the Commonwealth Highly 
Specialised Drugs Program Administrative arrangement state that each client is to 
be charged 1 co-payment for 1 month’s drug supply. The co-payment for clients with 
a Health Care Card is $5.30 per drug and $26.30 for those without, up to an annual 
family threshold (inclusive of same sex couples) of $1,200. Once the threshold has 
been reached, clients can then access a HCC and have their co-payment reduced to 
match the HCC level.  In the last quarter of 2005, the HIV Futures Five study [33] 
reported that 28.3% of people with HIV in Australia were living below the poverty line. 
When questioned about affordability, 31.5% of patients reported that co-payments 
for their antiretroviral medications were ‘a little difficult’ and an additional 8.9% ‘very 
difficult’ to afford. Additionally, anecdotal reports from tertiary treatment centres 
affirm that due to financial reasons some patients are postponing, interrupting or 
even ceasing treatment.   
The outcomes of antiretroviral treatment are of benefit at both the population and 
individual level.  Clinical outcomes such as a slow-down or reversal of disease 
progression [101] benefits the patient. Furthermore, effective treatment results in 
successful viral suppression  (reducing plasma viral load to undetectable levels, less 
than 50 copies per ml) in approximately 90% of cases [1]. Local and international 
research has demonstrated that such reductions in viral load results in an average of 
90-95% reduction in the infectiousness of HIV-infected people on ART compared 
with those not on ART [47, 71-72]. Consequently, there has been a recent call 
among the HIV/AIDS global health community to substantially increase rates of 
treatment uptake for the purposes of preventing new infections [102]. 
In this study we evaluate the cost-effectiveness of removing the co-payment 
requirement from HIV medications in South Australia. The analysis is conducted 
from a health sector (government as third party payer) perspective. Specifically, a 
mathematical model based on risk equations is used to calculate the expected 
average number of new HIV infections caused by persons who are not currently on 
ART compared with the average number expected from those who are on ART. The 
model reflects the HIV epidemiology in South Australia and is informed by available 
behavioural and biological data. We compare the extra financial investment required 
to cover the co-payments with the total treatment costs saved due to preventing HIV 
infections with increased treatment uptake. 
 
Methods 
In South Australia from 2004 to 2008, 93.1% of HIV diagnoses were attributed to 
three predominant routes of exposure: intercourse between men who have sex with 
men (MSM, 60%), heterosexual sex (25.3%) and transmission via injecting drug use 
(IDU, 7.8 %). We developed a mathematical model consisting of equations that 
measure HIV transmission risk for each of these transmission routes. Specifically, 
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the risk equations conservatively calculate the average number of new HIV infections 
that could be attributed to one infected person each year.  
The mathematical model incorporated the risk of HIV transmission per act for each 
type of sexual or injecting act and the prevalence of HIV in the relevant partnership 
groups. Additional biological factors that were included were the rate of circumcision 
among the male population and the reduction in infectiousness due to antiretroviral 
medication. To account for sexual behaviour, the model includes the average annual 
number of casual and regular sexual partners each person has and the frequency of 
sex with these partners. Similarly, for IDUs the model included the average yearly 
number of injection acts. HIV protection measures depicted in the model include the 
rate of condom use in each partnership type (with the efficacy of condoms) and the 
proportion of acts/partnerships in which a person discloses their HIV serostatus (and 
the resultant sexual position they generally perform as a consequence). In the 
context of transmission via injection, the rates of sharing injections and cleaning of 
injecting equipment (with the efficacy of cleaning) are included. Mathematically, the 
average number of new HIV transmissions per HIV-infected MSM per year can be 
expressed according to these factors as 
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where C is the average number of partners for each relationship type, P is the 
prevalence of the relevant partnership group, r is the rate of condom use, β is the 
transmission risk for each act type, δ is the rate of disclosure of serostatus, n is the 
number of acts per relationship type per year and ε is the efficacy of condoms/ 
cleaning of injecting equipment.  The risk of male-to-female transmission (MtoF), 
female-to-male transmission (FtoM) and transmission via injecting drug use (IDU) 
have the following similar expressions: 
         ^ `hethetreghethetreg rnmfcrnmffemhetreg PCMtoF ERE `11111 1   ; 
        ^ `hethetreghethetreg rnfmcrnfmmalhetreg PCFtoM ERE `11111 1   ; 
(1 )( (1 ) (1 ) )inj idu q idu iduI PU n q qD V E E    . 
These model equations are first used to calculate the risk of each exposure type 
prior to treatment and then recalculated with an allowance for the reduction in 
infectiousness ( E ) due to treatment. The difference between the resultant risk 
calculations is the expected number of new infections averted per person per year 
due to initiation of treatment. By estimating the number of extra people who would 
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initiate treatment due to removal of the co-payment requirement we calculated the 
expected number of infections averted. The costs of covering all co-payments were 
then evaluated in comparison with treatment costs. We also calculated the number 
of people needed to be on treatment to avert 1 HIV-infection and thus the financial 
cost per infection averted. All parameter values used in the analyses are provided in 
Table B.1. 
  
271 
 
Table B.1 
Parameter definition Value 
Reduction in transmission risk per risk event due to treatment compared to no 
treatment 
92% [47] 
Transmission risk per act of unprotected receptive anal act (with ejaculation) 1% [103] 
Transmission risk per act of unprotected receptive anal act (without ejaculation) 0.7% [103] 
Transmission risk per act of unprotected insertive anal act (with circumcision) 0.1% [103] 
Transmission risk per act of unprotected insertive anal act (without circumcision) 0.5% [103] 
Transmission risk per act of unprotected receptive vaginal act 0.1% [104-110] 
Transmission risk per act of unprotected insertive vaginal act (w/out 
circumcision) 
0.05%[104-110] 
Proportion of men that are circumcised  65% [111] 
Proportion of sexual acts in which condoms are 
used HIV discordant 
80-69% [112] 
HIV concordant 10% [112] 
HIV status not disclosed 40% [112] 
Efficacy of condoms 95% [51-55] 
Rate of disclosure of HIV status by HIV-positive MSM 45.9% [113] 
Distribution of the number of casual partners of 
gay men per 6 months (proportion of men in each 
category)   
1-1.5 26% [114] 
2-5 21% [114] 
6-10 16% [114] 
11-50 30% [114] 
51-60 7% [114] 
Estimated population size of gay men in South Australia 12,500 [115-116] 
Condom use among heterosexual couples in which discordant HIV status is 
known 
80% [33] 
Prevalence of HIV among heterosexual population 0.1% [12] 
Average number of regular sexual partners per year for heterosexuals 1  
Transmission probability of HIV per injection with a contaminated syringe 0.7%[117-118] 
Weighted average annual injecting frequency for IDUs in South Australia 300 [119] 
Proportion of IDUs who share syringes in South Australia 15% [11] 
Proportion of injections that are shared for IDUs who share syringes in South 
Australia 
14% [11] 
Prevalence of HIV among IDUs in South Australia 0.86% [119] 
Average number of acts per year  in regular MSM partnership 100 [120] 
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Average number of casual partners of HIV-positive MSM 14 [114] 
Average number of regular partners MSM 0.65 [50] 
Average number of acts per casual MSM partnership 1[120] 
Condom use in casual partnerships MSM 0.75 [50] 
Condom use in regular partnerships MSM 0.31[50] 
Rate of disclosure of serostatus by positive MSM 0.459[50] 
Prevalence of HIV in partners of positive MSM 0.398 [50] 
Prevalence of HIV in general MSM 0.1 [1, 12] 
Average number of acts per year  in regular MSM partnership 100 [120] 
Average number of casual partners of HIV-positive MSM 14 [114] 
Average number of regular partners MSM 0.65 [50] 
Average number of acts per casual MSM partnership 1[120] 
Condom use in casual partnerships MSM 0.75 [50] 
Condom use in regular partnerships MSM 0.31[50] 
Rate of disclosure of serostatus by positive MSM 0.459[50] 
Prevalence of HIV in partners of positive MSM 0.398 [50] 
Prevalence of HIV in general MSM 0.1 [1, 12] 
Proportion of MSM that are circumcised  0.65 [111] 
Number of acts per regular heterosexual partnership per year 100 
Transmission risk per injection act 0.007 [121-122] 
Number of injecting acts per year 320 [119] 
Rate of needle cleaning 0.75 [119] 
Proportion of injections that are shared for those that share needles 0.14 [119] 
Efficacy of cleaning syringes 0.675 [119] 
Prevalence of HIV in injecting drug users 0.0086 [119] 
Proportion of acts in which the negative partner 
will take role when partner is known to be 
positive 
Receptive with ejaculation 0.11[114] 
Receptive with withdrawal 
prior to ejaculation 
0.33 [114] 
Insertive 0.56 [114] 
Proportion of acts in which the negative partner 
will take role when partner’s serostatus is 
unknown 
Receptive with ejaculation 0.21 [114] 
Receptive with withdrawal 
prior to ejaculation 
0.33 [114] 
Insertive 0.46 [114] 
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Results 
According to the model, the expected number of new transmissions resulting from 
each infected person per year is much less than one for all transmission routes even 
without antiretroviral treatment. Injecting drug users have the highest average 
transmission rate, with an average of 0.1535 new infections per year without 
treatment, which is equivalent to 1 transmission every 6.5 years. In comparison, 
without treatment one transmission would occur after an average of 6.8 years per 
MSM, 42.2 years for heterosexual males, and 137 years for heterosexual females (or 
equivalently, an average of one infection would occur per year for every 137 HIV-
infected females). With treatment, the transmission rates are substantially reduced 
across the population.   
The model was used to estimate the annual per-capita rate of HIV transmission for 
each transmission route due to initiation of treatment, adjusting for the cumulative 
number of exposure events and average behaviours of each population group. It was 
conservatively estimated that an HIV infection is prevented each year for every: 7.6 
MSM, 45.9 heterosexual males, 91.3 heterosexual females, or 14.3 IDUs who 
receive ART that would have otherwise been untreated. Over the last 5 years in 
South Australia (2004-2008), a reported 60% of HIV diagnoses were among MSM, 
16.7% among heterosexual males, 8.6% among heterosexual females, and 7.8% 
among IDUs (and 6.9% were among other categorisations).  Adjusting for the 
proportion of diagnoses associated with each risk group as a weighted average, one 
HIV infection is prevented per year for every 26.7 people who receive treatment in 
South Australia.   
With current annual treatment costs of approximately $14,000 [123-126], the amount 
of treatment required to prevent one new infection (26.7 person-years of treatment) 
would cost $373,800. This is below the estimated $400,000 of lifetime treatment 
costs per HIV-infected person [126]. Therefore, if a treatment program targets people 
who would not have otherwise received therapy, then from a purely economic 
perspective, not only is provision of full treatment cost-effective but it is cost-saving. 
By considering the incremental change in costs and outcomes of a change in 
program from the current status quo such that co-payments are covered for people 
who would otherwise not receive treatment, then the cost-savings are very 
substantial: it would cost $15,187 per infection averted if ART is provided only 
according to a three drug combination or $11,812 per infection averted according to 
current treatment patterns whereby two-thirds of patients receive their three-drug 
regimen as a two-pill dose. This is an extremely cost-saving strategy.  
If co-payment costs are covered for all patients, including those who are currently 
able to pay these amounts, then the financial savings from the governmental 
perspective are reduced. According to the HIV Futures Five Study [33], 
approximately 8.9% report that co-payments for antiretroviral medications are ‘very 
difficult’ to afford. Conservatively we assume that one-half of these people (4.5% of 
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all HIV-infected people) are postponing or ceasing treatment for financial reasons 
and the others receive charitable financial assistance from elsewhere. Therefore, if 
the 95.5% of HIV-infected people who are currently making their own co-payments 
have them covered by the health system in addition to the 4.5% who additionally 
receive antiretroviral medications, then the financial return on investment changes. 
The extra expenses of financing the co-payments, adjusting for Medicare status of 
people in the population, would cost an estimated $337,488 (unadjusted, or 
$262,491 adjusted for drug combination) per infection averted compared to the 
status quo; this is still below the costs associated with treating a new infection. Since 
the program of covering co-payments for all HIV-infected patients would be cost-
saving, from a health economic perspective an analysis with health utilities is not 
required to determine the cost-effectiveness of the program.  
Discussion  
Policy in South Australia requires that the State pay for the co-payments of each 1 
month supply of antiretrovirals dispensed, regardless of whether it is recouped from 
the patient. This is similar to the policy in New South Wales, Queensland, Australian 
Capital Territory and Tasmania, although some of these States have no community 
pharmacy dispensation.  In Victoria, antiretrovirals are dispensed for free from the 
Melbourne Sexual Health Centre; otherwise a co-payment is required from all other 
Victorian public hospital pharmacy outlets. In Western Australian and the Northern 
Territory, antiretrovirals for HIV treatment are supplied free of charge. 
There exist precedents for provision of free treatment and/or immunisation for 
diseases that present a public health risk. In South Australia, treatment and/or 
immunisation for TB, hepatitis B, seasonal influenza and sexually transmitted 
infections other than HIV are available without cost to the patient.  
The inability to access consistent treatment for HIV not only impacts upon the 
individual, but also the health system and the general population. By delaying 
treatment uptake or ceasing it altogether due to inability to finance co-payment costs, 
HIV-infected individuals can experience persistently increased viral load. This can 
have a damaging effect on the general health of individuals and the population. At a 
macro level, increased average viral loads in the population will lead to increased 
incidence of HIV. Ultimately this will lead to increased costs associated with ART, as 
well as more hospital admissions and outpatient appointments.  
Facilitating increases in treatment rates by removing the co-payment requirement for 
HIV medication is likely to result in numerous beneficial outcomes including 
reductions in HIV transmissions and less resistance to antiretrovirals, improved 
health outcomes for HIV-infected individuals, and a reduced burden on public health 
resources. Recent discussions and recommendations about novel prevention 
strategies are also promoting increased treatment rates among all HIV-infected 
people [102]. There is strong clinical and epidemiological support for increasing 
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treatment rates in addition to the financial benefits. We carried out a health 
economics analysis from a governmental perspective of covering co-payments for 
HIV antiretroviral drugs and found that this initiative is not only cost-effective but 
cost-saving, and we therefore recommend its implementation. 
276 
 
References 
1. Wilson, D.P., et al., Mathematical models to investigate recent trends in HIV notifications 
among men who have sex with men in Australia. 2008, National Centre in HIV Epidemiology 
and Clinical Research, The University of New South Wales. 
2. HIV Action Plan 2009-2012. 2009, South Australian Department of Health: Adelaide. 
3. Prestage, G., et al., Homosexual men in Australia: population, distribution and HIV prevalence. 
Sexual Health, 2008. 5: p. In Press. 
4. Rawstorne, P., et al., e-male survey 2008: key findings from a national online survey of men 
who have sex with men. 2009, National Centre in HIV Social Research: Sydney, Australia. 
5. Adelaide Gay Community Periodic Survey. 2007, National Centre in HIV Social Research, 
University of New South Wales: Sydney, Australia. 
6. National Centre in HIV Epidemiology and Clinical Research., National Centre in HIV 
Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible 
infections in Australia Annual Surveillance Report 2008. 2008, Univeristy of New South Wales: 
Sydney. 
7. Wilson, D.P., et al., Serosorting may increase the risk of HIV acquisition among men who 
have sex with men. Sexually Transmitted Diseases, 2010. In Press. 
8. HIV prevalence study: suck it and see. 2009, Burnet Institute: Melbourne, Australia. 
9. Brown, T. and W. Peerapatanapokin, The Asian Epidemic Model: a process model for 
exploring HIV policy and programme alternatives in Asia. Sex Transm Infect, 2004. 80 Suppl 
1: p. i19-24. 
10. Wilson, D., et al., Return on investment 2: evaluating the cost-effectiveness of needle and 
syringe programs among injecting drug users in Australia. 2009, National Centre in HIV 
Epidemiology and Clinical Research, University of New South Wales: Sydney. 
11. Iversen J, Topp L, and Maher L, Australian CNP Survey National Data Report 2002--2006, 
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 
2007. 
12. HIV/AIDS, viral hepatitis and sexually transimissble infections in Australia. Annual 
Surveillance Report. 2009, National Centre in HIV Epidemiology and Clinical Research, 
University of New South Wales.: Sydney, Australia. 
13. Lee, D.M., et al., The incidence of sexually transmitted infections among frequently screened 
sex workers in a decriminalised and regulated system in Melbourne. Sex Transm Infect, 2005. 
81: p. 434-436. 
14. Rissel, C.E., et al., Sex in Australia: experiences of commercial sex in a representative 
sample of adults. Aust N Z J Public Health, 2003. 27(2): p. 191-7. 
15. Golden, M.R., C.M. Marra, and K.K. Holmes, Update on syphilis: resurgence of an old 
problem. JAMA, 2003. 290(11): p. 1510-4. 
16. Fenton, K.A., A multilevel approach to understanding the resurgence and evolution of 
infectious syphilis in Western Europe. Euro Surveill, 2004. 9(12): p. 3-4. 
17. CDC, Sexually transmitted disease surveillance 2004 supplement: syphilis surveillance report. 
2005, US Department of Health and Human Services, Centres for Disease Control and 
Prevention: Atlanta, GA. 
18. 2004 Canadian sexually transmitted infections surveillance report. Can Commun Dis Rep, 
2007. 33 (suppl 1): p. 1-69. 
19. Botham, S.J., et al., Epidemic infectious syphilis in inner Sydney--strengthening enhanced 
surveillance. Aust N Z J Public Health, 2006. 30(6): p. 529-33. 
20. Fenton, K.A. and J. Imrie, Increasing rates of sexually transmitted diseases in homosexual 
men in Western europe and the United States: why? Infect Dis Clin North Am, 2005. 19(2): p. 
311-31. 
21. Chen, S.Y., et al., Continuing increases in sexual risk behavior and sexually transmitted 
diseases among men who have sex with men: San Francisco, Calif, 1999-2001, USA. Am J 
Public Health, 2002. 92(9): p. 1387-8. 
22. Lee, D.M. and M.Y. Chen, The re-emergence of syphilis among homosexually active men in 
Melbourne. Aust N Z J Public Health, 2005. 29(4): p. 390-1. 
23. Branger, J., et al., Hign Incidence of Asymptomatic Syphilis in HIV-Infected MSM Justifies 
Routine Screening. Sexually Transmitted Diseases, 2009. 36(2): p. 84-85. 
277 
 
24. Thomas, S.B. and S.C. Quinn, The Tuskegee Syphilis Study, 1932 to 1972: implications for 
HIV education and AIDS risk education programs in the black community. Am J Public Health, 
1991. 81(11): p. 1498-505. 
25. Clark, E.G. and N. Danbolt, The Oslo study of the natural course of untreated syphilis. An 
epidemiologic investigation based on a re-study of the Boeck-Bruusgaard material. Med. Clin. 
North Am., 1964. 48: p. 613-623. 
26. Sellati, T.J., et al., Virulent Treponema pallidum, lipoprotein, and synthetic lipopeptides induce 
CCR5 on human monocytes and enhance their susceptibility to infection by human 
immunodeficiency virus type 1. J Infect Dis, 2000. 181(1): p. 283-93. 
27. Murphy, D. and M. Holt, Responses to syphilis outbreaks among gay and other men who 
have sex with men: Case studies from the United Kingdom and the United States. 2009, 
Australian Federation of AIDS Organisations: Sydney, Australia. 
28. HIV/AIDS, viral hepatitis and sexually transimissble infections in Australia. Annual 
Surveillance Report. 2008, National Centre in HIV Epidemiology and Clinical Research, 
University of New South Wales.: Sydney, Australia. 
29. Wilson, D.P., et al., Phase A of the National Gay Men's Syphilis Action Plan: Modelling 
evidence and research on acceptability of interventions for controlling syphilis in Australia. 
2009, National Centre in HIV Epidemiology and Clinical Research, The University of New 
South Wales: Sydney, Australia. 
30. Anderson, R.M. and R.M. May, Infectious Diseases of Humans: Dynamics and Control. 1991, 
NY: Oxford University Press. 
31. NSW, VIC and QLD Gay Periodic Surveys. 1998-2006. 
32. Richters, J., HIV/AIDS, Hepatitis C & Related Diseases in Australia: Annual Report of 
Behaviour 2006, National Centre in HIV Social Research, University of New South Wales: 
Sydney. 
33. Grierson, J., R. Thorpe, and M. Pitts, HIV Futures  5: Life as we know it, monograph series 
number 60. 2006, The Australian Research Centre in Sex, Health and Society, Latrobe 
University, Melbourne, Australia. 
34. Wilson, D.P., Modelling based on Australian HIV notifications data suggests homosexual age 
mixing is primarily assortative. J Acquir Immune Defic Syndr, 2009. 51(3): p. 356-60. 
35. Mao, L., et al., "Serosorting" in casual anal sex of HIV-negative gay men is noteworthy and is 
increasing in Sydney, Australia. Aids, 2006. 20(8): p. 1204-6. 
36. Suarez, T. and J. Miller, Negotiating risks in context: a perspective on unprotected anal 
intercourse and barebacking among men who have sex with men--where do we go from here? 
Arch Sex Behav, 2001. 30(3): p. 287-300. 
37. Suarez, T.P., et al., Influence of a partner's HIV serostatus, use of highly active antiretroviral 
therapy, and viral load on perceptions of sexual risk behavior in a community sample of men 
who have sex with men. J Acquir Immune Defic Syndr, 2001. 28(5): p. 471-7. 
38. Elford, J., et al., High-risk sexual behaviour among London gay men: no longer increasing. 
AIDS, 2005. 19(18): p. 2171-4. 
39. Elford, J., et al., Sexual behaviour of people living with HIV in London: implications for HIV 
transmission. AIDS, 2007. 21 Suppl 1: p. S63-70. 
40. Truong, H.M., et al., Increases in sexually transmitted infections and sexual risk behaviour 
without a concurrent increase in HIV incidence among men who have sex with men in San 
Francisco: a suggestion of HIV serosorting? Sex Transm Infect, 2006. 82(6): p. 461-6. 
41. Golden, M.R., et al., Ongoing risk behavior among persons with HIV in medical care. AIDS 
Behav, 2007. 11(5): p. 726-35. 
42. Elford, J., Changing patterns of sexual behaviour in the era of highly active antiretroviral 
therapy. Curr Opin Infect Dis, 2006. 19(1): p. 26-32. 
43. Xia, Q., et al., Knowledge of sexual partner's HIV serostatus and serosorting practices in a 
California population-based sample of men who have sex with men. Aids, 2006. 20(16): p. 
2081-9. 
44. Jin, F., et al., How homosexual men believe they became infected with HIV: the role of risk-
reduction behaviors. J Acquir Immune Defic Syndr, 2007. 46(2): p. 245-7. 
45. Jin, F., et al., Per-contact probability of HIV transmission in homosexual men in Sydney in the 
era of HAART. AIDS, 2010. 24(6): p. 907-913. 
46. Jin, F., et al., Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV 
infection in a cohort of homosexual men. AIDS, 2009. 23(2): p. 243-52. 
47. Attia, S., et al., Sexual transmission of HIV according to viral load and antiretroviral therapy: 
systematic review and meta-analysis. AIDS, 2009. 23(11): p. 1397-404. 
278 
 
48. Rawstorne, P., et al., Supplemental data analysis to the e-male survey: Data comparisons of 
the E-Male survey in South Australia and the Adelaide Gay Community Periodic Survey. 2009, 
NCHSR, University of New South Wales. 
49. Prestage, G., PASH: Pleasure and Sexual Health study. 2009. 
50. Frankland, A., et al., Gay Community Periodic Survey: Adelaide 2007. 2008, National Centre 
in HIV Social Research, The Univeristy of New South Wales: Sydney. 
51. Davis, K.R. and S.C. Weller, The effectiveness of condoms in reducing heterosexual 
transmission of HIV. Family Planning Perspectives, 1999. 31: p. 272-279. 
52. Weller, S.C. and K.R. Davis, Condom effectiveness in reducing heterosexual HIV 
transmission. Cochrane Database Syst Rev, 2002. (1): p. CD003255. 
53. Pinkerton, S.D. and P.R. Abtramson, Effectiveness of condoms in preventing HIV 
transmission. Social Science and Medicine, 1997. 44: p. 1303-1312. 
54. Weller, S.C., A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. 
Social Science and Medicine, 1993. 36(12): p. 1653-44. 
55. Fitch, T.J., et al., Condom Effectiveness: Factors that influence risk reduction. Sexually 
Transmitted Diseases, 2002. 29: p. 811-817. 
56. Wilson, D.P., et al., Mathematical models to investigate recent trends in HIV notifications 
among men who have sex with men in Australia (available at: 
http://www.nchecr.unsw.edu.au/nchecrweb.nsf/page/BioModInfectDis). 2008, National Centre 
in HIV Epidemiology and Clinical Research: Sydney, Australia. 
57. Van de Ven, P., et al., Undetectable viral load is associated with sexual risk taking in HIV 
serodiscordant gay couples in Sydney. AIDS, 2005. 19(2): p. 179-84. 
58. National Centre in HIV Social Research Annual Report of Trends in Behaviour. 2006, 
University of New South Wales: Sydney. 
59. Marks, G., et al., Meta-analysis of high-risk sexual behavior in persons aware and unaware 
they are infected with HIV in the United States: implications for HIV prevention programs. 
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2005. 39(4): p. 446-53. 
60. Cleary, P.D., et al., Behavior changes after notification of HIV infection. American Journal of 
Public Health, 1991. 81(12): p. 1586-90. 
61. Colfax, G.N., et al., Sexual risk behaviors and implications for secondary HIV transmission 
during and after HIV seroconversion. AIDS, 2002. 16(11): p. 1529-35. 
62. McCusker, J., et al., Effects of HIV antibody test knowledge on subsequent sexual behaviors 
in a cohort of homosexually active men. American Journal of Public Health, 1988. 78(4): p. 
462-7. 
63. Saah, A.J., et al., Association of HLA profiles with early plasma viral load, CD4+ cell count 
and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort 
Study. AIDS, 1998. 12(16): p. 2107-13. 
64. Smith, D.K., et al., Design and baseline participant characteristics of the Human 
Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of 
human immunodeficiency virus infection in US women. American Journal of Epidemiology, 
1997. 146(6): p. 459-69. 
65. Valleroy, L.A., et al., HIV prevalence and associated risks in young men who have sex with 
men. Young Men's Survey Study Group. JAMA, 2000. 284(2): p. 198-204. 
66. Law, M.G., et al., Modelling the effect of combination antiretroviral treatments on HIV 
incidence. AIDS, 2001. 15(10): p. 1287-94. 
67. Mellors, J.W., et al., Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 
infection. Ann Intern Med, 1997. 126(12): p. 946-54. 
68. Colette Smith, et al., Causes of death in the D:A:D study-initial results. 2008. 
69. Ledergerber, B., et al., Predictors of trend in CD4-positive T-cell count and mortality among 
HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, 
2004. 364(9428): p. 51-62. 
70. Jin, F., et al., Per-contact probability of HIV transmission in homosexual men in Sydney in the 
era of HAART. AIDS. 24(6): p. 907-13. 
71. Wilson, D.P., et al., Relation between HIV viral load and infectiousness: a model-based 
analysis. Lancet, 2008. 372(9635): p. 314-20. 
72. Quinn, T.C., et al., Viral load and heterosexual transmission of human immunodeficiency virus 
type 1. Rakai Project Study Group. N Engl J Med, 2000. 342(13): p. 921-9. 
73. Australian HIV Observational Database Annual Report. 2009, National Centre in HIV 
Epidemiology and Clinical Research, The University of New South Wales: Sydney, Australia. 
279 
 
74. Lodwick, R.K., et al., Stability of antiretroviral regimens in patients with viral suppression. 
AIDS, 2008. 22(9): p. 1039-46. 
75. Blower, S.M. and H. Dowlatabadi, Sensitivity and Uncertainty Analysis of Complex Models of 
Disease Transmission: An HIV Model, as an Example. International Statistical Review, 1994. 
62(2): p. 229-243. 
76. Hoare, A., D.G. Regan, and D.P. Wilson, Sampling and sensitivity analyses tools (SaSAT) for 
computational modelling. Theor Biol Med Model, 2008. 5(1): p. 4. 
77. Wilson, D.P., et al., Importance of promoting HIV testing for preventing secondary 
transmissions: modelling the Australian HIV epidemic among men who have sex with men. 
Sex Health, 2009. 6(1): p. 19-33. 
78. Kaufmann, G.R., et al., Patterns of viral dynamics during primary human immunodeficiency 
virus type 1 infection. The Sydney Primary HIV Infection Study Group. Journal of Infectious 
Diseases, 1998. 178(6): p. 1812-5. 
79. Richardson, B.A., et al., Comparison of Human Immunodeficiency Virus Type 1 Viral Loads in 
Kenyan Women, Men, and Infants during Primary and Early Infection. Journal of Virology, 
2003. 77(12): p. 7120-7123. 
80. Schacker, T.W., et al., Biological and Virologic Characteristics of Primary HIV Infection. 
Annals of Internal Medicine, 1998. 128(8): p. 613-620. 
81. Apoola, A., S. Ahmad, and K. Radcliffe, Primary HIV infection. Int J STD AIDS, 2002. 13(2): p. 
71-8. 
82. Prestage, G., et al., TOMS: Three or More Study. 2008, National Centre in HIV Epidemiology 
and Clinical Research, University of New South Wales.: Sydney, Australia. 
83. Granich, R.M., et al., Universal voluntary HIV testing with immediate antiretroviral therapy as 
a strategy for elimination of HIV transmission: a mathematical model. Lancet, 2009. 
373(9657): p. 48-57. 
84. Wilson, D.P., Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet, 
2009. 373(9669): p. 1077-8; author reply 1080-1. 
85. Subbarao, S., et al., Chemoprophylaxis with tenofovir disoproxil fumarate provided partial 
protection against infection with simian human immunodeficiency virus in macaques given 
multiple virus challenges. J Infect Dis, 2006. 194(7): p. 904-11. 
86. Tsai, C.C., et al., Prevention of SIV infection in macaques by (R)-9-(2-
phosphonylmethoxypropyl)adenine. Science, 1995. 270(5239): p. 1197-9. 
87. Van Rompay, K.K., et al., Two low doses of tenofovir protect newborn macaques against oral 
simian immunodeficiency virus infection. J Infect Dis, 2001. 184(4): p. 429-38. 
88. Van Rompay, K.K., et al., Prophylactic and therapeutic benefits of short-term 9-[2-(R)-
(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following 
oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J 
Virol, 2000. 74(4): p. 1767-74. 
89. Garcia-Lerma, J.G., et al., Prevention of Rectal SHIV Transmission in Macaques by Daily or 
Intermittent Prophylaxis with Emtricitabine and Tenofovir. PLoS Med, 2008. 5(2): p. e28. 
90. Peterson, L., et al., Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: 
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. PLOS Clin Trial, 2007. 2(5): 
p. e27. 
91. Grant, R.M., et al., AIDS: Promote HIV Chemoprophylaxis Research, Don't Prevent It. 
Science, 2005. 309(5744): p. 2170-2171. 
92. AVAX. Ongoing PrEP Trials.  2009  15 Decmber 2009]; Available from: 
http://www.avac.org/ht/d/sp/i/3507/pid/3507. 
93. Cassell, M., et al., HIV and risk behaviour: Risk compensation: the Achilles' heel of 
innovations in HIV prevention? BMJ: British Medical Journal, 2006. 332(7541): p. 605. 
94. Wilson, D.P. and S.M. Blower, Microbicides: anti-HIV efficacy and ethics. Science, 2004. 
306(5703): p. 1890; author reply 1890. 
95. Auvert, B., et al., Randomized, controlled intervention trial of male circumcision for reduction 
of HIV infection risk: The ANRS 1265 trial. PLoS Medicine, 2005. 2(11): p. 1112-1122. 
96. Bailey, R.C., et al., Male circumcision for HIV prevention in young men in Kisumu, Kenya: a 
randomised controlled trial. Lancet, 2007. 369(9562): p. 643-656. 
97. Gray, R.H., et al., Male circumcision for HIV prevention in men in Rakai, Uganda: a 
randomised trial. Lancet, 2007. 369(9562): p. 657-666. 
98. Templeton DJ, J.F., Mao L, Prestage GP, Donovan B, Imrie J, Kippax S,Kaldor JM,Grulich 
AE,, Reduced Risk of HIV Seroconversion Among Circumcised Homosexual Men who Report 
280 
 
a Preference for the Insertive Role in Anal Intercourse, in Australasian Society for HIV 
Medicine conference. 2008: Perth. 
99. Anderson, J.S., et al., Cost-effectiveness of adult circumcision for HIV prevention in men who 
have sex with men in a resource-rich setting. Journal of Infectious Diseases, 2009. 200: p. 
1803-1812. 
100. Hynd, A., et al., The impact of co-payment increases on dispensings of government-
subsidised medicines in Australia. Pharmacoepidemiol Drug Saf, 2008. 17(11): p. 1091-9. 
101. Thaker, H.K. and M.H. Snow, HIV viral suppression in the era of antiretroviral therapy. 
Postgrad Med J, 2003. 79(927): p. 36-42. 
102. Granich, R.M., et al., Universal voluntary HIV testing with immediate antiretroviral therapy as 
a strategy for elimination of HIV transmission: a mathematical model. Lancet, 2008. 
103. Jin, F., et al., Per-contact probability of HIV transmission in homosexual men in Sydney in the 
era of HAART. Under Review, 2009. 
104. de Vincenzi, I., A longitudinal study of human immunodeficiency virus transmission by 
heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl 
J Med, 1994. 331(6): p. 341-6. 
105. Padian, N.S., et al., Heterosexual transmission of human immunodeficiency virus (HIV) in 
northern California: results from a ten-year study. Am J Epidemiol, 1997. 146(4): p. 350-7. 
106. Vittinghoff, E., et al., Per-contact risk of human immunodeficiency virus transmission between 
male sexual partners. Am J Epidemiol, 1999. 150(3): p. 306-11. 
107. Gray, R.H., et al., Probability of HIV-1 transmission per coital act in monogamous, 
heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet, 2001. 357(9263): p. 1149-
53. 
108. Wawer, M.J., et al., Rates of HIV-1 Transmission per Coital Act, by Stage of HIV-1 Infection, 
in Rakai, Uganda. J Infect Dis, 2005. 191(9): p. 1403-9. 
109. Koblin, B.A., et al., Risk factors for HIV infection among men who have sex with men. AIDS, 
2006. 20(5): p. 731-9. 
110. Read, T.R.H., et al., Risk factors for incident HIV infection in men having sex with men: a 
case-control study. Sexual Health, 2007. 4: p. 35-39. 
111. Templeton, D.J., et al., Demographic predictors of circumcision status in a community-based 
sample of homosexual men in Sydney, Australia. Sex Health, 2006. 3(3): p. 191-3. 
112. Burstein, G.R., et al., Incident Chlamydia trachomatis infections among inner-city adolescent 
females. JAMA, 1998. 280(6): p. 521-6. 
113. SA Gay Periodic Surveys. 2001-2007. 
114. Fogarty, A., et al., The Health in Men and Positive Health cohorts: A comparison of trends in 
the health and sexual behaviour of HIV-negative and HIV-positive gay men, 2002–2005, 
National Centre in HIV Social Research Annual Report of Trends in Behaviour. 2006, 
University of New South Wales: Sydney. 
115. Prestage, G., et al., Homosexual men in Australia: population, distributionand HIV prevalence. 
Sexual Health, 2008. 5: p. 97-102. 
116. ABS, 'Australian Bureau of Statistics, South Australia, Age (full classification list) by Sex'. 
2006. 
117. Baggaley, R.F., et al., Risk of HIV-1 transmission for parenteral exposure and blood 
transfusion: a systematic review and meta-analysis. AIDS, 2006. 20(6): p. 805-12. 
118. Hudgens, M.G., et al., Subtype-specific transmission probabilities for human 
immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am J 
Epidemiol, 2002. 155(2): p. 159-68. 
119. Wilson, D.P., et al., Return on investment 2: evaluating the cost-effectivess of needle and 
syringe programs in Australia. 2009, National Centre in HIV Epidemiology and Clinical 
Research, The University of New South Wales: Sydney, Australia. 
120. Crawford, J.M., et al., Number of risk acts by relationship status and partner serostatus: 
Findings from the HIM cohort of homosexually active men in Sydney, Australia. AIDS Behav, 
2006. 10(3): p. 325-31. 
121. Baggaley, R.F., et al., Risk of HIV-1 transmission for parenteral exposure and blood 
transfusion: a systematic review and meta-analysis. AIDS, 2006. 20(6): p. 805-812. 
122. Hudgens, M.G., et al., Subtype-specific transmission probabilities for human 
immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. American 
Journal of Epidemiology, 2002. 155(2): p. 159-168. 
281 
 
123. Medicare Australia. MBS online.  2008  24 October 2008]; Available from: 
http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-
Schedule-MBS-1. 
124. Department of Health and Ageing. Pharmaceutical Benefits Schedule.  2008  24 october 
2008]; Available from: http://www.pbs.gov.au/html/healthpro/home. 
125. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, Australian Commentary 
on DHHS Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and 
Adolescents. 2008. 
126. Health Outomes International Pty Ltd. and National Centre in HIV Epidemiology and Clinical 
Research., The impact of HIV/AIDS in NSW mortality, morbidity and economic impact. 2007, 
NSW Health. 
 
 
  
National Centre in HIV  
Epidemiology and Clinical Research 
For more information contact: 
Associate Professor David Wilson 
282 
 
 
283 
 
Appendix for Chapter 5 
 
 
Expected value analysis for costs and utilities for gonorrhoea and chlamydia 
 
 
Introduction 
 
There are no published data of the costs or utilities of chlamydia and gonorrhoea 
infection in men. We use an expected value analysis to estimate the costs and utilities of 
infection and associated complications in men who acquire infection over a 12 month 
period, from a health perspective. The costs are undiscounted in Australian dollars and 
based on costs for 2006-7.  
 
Method 
 
An expected value tree was constructed using TreeAge with input variables drawn from 
Australian government medical and pharmaceutical rebates and the published literature; 
when variables were not available we use the assumptions of an experienced sexual 
health physician (BD) and primary care doctor (JA); for epididymitis we adapt the utility 
loss associated with erectile dysfunction to mimic the loss of quality of life associated 
with sexual dysfunction.  No utility loss is assumed for simple uncomplicated cases of 
infection. The variables include costs, probabilities and the decrements in utility over a 
12 month period associated with specific complications.  
 
The expected value analysis tree for both conditions is represented in Figure 1. Input 
variables for chlamydia are in Table 1 and for gonorrhoea in Table 2. The components for 
reactive arthritis related to chlamydia and septic arthritis for gonorrhoea are calculated 
from the clinical pathways described in Tables 3 and 4 respectively.  
 
We assume that 3% of men will experience arthritis and/or epididymitis associated with 
each condition. In the chlamydia tree, arthritis is reactive arthritis, in the gonorrhoea 
tree it is septic arthritis. We also assume that 10% of men with epididymitis will become 
infertile.  
 
To estimate the costs of admission with septic arthritis due to gonorrhoea, a multi- step 
approach is taken: the International Classification of Diseases version 10 classifies septic 
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arthritis due to gonorrhoea as A54.4+ [1]; using this code we search the clinical profiles 
of National Admitted Patient Care Collection (NAPCC) [2] to identify the diagnostic 
related group (DRG) codes associated with admission for septic arthritis, I67A/B; with 
these DRG codes, we search the 2006-7 National Admitted Patient Care Collection[3] to 
discover the number of separations for each DRG; the values of both DRGs is contained 
in Round 11 (2006-07) Cost Report[3]; a weighted-average cost per separation is 
calculated using the proportions of each type of DRG to produce a cost per inpatient 
separation with septic arthritis.  
 
Conclusion 
 
Our expected value analysis estimates the cost per case of chlamydia infection of $57 
and the cost of gonorrhoea of $82. The utility lost in a year for each case of disease is 
0.0085 quality adjusted life years or just over 3 quality adjusted life days.  
 
The estimate is only slightly sensitive to the cost of treatment of arthritis and 
epididymitis; for example, the cost of gonorrhoea falls by $3 when the cost of inpatient 
care is 50% of the base-case value.  
 
 
Tables 
 
 
Table 1: chlamydia  Value Comment 
Cost arthritis $1310 See Table 3 
Cost of epididymitis $56 Azithromycin[4]+ medical [5] 
Cost treating simple chlamydia $56 Azithromycin[4]+ medical [5]   
Utility decrement arthritis 0.25 Utility arthritis aged 18-35 [6] 
Utility decrement epididymitis 0.016667 Assume 0.1 decrement for 8 weeks 
similar to erectile dysfunction [7] 
Utility decrement infertility 0.18 [8] 
probability arthritis after infection 0.03 expert opinion   
probability epididymitis 0.03 [9] + expert opinion 
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probability infertile after epididymitis 0.1 [10] 
 
 
 
Table 2: Gonorrhoea Value Comment 
Cost septic arthritis $6413 See Table 4 
Cost of epididymitis $302 Medications [4] + medical consultations 
[5] 
Cost treating simple gonorrhoea $70 Medication [4] + medical [5]   
Utility decrement arthritis 0.25 Utility arthritis aged 18-35[6] 
Utility decrement epididymitis 0.016667 Assume 0.1 decrement for 8 weeks 
similar to erectile dysfunction[7] 
Utility decrement infertility 0.18 [8] 
probability arthritis after infection 0.03 expert opinion   
probability epididymitis 0.03 [9, 11] + expert opinion 
probability infertile after epididymitis 0.1 [10] 
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Table 3 Cost reactive arthritis 
(chlamydia)  
Unit 
cost 
Number of units 
year  
Total Sources [4, 5] 
Full blood examination    $14.65 4 $59 MBS item 65070 
C-reactive protein test (3 monthly)  $7.35 4 $29 MBS item 66500 
X-ray of feet, knees   $32.55 1 $33 MBS item 57521 
Physiotherapy  $44.85 2 $90 MBS item 10960 
GP consultations quarterly                $32.40 4 $130 MBS item 23 
Specialist consultation(Initial)           $128.05 1 $128 MBS item 110  
Specialist consultations (review)       $48.10 3 $144 MBS item 116  
Diclofenac 50mg tds $11.03 12 $132 PBS item 1300K 
Methotrexate or  similar $47.10 12 $565 PBS items 2272N and 
Total     $1,310   
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Table 4 cost of septic arthritis  Unit 
cost 
number 
of units  
total  
GP  $32.40 4 $130 initial consult and 
3 follow-up to give 
injections  
Admission hospital   $5,921 1 $5,921  weighted average  
DRG code I67A 
and I67B 
Specialist consultations initial 
outpatient                                    
$115.60 1 $116 MBS item 110  
Specialist consultations review 
outpatient 
$58.00 1 $58 MBS item 116 f 
ceftriaxone 1 g IM/IV q24 h after 
discharge for 5 days 
$37.79 5 $189 PBS 
TOTAL   $6,413  
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Appendix for Chapter 6 
 
A mathematical model was developed to estimate the relationship between the proportion of the HIV-infected 
population that is undiagnosed and the relative risk per contact of unprotected anal intercourse (UAI); acts 
where condoms are used were not considered because the majority of transmissions occur due to UAI. The 
model was formulated as follows. 
 
If serosorting does not occur then each casual partnership formed with an HIV-uninfected MSM has average 
probability of being serodiscordant represented by the following mathematical expression: 
Qserosort = (NND+ND+NT)/(NS+NND+ND+NT).                                                    (1) 
Here NS, NND, ND, and NT represent the number of HIV-uninfected MSM who are potentially susceptible to 
infection, HIV-infected MSM who are not diagnosed and thus unaware of their serostatus, HIV-infected MSM 
who have been diagnosed with their infection, and MSM who are on antiretroviral therapy (ART) for their 
known HIV infection, respectively. If serosorting does occur and false disclosure does not occur then each new 
partnership has average probability of being discordant given by: 
Qno serosort = NND/(NS+NND).                                                                 (2) 
 
Average transmission probabilities per serodiscordant act of UAI with a casual partner who is undiagnosed 
( NDE ), diagnosed but untreated ( DE ), and on ART ( TE ), can be estimated as weighted averages based on the 
proportion of acts that are insertive, receptive with withdrawal, or receptive with ejaculation, according to the 
perceived HIV status of the partner. We use detailed behavioral data from the Health in Men (HIM) cohort 1,2, a 
highly studied cohort of gay men, to inform these estimates (see Fig. 1a). For example, based on the HIM study 
2, if a partner’s HIV status is unknown then an average of Uiq =46% of UAI acts are likely to be insertive, 
U
rwq
=33% are likely to be receptive but with withdrawal prior to ejaculation, and Urq =21% are likely to be receptive 
with ejaculation (Fig. A1). Then, the average risk of HIV transmission per serodiscordant act of UAI with a 
partner whose serostatus is unknown is given by 
U U U
U i i rw rw r rq q qE E E E   ,                                                     (3) 
 yielding a value of ~0.0032, where the respective transmission probabilities are taken to be iE =0.001, rwE
=0.002, and rE =0.010 3,4. 
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Similarly, the risks per contact with a partner of known HIV infection, based on the change in sexual positioning 
(Fig. 1a), are given by 
D D D
D i i rw rw r rq q qE E E E   ,                                                    (4) 
yielding a value of ~0.0023 and 
  1T DE I E  ,                                                               (5) 
yielding a value of ~0.0001, where I  0.95 is the estimated reduction in infectiousness due to effective 
treatment  4. 
 
The average HIV transmission probability per act of UAI with a partner who is HIV-positive but is not aware of 
his infection is given by 
 N N NND i i rw rw r rq q qE E E E   ,                                                   (6) 
yielding a value of ~0.0069, which is considerably greater than the risk of UAI with partners of any other 
perceived HIV status. 
 
We do not consider different infectiousness periods during the natural history of infection but use estimates 
from the chronic asymptomatic stage of infection (ignoring the greater infectiousness of newly acquired 
infections) 3,5. 
 
We estimate the relative risks of HIV acquisition associated with serosorting compared with not serosorting and 
refer to this as the relative risk of serosorting. For serosorting, if HIV status is disclosed then partnerships where 
UAI takes place will only form if the partner is thought to be seroconcordant and the sexual positioning 
(insertive or receptive UAI with or without ejaculation) within the partnership is then based on perceived 
knowledge of the partner’s serological concordance (Fig. A1). In comparison, if serosorting does not occur a 
sexual partnership may form regardless of the partner’s serostatus and sexual positioning within the partnership 
is more conservative (Fig. A1). Accordingly, if the prevalence of HIV in the population is P , NDp  is the 
proportion of HIV-infected MSM that are not diagnosed, and Tp  is the proportion of HIV-infected MSM who 
are diagnosed that are on treatment, then 
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1SN N P  , ND NDN NPp ,   1 1D ND TN NP p p   ,  1T ND TN NP p p  ,     (7) 
and the relative risk of serosorting compared with not serosorting can be represented mathematically by the ratio 
of the chance of transmission when serosorting to the chance of transmission when not serosorting, namely,  
        1 1 1 1 1ND ND ND U ND U ND T U T NDp P Pp p p p p pU E E E E Iª º        ¬ ¼ .  (8) 
This relative risk has maximum value (when there is no HIV testing) of  
max
N N N
i i rw rw r r
U U U
i i rw rw r r
q q q
q q q
E E EU E E E
    ,                                                      (9) 
yielding a value of ~2.15, and a minimum value (when everyone knows their true HIV status) of min 0U  . 
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